 MERGER AGREEMENT     

 

 

  

 

  Exhibit 2.1 

 

 

 

  Execution Version

 

 

 

  

 

 

 

 

 

  AGREEMENT AND PLAN OF MERGER

 

 

  BY AND AMONG

 

 

  BIG ROCK PARTNERS ACQUISITION CORP.,

 

 

  NEURORX, INC., and

 

 

  BIG ROCK MERGER CORP.

 

 

 

 

 

 

 

 

  DATED AS OF DECEMBER 13, 2020

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

  

 

 

 

  TABLE OF CONTENTS

 

 

    

 ARTICLE I THE MERGER

  |  

 2

   
---|--- 
  

 1.1

  |  

 The Merger

  |  

 2

   
  

 1.2

  |  

 Governing Documents

  |  

 2

   
  

 1.3

  |  

 Effect on Securities

  |  

 2

   
  

 1.4

  |  

 Exchange Procedures.

  |  

 6

   
  

 1.5

  |  

 The Closing

  |  

 7

   
  

 1.6

  |  

 Deliveries at Closing

  |  

 7 
 

   
  

 1.7

  |  

 Lock-Up Agreement

  |  

 8 
 

   
  

 1.8

  |  

 Earnout

  |  

 8

   
  

 1.9

  |  

 Sponsor Agreement

  |  

 9

   
  

 1.10

  |  

 Amendment to Stock Escrow Agreement

  |  

 10

   
  

 1.11

  |  

 Amendment to BCMA

  |  

 10

   
  

 1.12

  |  

 Amendment to BRPA Loan Agreements

  |  

 10

   
  

 1.13

  |  

 Registration Rights Agreement

  |  

 10

   
  

 1.14

  |  

 Taking of Necessary Action; Further Action

  |  

 11

   
  

 1.15

  |  

 Tax Consequences

  |  

 11

   
  

 1.16

  |  

 Payment of Expenses

  |  

 11

   
  

 1.17

  |  

 Dissenting Shares

  |  

 11

   
  

 ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  |  

 12

   
  

 2.1

  |  

 Organization and Qualification

  |  

 12

   
  

 2.2

  |  

 Subsidiaries

  |  

 12

   
  

 2.3

  |  

 Capitalization

  |  

 13

   
 

 

 

 

 

 

 

i

 

 

 

 

 

 

 

 

 

 

 

    

 2.4

  |  

 Authority Relative to this Agreement

  |  

 14

   
---|---|--- 
  

 2.5

  |  

 No Conflict; Required Filings and Consents

  |  

 15

   
  

 2.6

  |  

 Compliance

  |  

 15

   
  

 2.7

  |  

 Permits

  |  

 16

   
  

 2.8

  |  

 Financial Matters

  |  

 16

   
  

 2.9

  |  

 Absence of Certain Developments

  |  

 17

   
  

 2.10

  |  

 Condition and Sufficiency of Assets

  |  

 18

   
  

 2.11

  |  

 Litigation

  |  

 18

   
  

 2.12

  |  

 Employee Benefit Plans

  |  

 18

   
  

 2.13

  |  

 Labor Matters

  |  

 19

   
  

 2.14

  |  

 Restrictions on Business Activities

  |  

 20

   
  

 2.15

  |  

 Title to Property

  |  

 20

   
  

 2.16

  |  

 Taxes

  |  

 21

   
  

 2.17

  |  

 Environmental Matters

  |  

 21

   
  

 2.18

  |  

 Brokers

  |  

 22

   
  

 2.19

  |  

 Intellectual Property

  |  

 22

   
  

 2.20

  |  

 Product Warranties; Product Liability

  |  

 24

   
  

 2.21

  |  

 Agreements, Contracts and Commitments

  |  

 25

   
  

 2.22

  |  

 Insurance

  |  

 28

   
  

 2.23

  |  

 Interested Party Transactions

  |  

 28

   
  

 2.24

  |  

 Registration Statement

  |  

 28

   
  

 2.25

  |  

 Certain Business Practices

  |  

 28

   
  

 2.26

  |  

 FDA and EMEA Approval

  |  

 29 
 

   
  

 2.27

  |  

 Health Care Regulatory Compliance

  |  

 31

   
  

 2.28

  |  

 Board Approval

  |  

 32

   
  

 2.29

  |  

 Company Stockholder Approval

  |  

 32

   
  

 2.30

  |  

 No Additional Representations and Warranties; No Reliance

  |  

 32

   
  

 ARTICLE III REPRESENTATIONS AND WARRANTIES OF BRPA AND MERGER SUB

  |  

 33

   
  

 3.1

  |  

 Organization and Qualification

  |  

 33

   
  

 3.2

  |  

 Subsidiaries

  |  

 33

   
  

 3.3

  |  

 Capitalization

  |  

 34

   
  

 3.4

  |  

 Authority Relative to this Agreement

  |  

 35

   
  

 3.5

  |  

 No Conflict; Required Filings and Consents

  |  

 36

   
  

 3.6

  |  

 Compliance

  |  

 36

   
  

 3.7

  |  

 BRPA SEC Reports and Financial Statements

  |  

 37

   
  

 3.8

  |  

 No Undisclosed Liabilities

  |  

 38

   
  

 3.9

  |  

 Absence of Certain Developments

  |  

 38

   
  

 3.10

  |  

 Litigation

  |  

 38 
 

   
  

 3.11

  |  

 Employee Benefit Plans

  |  

 38 
 

   
  

 3.12

  |  

 Labor Matters

  |  

 38 
 

   
  

 3.13

  |  

 Business Activities

  |  

 39 
 

   
  

 3.14

  |  

 Title to Property

  |  

 39 
 

   
  

 3.15

  |  

 Intellectual Property

  |  

 39 
 

   
  

 3.16

  |  

 Taxes

  |  

 39 
 

   
  

 3.17

  |  

 Brokers

  |  

 40 
 

   
  

 3.18

  |  

 Agreements, Contracts and Commitments

  |  

 40

   
  

 3.19

  |  

 Insurance

  |  

 40

   
  

 3.20

  |  

 Interested Party Transactions

  |  

 41

   
  

 3.21

  |  

 BRPA Listing

  |  

 41 
 

   
  

 3.22

  |  

 Trust Fund

  |  

 41

   
  

 3.23

  |  

 Registration Statement

  |  

 41

   
  

 3.24

  |  

 No Additional Representations and Warranties; No Reliance

  |  

 41

   
  

 ARTICLE IV CONDUCT PRIOR TO CLOSING

  |  

 42

   
  

 4.1

  |  

 Conduct of Business by the Company

  |  

 42

   
  

 4.2

  |  

 Conduct of Business by BRPA and Merger Sub

  |  

 45

   
  

 4.3

  |  

 Confidentiality; Access to Information

  |  

 47

   
  

 4.4

  |  

 Exclusivity

  |  

 49 
 

   
  

 4.5

  |  

 Reasonable Best Efforts

  |  

 50

   
  

 ARTICLE V ADDITIONAL AGREEMENTS

  |  

 51

   
  

 5.1

  |  

 Registration Statement; BRPA Special Meeting

  |  

 51

   
 

 

 

 

 

 

 

ii

 

 

 

 

 

 

 

 

 

 

 

    

 5.2

  |  

 Directors and Officers of BRPA After Transactions

  |  

 52

   
---|---|--- 
  

 5.3

  |  

 HSR Act

  |  

 53

   
  

 5.4

  |  

 Public Announcements

  |  

 54

   
  

 5.5

  |  

 Required Information

  |  

 54

   
  

 5.6

  |  

 No Securities Transactions

  |  

 55

   
  

 5.7

  |  

 No Claim Against Trust Fund

  |  

 55

   
  

 5.8

  |  

 Disclosure of Certain Matters

  |  

 55

   
  

 5.9

  |  

 Securities Listing

  |  

 55

   
  

 5.10

  |  

 Charter Protections; Directors' and Officers' Liability Insurance

  |  

 56

   
  

 5.11

  |  

 Insider Loans

  |  

 57

   
  

 5.12

  |  

 BRPA Borrowings

  |  

 57

   
  

 5.13

  |  

 Trust Fund Disbursement

  |  

 57

   
  

 5.14

  |  

 Tax Matters

  |  

 57 
 

   
  

 5.15

  |  

 Incentive Equity Plan

  |  

 58 
 

   
  

 5.16

  |  

 Company Stockholder Approval

  |  

 58 
 

   
  

 5.17

  |  

 Third Party Consents

  |  

 59 
 

   
  

 5.18

  |  

 BRPA Financing

  |  

 59 
 

   
  

 5.19

  |  

 Employment Agreements

  |  

 59 
 

   
  

 5.20

  |  

 Termination of Company Stockholder Agreements

  |  

 59 
 

   
  

 5.21

  |  

 Section 16 of the Exchange Act

  |  

 59 
 

   
  

 5.22

  |  

 Extension

  |  

 59 
 

   
  

 5.23

  |  

 Company Support Agreements

  |  

 60

   
  

 ARTICLE VI CONDITIONS TO THE TRANSACTION

  |  

 60

   
  

 6.1

  |  

 Conditions to Obligations of Each Party to Effect the Merger

  |  

 60

   
  

 6.2

  |  

 Additional Conditions to Obligations of the Company

  |  

 61

   
  

 6.3

  |  

 Additional Conditions to the Obligations of BRPA

  |  

 62

   
  

 ARTICLE VII TERMINATION

  |  

 63

   
  

 7.1

  |  

 Termination

  |  

 63

   
  

 7.2

  |  

 Notice of Termination; Effect of Termination

  |  

 64

   
  

 7.3

  |  

 Fees and Expenses

  |  

 65

   
  

 ARTICLE VIII GENERAL PROVISIONS

  |  

 65

   
  

 8.1

  |  

 Notices

  |  

 65

   
  

 8.2

  |  

 Interpretation

  |  

 66

   
  

 8.3

  |  

 Counterparts; Electronic Delivery

  |  

 66 
 

   
  

 8.4

  |  

 Entire Agreement; Third Party Beneficiaries

  |  

 67 
 

   
  

 8.5

  |  

 Severability

  |  

 67 
 

   
  

 8.6

  |  

 Other Remedies; Specific Performance

  |  

 67 
 

   
  

 8.7

  |  

 Governing Law

  |  

 67 
 

   
  

 8.8

  |  

 Consent to Jurisdiction; WAIVER OF TRIAL BY JURY

  |  

 68 
 

   
  

 8.9

  |  

 Rules of Construction

  |  

 68 
 

   
  

 8.10

  |  

 Assignment

  |  

 68 
 

   
 

 

 

 

 

 

 

iii

 

 

 

 

 

 

 

 

 

 

 

    

 8.11

  |  

 Amendment

  |  

 68 
 

   
---|---|--- 
  

 8.12

  |  

 Extension; Waiver

  |  

 68 
 

   
  

 8.13

  |  

 Currency

  |  

 69 
 

   
  

 8.14

  |  

 Schedules

  |  

 69 
 

   
  

 8.15

  |  

 Nonsurvival of Representations, Warranties and Covenants

  |  

 69 
 

   
  

 8.16

  |  

 Non-Recourse

  |  

 69 
 

   
 

 

 

  Exhibits

 

 

 Exhibit A - Certain Definitions

 

 Exhibit B - Form of Voting and Support Agreement

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

iv

 

 

 

 

 

 

 

 

 

 

 

  Index to Defined Terms

 

 

 

  This index is included for convenience only and does not constitute a
part of the agreement

 

 

    

  Term

  |  

  Section

   
---|--- 
  

 AandR Charter Proposal

  |  

 5.1(b)

   
  

 Acquisition Proposal

  |  

 4.4(d)

   
  

 Action

  |  

 Exhibit A

   
  

 Additional Forfeited Shares

  |  

 1.9(a)

   
  

 Additional Proposal

  |  

 5.1(b)

   
  

 Affiliate

  |  

 Exhibit A

   
  

 Agreement

  |  

 Preamble

   
  

 Ancillary Agreements

  |  

 Exhibit A

   
  

 Antitrust Law

  |  

 Exhibit A

   
  

 Approvals

  |  

 2.1(a)

   
  

 Assets

  |  

 2.10

   
  

 BCMA

  |  

 1.11

   
  

 BCMA Amendment Agreement

  |  

 1.11

   
  

 BRAC

  |  

 Exhibit A

   
  

 BRPA

  |  

 Preamble

   
  

 BRPA AandR Bylaws

  |  

 Recital G

   
  

 BRPA AandR Charter

  |  

 Recital F

   
  

 BRPA Affiliate Agreement

  |  

 3.20

   
  

 BRPA Audited Financial Statements

  |  

 3.7(b)

   
  

 BRPA Board

  |  

 3.4(b)

   
  

 BRPA Board Recommendation

  |  

 5.1(f)

   
  

 BRPA Borrowings

  |  

 5.12

   
  

 BRPA Change in Recommendation

  |  

 5.1(f)

   
  

 BRPA Competing Transactions

  |  

 4.4(a)

   
  

 BRPA Common Stock

  |  

 Exhibit A

   
  

 BRPA Contracts

  |  

 3.18(a)

   
  

 BRPA Cure Period

  |  

 7.1(e)

   
  

 BRPA Financial Statements

  |  

 3.7(b)

   
  

 BRPA Lenders

  |  

 Exhibit A

   
  

 BRPA Material Adverse Effect

  |  

 Exhibit A

   
  

 BRPA Plan

  |  

 5.15

   
  

 BRPA Plan Proposal

  |  

 5.1(b)

   
  

 BRPA Preferred Stock

  |  

 Exhibit A

   
  

 BRPA Rights

  |  

 Exhibit A

   
  

 BRPA Schedules

  |  

 Article III

   
  

 BRPA SEC Reports

  |  

 3.7(a)

   
  

 BRPA Securities

  |  

 Exhibit A

   
  

 BRPA Stockholder Approval

  |  

 3.4(c)

   
  

 BRPA Stockholder Matters

  |  

 5.1(b)

   
  

 BRPA Stockholders

  |  

 Exhibit A

   
  

 BRPA Unaudited Financial Statements

  |  

 3.7(b)

   
  

 BRPA Units

  |  

 Exhibit A

   
 

 

 

 

 

 

 

 

v

 

 

 

 

 

 

 

 

 

 

 

    

  Term

  |  

  Section

   
---|--- 
  

 BRPA Warrants

  |  

 Exhibit A

   
  

 Business Combination

  |  

 Exhibit A

   
  

 Business Day

  |  

 Exhibit A

   
  

 CARES Act

  |  

 2.8(f)

   
  

 Cash and Cash Equivalents

  |  

 Exhibit A

   
  

 Certificate of Merger

  |  

 1.1

   
  

 Charter Documents

  |  

 Exhibit A

   
  

 Closing

  |  

 1.5

   
  

 Closing Date

  |  

 1.5

   
  

 Code

  |  

 Recital H

   
  

 Company

  |  

 Preamble

   
  

 Company Annual Financial Statements

  |  

 2.8(a)(i)

   
  

 Company Antidepressant Drug Regimen

  |  

 Exhibit A

   
  

 Company Board

  |  

 2.28

   
  

 Company Board Recommendation

  |  

 5.16

   
  

 Company Certificate of Incorporation

  |  

 Exhibit A

   
  

 Company Common Stock

  |  

 Exhibit A

   
  

 Company Competing Transactions

  |  

 4.4(b)

   
  

 Company Contracts

  |  

 2.21(a)

   
  

 Company COVID-19 Drug

  |  

 Exhibit A

   
  

 Company Cure Period

  |  

 7.1(e)

   
  

 Company Schedule

  |  

 Article II

   
  

 Company Financial Statements

  |  

 2.8(a)(ii)

   
  

 Company Intellectual Property

  |  

 Exhibit A

   
  

 Company Interim Financial Statements

  |  

 2.8(a)(ii)

   
  

 Company IP Registrations

  |  

 2.19(b)

   
  

 Company Material Adverse Effect

  |  

 Exhibit A

   
  

 Company Preferred Stock

  |  

 Exhibit A

   
  

 Company Products

  |  

 Exhibit A

   
  

 Company Schedules

  |  

 Article II

   
  

 Company Series A Preferred Stock

  |  

 Exhibit A

   
  

 Company Series B Preferred Stock

  |  

 Exhibit A

   
  

 Company Series B-1 Preferred Stock

  |  

 Exhibit A

   
  

 Company Series B-1A Preferred Stock

  |  

 Exhibit A

   
  

 Company Series B-2 Preferred Stock

  |  

 Exhibit A

   
  

 Company Stock

  |  

 Exhibit A

   
  

 Company Stock Options

  |  

 Exhibit A

   
  

 Company Stockholder

  |  

 Exhibit A

   
  

 Company Stockholder Agreements

  |  

 Exhibit A

   
  

 Company Stockholder Approval

  |  

 2.29

   
  

 Company Stockholders Meeting

  |  

 5.16

   
  

 Company Warrants

  |  

 Exhibit A

   
  

 Consent Solicitation Statement

  |  

 Exhibit A

   
  

 Continental

  |  

 1.4(a)

   
  

 Copyrights

  |  

 Exhibit A

   
 

 

 

 

 

 

 

 

vi

 

 

 

 

 

 

 

 

 

 

 

    

  Term

  |  

  Section

   
---|--- 
  

 DGCL

  |  

 Recital A

   
  

 Dissenting Shares

  |  

 1.17

   
  

 Earnout Cash

  |  

 1.8(b)

   
  

 Earnout Cash Milestone

  |  

 1.8(b)

   
  

 Earnout Consideration

  |  

 1.8 (b)

   
  

 Earnout Shares

  |  

 1.8(a)

   
  

 Earnout Shares Milestone

  |  

 1.8(a)

   
  

 EBC

  |  

 1.11

   
  

 Effective Time

  |  

 1.1

   
  

 Election of Directors Proposal

  |  

 5.1(b)

   
  

 EMEA

  |  

 Exhibit A

   
  

 Environmental Law

  |  

 Exhibit A

   
  

 ERISA

  |  

 2.12(a)

   
  

 Exchange Act

  |  

 2.8(b)

   
  

 Exchange Agent

  |  

 1.4(a)

   
  

 Exchange Agent Agreement

  |  

 1.4(a)

   
  

 Exchange Ratio

  |  

 Exhibit A

   
  

 Export Control Laws

  |  

 Exhibit A

   
  

 Extension

  |  

 5.22

   
  

 FDA

  |  

 Exhibit A

   
  

 Financing

  |  

 5.18

   
  

 Forfeited Shares

  |  

 1.9(a)

   
  

 Governmental Entity

  |  

 Exhibit A

   
  

 Governmental Order

  |  

 Exhibit A

   
  

 Hazardous Substance

  |  

 Exhibit A

   
  

 Health Care Programs

  |  

 Exhibit A

   
  

 Health Care Regulatory Laws

  |  

 Exhibit A

   
  

 HIPAA

  |  

 Exhibit A

   
  

 HSR Act

  |  

 Exhibit A

   
  

 IEC

  |  

 Exhibit A

   
  

 immediate family

  |  

 Exhibit A

   
  

 Inbound IP Contracts

  |  

 2.19(c)

   
  

 Information Privacy and Security Laws

  |  

 Exhibit A

   
  

 Initial Forfeited Shares

  |  

 1.9(a)

   
  

 Insider

  |  

 Exhibit A

   
  

 Insurance Policies

  |  

 Exhibit A

   
  

 Intellectual Property Rights

  |  

 Exhibit A

   
  

 Interim Period

  |  

 4.1

   
  

 IP Contracts

  |  

 2.19(c)

   
  

 IRB

  |  

 Exhibit A

   
  

 knowledge

  |  

 Exhibit A

   
  

 Legal Requirements

  |  

 Exhibit A

   
  

 Letter of Transmittal

  |  

 1.4(c)

   
  

 Lien

  |  

 Exhibit A

   
  

 Material Company Contracts

  |  

 2.21(a)

   
 

 

 

 

 

 

 

 

vii

 

 

 

 

 

 

 

 

 

 

 

    

  Term

  |  

  Section

   
---|--- 
  

 Merger

  |  

 Recital A

   
  

 Merger Consideration

  |  

 Exhibit A

   
  

 Merger Sub

  |  

 Preamble

   
  

 Most Recent Balance Sheet

  |  

 2.8(a)(ii)

   
  

 Most Recent Balance Sheet Date

  |  

 2.8(a)(ii)

   
  

 Nasdaq

  |  

 3.21

   
  

 Nasdaq Proposal

  |  

 5.1(b)

   
  

 Note Amendment

  |  

 1.12

   
  

 OFAC

  |  

 Exhibit A

   
  

 Offer

  |  

 Recital C

   
  

 Option Post Earnout Adjustment

  |  

 1.3

   
  

 Outbound IP Contracts

  |  

 2.19(c)

   
  

 Outside Date

  |  

 7.1(b)

   
  

 Outstanding BRPA Transaction Expenses

  |  

 1.16(b)

   
  

 Outstanding Company Transaction Expenses

  |  

 1.16(a)

   
  

 Parties

  |  

 Preamble

   
  

 Patents

  |  

 Exhibit A

   
  

 Per Share Merger Consideration

  |  

 1.3(b)

   
  

 Permits

  |  

 2.7

   
  

 Permitted Liens

  |  

 Exhibit A

   
  

 Permitted Transferee

  |  

 Exhibit A

   
  

 Person

  |  

 Exhibit A

   
  

 Personal Confidential Information

  |  

 Exhibit A

   
  

 Personal Property

  |  

 2.15(b)

   
  

 Plan

  |  

 2.12(a)

   
  

 Post Earnout Substitute Option

  |  

 1.3

   
  

 Protected Health Information

  |  

 Exhibit A

   
  

 Proxy Statement

  |  

 Exhibit A

   
  

 Registration Rights Agreement

  |  

 1.13

   
  

 Registration Statement

  |  

 5.1(a)

   
  

 Representative

  |  

 Exhibit A

   
  

 Retained Shares

  |  

 1.3

   
  

 Returns

  |  

 2.16(a)

   
  

 Reviewable Document

  |  

 5.5(a)

   
  

 Sanctions

  |  

 2.25(c)

   
  

 Schedules

  |  

 Exhibit A

   
  

 SEC

  |  

 Exhibit A

   
  

 SEC Approval Date

  |  

 5.1(d)

   
  

 Securities Act

  |  

 Exhibit A

   
  

 Signing Press Release

  |  

 5.4

   
  

 Sponsor

  |  

 Exhibit A

   
  

 Sponsor Agreement

  |  

 1.9

   
  

 Sponsor Earnout Shares

  |  

 1.9(b)

   
  

 Stimulus Funds

  |  

 2.8(f)

   
  

 Stock Escrow Agreement

  |  

 1.10

   
 

 

 

 

 

 

 

 

viii

 

 

 

 

 

 

 

 

 

 

 

    

  Term

  |  

  Section

   
---|--- 
  

 Stock Escrow Amendment

  |  

 1.10

   
  

 Subsidiaries

  |  

 Exhibit A

   
  

 Substitute Options

  |  

 1.3(c)

   
  

 Superior Proposal

  |  

 4.4(d)

   
  

 Support Agreements

  |  

 Recital D

   
  

 Supporting Stockholders

  |  

 Recital D

   
  

 Surviving Corporation

  |  

 Recital A

   
  

 Tax

  |  

 Exhibit A

   
  

 Tax Opinion

  |  

 Exhibit A

   
  

 Tax Opinion Counsel

  |  

 Exhibit A

   
  

 Terminating BRPA Breach

  |  

 7/1(d)

   
  

 Terminating Company Breach

  |  

 7.1(e)

   
  

 Trademarks

  |  

 Exhibit A

   
  

 Transaction Proposal

  |  

 5.1(b)

   
  

 Transactions

  |  

 Exhibit A

   
  

 Trust Agreement

  |  

 3.22

   
  

 Trust Fund

  |  

 3.22

   
  

 U.S. GAAP

  |  

 Exhibit A

   
  

 Written Consent

  |  

 5.16

   
 

 

 

 

 

 

 

 

 

 

ix

 

 

 

 

 

  Execution Version

 

 

 

  

 

 

 

  AGREEMENT AND PLAN OF MERGER

 

 

 THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of December
13, 2020, by and among Big Rock Partners Acquisition Corp., a Delaware
corporation ("BRPA"), NeuroRx, Inc., a Delaware corporation (the "Company"),
and Big Rock Merger Corp., a Delaware corporation and wholly owned Subsidiary
of BRPA ("Merger Sub"). The term "Agreement" as used herein refers to this
Agreement and Plan of Merger, as the same may be amended from time to time,
and all schedules hereto (including the Company Schedules and the BRPA
Schedules, as defined in the preambles to Articles II and III hereof,
respectively). Each of BRPA, Merger Sub, and the Company, are referred to
herein, individually, as a "Party" and, collectively, as the "Parties".
Except as otherwise indicated, capitalized terms used herein and
not otherwise defined shall have the meanings ascribed to them
in Exhibit A.

 

 

 RECITALS

 

 

 A. Upon the terms and subject to the conditions of this Agreement and
in accordance with the Delaware General Corporation Law (the "DGCL"), the
Parties intend to enter into a business combination transaction by which
Merger Sub will merge with and into the Company (the "Merger") with the
Company being the surviving entity of the Merger and becoming a wholly-owned
Subsidiary of BRPA ("Surviving Corporation"), on the terms and subject to
the conditions set forth in this Agreement.

 

 

 B. The respective boards of directors of each of BRPA, Merger Sub and
the Company have each approved, declared advisable and resolved to recommend
to their respective stockholders the Transactions upon the terms and subject
to the conditions of this Agreement and in accordance with the DGCL.

 

 

 C. Pursuant to BRPA's Charter Documents, BRPA shall provide an opportunity
to its stockholders to have their BRPA Common Stock redeemed for the
consideration, and on the terms and subject to the conditions and
limitations, set forth in this Agreement, BRPA's Charter Documents, the Trust
Agreement, and the Proxy Statement in conjunction with, inter alia,
obtaining approval from the BRPA Stockholders for the Business Combination
(the "Offer").

 

 

 D. Prior to the consummation of the Transactions, certain
Company Stockholders (such Company Stockholders,
the "Supporting Stockholders") shall enter into certain Voting and Support
Agreements (the "Support Agreements"), with BRPA and Merger Sub, in the
form set forth on  Exhibit B.

 

 

 E. Prior to the consummation of the Transactions, BRPA shall, subject
to obtaining the BRPA Stockholder Approval, adopt the BRPA Plan in a form
reasonably acceptable to BRPA and the Company.

 

 

 F. Prior to the consummation of the Transactions, BRPA shall, subject
to obtaining the BRPA Stockholder Approval, adopt an amended and restated
certificate of incorporation (the "BRPA AandR Charter") in a form reasonably
acceptable to BRPA and the Company.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 G. Prior to the consummation of the Transactions, BRPA shall adopt
the amended and restated bylaws (the "BRPA AandR Bylaws") in a
form reasonably acceptable to BRPA and the Company.

 

 

 H. The Parties intend, for U.S. federal income tax purposes, that
the Merger shall constitute a transaction that qualifies as a reorganization
governed by Section 368 of the Internal Revenue Code of 1986, as amended (the
"Code").

 

 

 NOW, THEREFORE, in consideration of the covenants, promises
and representations set forth herein, and for other good and
valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties agree as follows:

 

 

  ARTICLE I

 

 

 THE MERGER

 

 

 1.1 The Merger. At the Effective Time, and subject to and upon the terms
and conditions of this Agreement and the applicable provisions of the DGCL,
Merger Sub shall merge with and into the Company, the separate
corporate existence of Merger Sub shall cease, and the Company shall
continue as the Surviving Corporation after the Merger and as a wholly
owned Subsidiary of BRPA. The Merger will be consummated in accordance with
this Agreement and the DGCL immediately upon the filing of a certificate of
merger between Merger Sub and the Company (the "Certificate of Merger") with
the Secretary of State of the State of Delaware, or at such other time as may
be agreed by BRPA and the Company in writing and specified in such filings
(the "Effective Time"). The effect of the Merger will be as provided in
this Agreement, the Certificate of Merger, and the applicable provisions of
the DGCL. Without limiting the generality of the foregoing, and subject
thereto, at the Effective Time, by virtue of the Merger and without any
further action on the part of the Parties or the holders of any of the
securities of the Company, all of the property, rights, privileges, powers,
franchises, debts, liabilities, and duties of the Company and Merger Sub
shall vest in the Surviving Corporation.

 

 

 1.2 Governing Documents.

 

 

 (a) At the Effective Time, the Certificate of Incorporation and Bylaws
of Merger Sub shall become the Certificate of Incorporation and Bylaws of
the Surviving Corporation, in each case, until thereafter supplemented or
amended in accordance with its terms and the DGCL.

 

 

 (b) Prior to the Effective Time, the bylaws of BRPA shall be amended
and restated to be the BRPA AandR Bylaws.

 

 

 (c) Subject to obtaining the BRPA Stockholder Approval, BRPA shall file
the BRPA AandR Charter with the Secretary of State of the State of Delaware
prior to the Effective Time.

 

 

 1.3 Effect on Securities.

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 (a) Preferred Stock Conversion. The Company shall take all actions
necessary to cause each share of Company Preferred Stock that is issued and
outstanding immediately prior to the Effective Time to be converted
immediately prior to the Effective Time into a number of shares of Company
Common Stock at the then-effective conversion rate (as calculated pursuant to
the Company Certificate of Incorporation) in accordance with the Company
Certificate of Incorporation (such conversions, the "Company Preferred Stock
Conversion"). Following the Company Preferred Stock Conversion all of
the shares of Company Preferred Stock shall be canceled or terminated, as
applicable, shall no longer be outstanding and shall cease to exist and no
payment or distribution shall be made with respect thereto, and each holder
of Preferred Stock shall thereafter cease to have any rights with respect to
such securities. The Preferred Stock Conversion may be made contingent upon
the occurrence of the Closing.

 

 

 (b) Conversion of Company Common Stock. Subject to the terms and
conditions of this Agreement, at the Effective Time (and, for the avoidance
of doubt, following the Preferred Stock Conversion), by virtue of the Merger
and without any further action on the part of Parties or the holders of any
of the securities of the Company, each share of Company Common
Stock (including shares of Company Common Stock resulting from the Preferred
Stock Conversion) that is issued and outstanding immediately prior to the
Effective Time (other than any shares to be canceled pursuant to Section
1.3(g) and the Dissenting Shares), will be automatically converted into the
right to receive (i) a number of shares of BRPA Common Stock equal to the
Exchange Ratio (the "Per Share Merger Consideration") and (ii) a contingent
right to receive (1) a number of Earnout Shares issuable pursuant to Section
1.8(a), if any and (2) an amount of Earnout Cash payable pursuant to Section
1.8(b), if any.

 

 

 (c) Assumption of Company Stock Options.

 

 

 (i) At the Closing, without any action on the part of the holders of
any options exercisable for shares of Company Common Stock ("Company
Stock Options"), each then outstanding Company Stock Option will be assumed
by BRPA and automatically exchanged for an option to purchase shares of
BRPA Common Stock ("Substitute Options"). Each Substitute Option will be
issued pursuant to the BRPA Plan and will continue to have, and be subject
to, the same terms and conditions set forth in the applicable documents
evidencing the terms of the Company Stock Option (including any applicable
incentive plan and stock option agreement or other document evidencing such
Company Stock Option) immediately prior to the Closing, including
any repurchase rights or vesting provisions, except that (i) each Substitute
Option will be exercisable (or will become exercisable in accordance with its
terms) for that number of whole shares of BRPA Common Stock equal to the
product of the number of shares of Company Common Stock that were issuable
upon exercise of such Company Stock Option immediately prior to the Closing
multiplied by the Option Exchange Ratio, rounded down to the nearest whole
number of shares of BRPA Common Stock and (ii) the per share exercise price
for the shares of BRPA Common Stock issuable upon exercise of such Substitute
Option will be equal to the quotient determined by dividing the exercise
price per share of Company Common Stock at which such Company Stock Option
was exercisable immediately prior to the Closing by the Option Exchange
Ratio, rounded up to the nearest whole cent. The Company shall take no
action, other than those actions contemplated by this Agreement, that will
cause or result in the accelerated vesting of the assumed Company
Stock Options. Each Substitute Option shall be vested immediately following
the Closing as to the same percentage of the total number of shares subject
thereto as the Company Stock Option was vested as to immediately prior to the
Closing. BRPA shall file with the SEC a registration statement on Form S-8
(or any successor form or comparable form in another relevant jurisdiction)
relating to the Substitute Options promptly in accordance with applicable
Legal Requirements, and BRPA shall use reasonable best efforts to maintain
the effectiveness of such registration statement for so long as any
Substitute Options remain outstanding. As soon as reasonably practicable
following the Closing Date, BRPA will use reasonable best efforts to issue to
each Person who holds a Substitute Option a document evidencing the foregoing
assumption of such Company Stock Option by BRPA.

 

 

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

 

 

 (ii) In the event that either the Earnout Shares Milestone or the
Earnout Cash Milestone has not occurred during the Earnout Period,
promptly following the end of the Earnout Period the Company shall
adjust each Substitute Option (each such Substitute Option adjusted pursuant
to this Section 1.3(c)(ii), a "Post-Earnout Substitute Option")
by reducing the number of shares of BRPA Common Stock underlying any such
Substitute Option and increasing the exercise price of any such Substitute
Option such that following such adjustment contemplated by this
Section 1.3(c)(ii), the number of shares of BRPA Common Stock underlying
such Post-Earnout Substitute Option, the exercise price per share of each
such Post-Earnout Substitute Option and the aggregate intrinsic value of each
such Post-Earnout Substitute Option (and taking into account any intervening
exercises of the Substitute Option and the provisions of Section 1.3(c)(iii)
below) shall equal the respective number of shares, exercise price per share
and aggregate intrinsic value that would have resulted following
the adjustment of the applicable underlying Substitute Option had
the conversion procedures set forth in Section 1.3(c)(i) been applied
using the Option Post-Earnout Exchange Ratio in lieu of the Option Exchange
Ratio (the "Option Post-Earnout Adjustment"). Notwithstanding the
immediately preceding sentence, in the event that neither the Earnout Shares
Milestone nor the Earnout Cash Milestone occur, the Option Post-Earnout
Adjustment shall be based on the Exchange Ratio instead of the Option
Exchange Ratio (and shall take into account any intervening exercises of the
Substitute Option and the provisions of Section 1.3(c)(iii) below).

 

 

 (iii) In the event that any Substitute Option is exercised prior to
the earlier of the date on which both the Earnout Share Milestone and the
Earnout Cash Milestone have been achieved and December 31, 2022, the
optionholder shall agree, as a condition to such exercise, that a sufficient
number of shares of BRPA Common Stock (as determined below) shall not be
delivered to the optionholder but shall be held in escrow by the Company (and
may not be sold, transferred or otherwise disposed) pending the determination
of any Option Post-Earnout Adjustment. The number of shares of BRPA
Common Stock to be retained by the Company shall be the number that would be
forfeited as a result of the reduction pursuant to the Option Post-Earnout
Adjustment if any of the Earnout Shares Milestone or the Earnout Cash
Milestone that had not been achieved as of the date of such option exercise
was not achieved by December 31, 2022 (the "Retained Shares"). At the time
of any such exercise, the Company shall determine reasonably and in good
faith the applicable number of Retained Shares. Following the determination
of any Option Post-Earnout Adjustment, then the Company shall permanently
retain the applicable number of Retained Shares that shall be forfeited by
such optionholder, and the remaining Retained Shares shall be released
promptly thereafter to such optionholder.

 

 

 (d) Assumption of Company Warrants. At the Closing, without any action on
the part of the holders of any Company Warrants, each then outstanding
Company Warrant will be assumed by BRPA and automatically treated as if such
Company Warrant were a Company Stock Option in accordance
with Section 1.3(c).

 

 

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

 

 

 

 (e) Adjustments to Merger Consideration. The number of shares of BRPA
Common Stock issuable as Merger Consideration or any amount contained herein
which is based upon the number of shares of Company Common Stock or Company
Preferred Stock, as applicable, shall be equitably adjusted to
reflect appropriately the effect of any stock split, reverse stock
split, stock dividend (including any dividend or distribution of securities
convertible into shares of BRPA Common Stock, Company Common Stock or Company
Preferred Stock, as applicable), extraordinary cash dividend, reorganization,
recapitalization, reclassification, combination, exchange of shares or other
like change with respect to shares of BRPA Common Stock, Company
Common Stock or Company Preferred Stock, as applicable occurring on or after
the date hereof but at or prior to the Effective Time (or, as it relates to
the Earnout Shares, prior to the date of issuance of such Earnout Shares in
accordance with Section 1.8); provided, however, that this Section
1.3(e) shall not be construed to permit BRPA or the Company to take any
action with respect to their respective securities that is prohibited by the
terms and conditions of this Agreement.

 

 

 (f) Fractional Shares. No certificates or scrip representing fractional
shares of BRPA Common Stock will be issued upon the conversion of Company
Common Stock (including shares of Company Common Stock resulting from the
Company Preferred Stock Conversion), and each holder of Company Common Stock
or Company Preferred Stock who would otherwise be entitled to a fraction of
a share of BRPA Common Stock at any time shares of BRPA Common Stock are
distributed to any such Person pursuant to this Agreement (after aggregating
all fractional shares that otherwise would be received by such holder in
connection with such distribution) shall receive from BRPA, in lieu of such
fractional share, one (1) share of BRPA Common Stock.

 

 

 (g) Cancellation of Treasury Stock. At the Effective Time, by virtue of
the Merger and without any further action on the part of any holder thereof,
each share of Company Common Stock held by the Company, BRPA, or Merger Sub
or any direct or indirect wholly owned Subsidiary of any of the
foregoing immediately prior to the Effective Time shall be canceled
and extinguished without any conversion or payment in respect thereof.

 

 

 (h) Conversion of Merger Sub Stock into Stock of the
Surviving Corporation. At the Effective Time, by virtue of the Merger and
without any further action on the part of any holder thereof, each share of
common stock, par value $0.0001 per share, of Merger Sub outstanding
immediately prior to the Effective Time shall be converted into and become
one share of common stock, par value $0.0001 per share, of the
Surviving Corporation with the same rights, powers and privileges as
the shares so converted and all such shares shall constitute the
only outstanding shares of capital stock of the Surviving
Corporation immediately following the Effective Time. From and after
the Effective Time, each share of capital stock of Merger Sub shall
no longer be outstanding and shall automatically be cancelled and cease to
exist.

 

 

 (i) No Further Ownership Rights. Until surrendered as contemplated by
Section 1.4, all of the shares of Company Common Stock (including any shares
of Company Common Stock resulting from the Preferred Stock Conversion)
converted into the right to receive the Per Share Merger Consideration shall
be deemed, from and after the Closing, to represent only the right
to receive the Per Share Merger Consideration and any dividends or other
distributions as contemplated by Section 1.3(e) and the contingent right to
receive the Earnout Consideration. If, after the Closing, shares of
Company Common Stock (including any shares of Company Common Stock resulting
from the Preferred Stock Conversion) are presented to BRPA or the Company for
any reason, they shall be cancelled and exchanged as provided in this
Agreement.

 

 

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

 

 

 

 1.4 Exchange Procedures.

 

 

 (a) Appointment of Exchange Agent. BRPA and the Company shall appoint
Continental Stock Transfer and Trust Company ("Continental"), or if
Continental shall be unavailable, a mutually agreeable bank or trust company,
to act as exchange agent and paying agent ("Exchange Agent") for
the distribution of the aggregate Per Share Merger Consideration and the
Earnout Consideration (if earned pursuant to Section 1.8) to the
Company Stockholders pursuant to this Section 1.4 and an exchange agent
agreement in form and substance mutually agreeable to BRPA and the
Company ("Exchange Agent Agreement").

 

 

 (b) Delivery of Closing Consideration to Exchange Agent. Immediately
following the Effective Time, BRPA will deliver or cause to be delivered to
the Exchange Agent such number of shares of BRPA Common Stock equal to the
aggregate Per Share Merger Consideration deliverable pursuant to this
Agreement. The Exchange Agent will be deemed to be the agent for the
Company Stockholders for the purpose of receiving the aggregate Per
Share Merger Consideration and BRPA shall cause the Exchange Agent, pursuant
to irrevocable instructions, to pay the aggregate Per Share Merger
Consideration in accordance with the terms of this Agreement. Until they are
distributed, the shares of BRPA Common Stock held by the Exchange Agent will
be deemed to be outstanding from and after the Effective Time, but the
Exchange Agent will not vote those shares or exercise any rights of a
stockholder with regard to them. If any dividends or distributions are paid
with regard to shares of BRPA Common Stock while they are held by
the Exchange Agent, the Exchange Agent will hold the dividends
or distributions, uninvested, until shares of BRPA Common Stock
are distributed to the Company Stockholders, at which time the
Exchange Agent will distribute the dividends or distributions that have
been paid with regard to those shares of BRPA Common Stock to the
former Company Stockholders.

 

 

 (c) Letters of Transmittal. Concurrently with the mailing of the Consent
Solicitation Statement, BRPA shall cause the Exchange Agent to deliver to
each Company Stockholder a letter of transmittal (and any instructions
related thereto) in form and substance reasonably acceptable to BRPA and the
Surviving Corporation (the "Letter of Transmittal") to be completed and
executed by such Company Stockholder to receive such Company Stockholder's
Per Share Merger Consideration as contemplated by Section 1.3(a) and such
Company Stockholder's pro rata portion of the Earnout Consideration, if
payable pursuant to Section 1.8. The Letter of Transmittal will contain,
among other things, customary representations of each Company Stockholder
relating to (as applicable for Company Stockholders that are individuals)
existence, power and authority, due authorization, due execution,
enforceability and ownership of the shares of Company Common Stock owned by
such Company Stockholder (including shares of Company Common Stock owned by
such Company Stockholder resulting from the Preferred Stock Conversion).

 

 

 (d) Delivery of Per Share Merger Consideration. Upon receipt by the
Exchange Agent of a validly executed and delivered Letter of Transmittal,
together with the share certificate(s) evidencing the Company Common Stock,
and/or Company Preferred Stock, as applicable, or evidence that
such securities have been transferred by book entry transfer to an account
established by the Exchange Agent, the Exchange Agent shall issue to the
applicable Company Stockholder (or its designee) the Per Share Merger
Consideration to which such Company Stockholder is entitled under
Section 1.3(b).

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

 

 

 (e) Delivery of Earnout Consideration. BRPA will deliver, or cause to be
delivered, to the Exchange Agent the Earnout Shares and/or Earnout Cash, as
applicable, in each case, in accordance with Section 1.8. Promptly after
the Exchange Agent's receipt of the Earnout Shares and/or Earnout Cash from
BRPA, the Exchange Agent shall deliver the Earnout Shares and/or Earnout Cash
to the Company Stockholders entitled to receive the Earnout Shares and/or
Earnout Cash pursuant to and in accordance with Section 1.8.

 

 

 (f) Payment to Third Parties. If payment of the Per Share Merger
Consideration in respect of a Company Stockholder is to be made to a
recipient other than the Person in whose name shares of Company Common Stock
(including shares of Company Common Stock resulting from the Preferred Stock
Conversion) are registered, it shall be a condition of payment that the
Person requesting such payment must provide funds for payment of
any transfer or other Taxes required by reason of the payment to a Person
other than the registered holder of such securities or establish to the
satisfaction of BRPA that the Tax has been paid or is not applicable.

 

 

 (g) Termination of Exchange Agreement. On June 30, 2023, BRPA shall
instruct the Exchange Agent to deliver to BRPA any portion of the Merger
Consideration deposited with the Exchange Agent that remains undistributed to
the Company Stockholders pursuant to instructions provided to the Exchange
Agent by BRPA at such time, unless required otherwise by applicable
Legal Requirements. Thereafter, any Company Stockholders who have
not complied with the provisions of this Agreement for receiving any Merger
Consideration from the Exchange Agent shall look only to BRPA for such
amounts.

 

 

 1.5 The Closing. Subject to the terms and conditions of this Agreement,
the closing of the Merger and the other Transactions (the "Closing") will
take place remotely via the exchange of electronic signature pages on
the second Business Day following the satisfaction or waiver of each of the
conditions set forth in Article VI hereof (other than those conditions which
can be satisfied only at the Closing, but subject to the satisfaction or
waiver of such conditions at Closing), or at such other time and place as may
be agreed to by BRPA and the Company (such date, the "Closing Date").
Subject to the provisions of Article VII of this Agreement, the failure to
consummate the Closing on the date and time determined pursuant to this
Section 1.5 will not result in the termination of this Agreement and will not
relieve any Party of any obligation under this Agreement. Subject to the
satisfaction or waiver of all of the conditions set forth in Article VI of
this Agreement, and provided this Agreement has not theretofore been
terminated pursuant to its terms, on the Closing Date, the Company and
Merger Sub shall cause the Certificate of Merger to be
executed, acknowledged and filed with the Secretary of State of the State
of Delaware as provided in Sections 251 and 103 of the DGCL.

 

 

 1.6 Deliveries at Closing. At the Closing, each Party shall deliver or
cause to be delivered all of the certificates, instruments, and other
documents required to be delivered by such Party pursuant to Article VI.

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

 

 

 

 1.7 Lock-Up Agreement. At the Closing, BRPA and the Company Stockholders
listed on Schedule 1.7 of the Company Schedules (the "Lock-Up
Stockholders") shall enter into an agreement which shall provide that the
Lock-Up Stockholders shall not transfer the shares of BRPA Common
Stock received hereunder as Per Share Merger Consideration except
to Permitted Transferees, until the earlier of (a) the six-month anniversary
of the Closing Date, (b) with respect to 50% of the shares of BRPA Common
Stock issued to the Lock-Up Stockholders, the date on which the closing price
of the BRPA Common Stock equals or exceeds $12.00 per share (as adjusted for
stock splits, stock dividends, reorganizations, recapitalizations and the
like) for any 20 trading days within any 30-trading day period commencing
after the Closing Date, and (c) the date after the Closing on which BRPA
consummates a liquidation, merger, stock exchange or other similar
transaction which results in all of BRPA's stockholders having the right to
exchange their BRPA Common Stock for cash, securities or other property. The
book entry positions or certificates evidencing shares of BRPA Common
Stock issued to the Lock-Up Stockholders hereunder will each
include prominent disclosure or bear a prominent legend evidencing the
fact that such shares are subject to the foregoing transfer restrictions.

 

 

 1.8 Earnout.

 

 

 (a) Earnout Shares Milestone. If, prior to December 31, 2022, (1) the
COVID-19 Drug receives emergency use authorization by the FDA and (2) the
Company submits and FDA files for review a new drug application for the
Company COVID-19 Drug (the occurrence of the foregoing, the "Earnout
Shares Milestone"), then BRPA shall issue, in accordance with Section
1.8(c) and subject to the terms and conditions set forth herein, to each
holder of Company Common Stock outstanding immediately prior to the Effective
Time (including the holders of shares of Company Common Stock resulting from
the Preferred Stock Conversion), a number of shares of BRPA Common Stock
equal to such holder's Earnout Pro Rata Portion multiplied by twenty-five
million (25,000,000) shares of BRPA Common Stock (the aggregate number
of such shares being referred to as the "Earnout Shares").

 

 

 (b) Earnout Cash Milestone. Upon the earlier to occur of (1) FDA approval
of the Company COVID-19 Drug and the listing of the Company COVID-19 Drug in
the FDA's "Orange Book" and (2) FDA approval of the Company Antidepressant
Drug Regimen and the listing of the Company Antidepressant Drug Regimen in
the FDA's "Orange Book", in each case prior to December 31, 2022
(the occurrence of either of clauses (1) or (2), the "Earnout
Cash Milestone"), BRPA shall deliver, in accordance with Section 1.8(c) and
subject to the terms and conditions set forth herein, to each holder of
Company Common Stock outstanding immediately prior to the Effective Time
(including the holders of shares of Company Common Stock resulting from
the Preferred Stock Conversion), an amount of cash equal to such holder's
Earnout Pro Rata Portion multiplied by one hundred million
dollars ($100,000,000) (the aggregate amount of such cash being referred
to as the "Earnout Cash", and together with the Earnout Shares, the
"Earnout Consideration").

 

 

 

 

 

 

 

 

8

 

 

 

 

 

 

 

 

 

 

 

 (c) BRPA's obligation to issue the Earnout Shares is solely conditioned
upon and contingent on the occurrence of the Earnout Share Milestone and not
conditioned upon or contingent on the occurrence of the Earnout Cash
Milestone; BRPA's obligation to deliver the Earnout Cash is solely
conditioned upon and contingent on the occurrence of the Earnout Cash
Milestone and not conditioned upon or contingent on the occurrence of the
Earnout Share Milestone. Within five (5) Business Days after the occurrence
of the Earnout Shares Milestone, BRPA shall deliver the Earnout Shares to the
Exchange Agent for distribution to the Company Stockholders entitled to
receive the Earnout Shares pursuant to Section 1.8(a) which shall be
distributed promptly to such Company Stockholders in accordance with the
Letters of Transmittal with no action required on the part of the
Company Stockholders. Following the occurrence of the Earnout Cash Milestone
and on a date that the BRPA Board reasonably determines in good faith to pay
the Earnout Cash, BRPA shall deliver the Earnout Cash to the Exchange Agent
for distribution to the Company Stockholders entitled to receive the Earnout
Cash pursuant to Section 1.8(b) which shall be distributed promptly to such
Company Stockholders in accordance with the Letters of Transmittal with no
action required on the part of the Company Stockholders. The Parties
understand and agree that (i) the right to receive any Earnout Shares or
Earnout Cash pursuant to the terms of this Agreement is a contingent right
that is not transferable except by operation of Legal Requirements relating
to descent and distribution, divorce and community property, and such
contingent right does not constitute an equity or ownership interest in
BRPA, and (ii) no Company Stockholder shall have any rights as a stockholder
of BRPA solely as a result of such Company Stockholder's contingent right to
receive Earnout Shares pursuant to the terms of this Agreement

 

 

 1.9 Sponsor Agreement

 

 

 . On or prior to the Closing Date, BRPA, the Sponsor, and BRAC shall
enter into an agreement in a form and on terms and conditions
reasonably acceptable to the Company (the "Sponsor Agreement") providing
that, immediately prior to the Effective Time:

 

 

 (a) the Sponsor and BRAC will forfeit, and BRPA will terminate and
cancel: (i) an aggregate of 875,000 shares of BRPA Common Stock
(the "Initial Forfeited Shares") and (ii) one share of BRPA Common Stock
for each share of BRPA Common Stock validly redeemed by BRPA Stockholders in
connection with the Offer, up to a maximum of 300,000 shares of BRPA Common
Stock (the "Additional Forfeited Shares," and together with the Initial
Forfeited Shares, the "Forfeited Shares"); and

 

 

 (b) subject an aggregate of 125,000 shares of BRPA Common Stock owned
by Sponsor to escrow (the "Sponsor Earnout Shares"), which Sponsor Earnout
Shares shall either be released from escrow to the Sponsor upon the
achievement of the Earnout Shares Milestone or terminated and cancelled by
BRPA on December 31, 2022 in the event that the Earnout Shares Milestone is
not achieved.

 

 

 

 

 

 

 

 

9

 

 

 

 

 

 

 

 

 

 

 

 1.10 Amendment to Stock Escrow Agreement. On or prior to the Closing Date,
BRPA, Sponsor, BRAC, Graubard Miller and Continental shall enter into an
amendment ("Stock Escrow Amendment") to that certain escrow agreement entered
into between Continental, BRPA, BRAC, Graubard Miller and the Sponsor on
November 20, 2017 (as amended by that certain letter agreement dated November
17, 2018, "Stock Escrow Agreement"), providing: (a) for the forfeiture
and cancellation of the Forfeited Shares, (b) that the Sponsor
Earnout Shares shall be subject to escrow pursuant to the Sponsor
Agreement and the terms of Section 1.9(b), (c) that the 40,000 shares of
BRPA Common Stock held by Graubard Miller shall be released from escrow and
(d) that all remaining shares of BRPA Common Stock held in escrow
thereunder will be released from escrow on the earlier of (i) the six-
month anniversary of the Closing Date, (ii) with respect to 50% of
the shares of BRPA Common Stock, the date on which the closing price of the
BRPA Common Stock equals or exceeds $12.00 per share (as adjusted for stock
splits, stock dividends, reorganizations, recapitalizations and the like) for
any 20 trading days within any 30-trading day period commencing after the
Closing Date, and (iii) the date after the Closing on which BRPA consummates
a liquidation, merger, stock exchange or other similar transaction which
results in all of BRPA's stockholders having the right to exchange their BRPA
Common Stock for cash, securities or other property.

 

 

 1.11 Amendment to BCMA. On or prior to the Closing Date, BRPA and
EarlyBirdCapital, Inc. ("EBC") shall enter into an amendment ("BCMA
Amendment Agreement") to that certain Business Combination Marketing
Agreement, dated as of November 20, 2017, between BRPA and EBC ("BCMA"). The
BCMA Amendment Agreement will provide that (a) in lieu of the Fee (as such
term is defined in the BCMA), BRPA shall issue to EBC at the Effective
Time an aggregate of 200,000 shares of BRPA Common Stock and (b) the BCMA
(as amended by the BCMA Amendment Agreement) shall terminate immediately
following the Effective Time.

 

 

 1.12 Amendment to BRPA Loan Agreements. On or prior to the Closing Date,
BRPA, Sponsor, and the BRPA Lenders shall enter into an omnibus amendment to
each outstanding promissory note or other BRPA Borrowing with BRPA as maker
(including, for the avoidance of doubt, BRPA Borrowings entered into during
the Interim Period in accordance with Section 5.12) in a form and on terms
and conditions reasonably acceptable to the Company ("Note Amendment"),
providing that the outstanding principal and accrued unpaid interest pursuant
to such promissory notes, after any repayments permitted pursuant to Section
5.13(e), shall be converted into convertible notes of BRPA with an
aggregate principal amount of no more than $3,000,000, which bear interest
at three percent (3%) per annum, may be converted from time to time, at the
holder's option, into shares of BRPA Common Stock at a price of $10.00 per
share, and which mature on the date that is twenty-four (24) months after the
Closing Date. The maximum amount of all BRPA Borrowings outstanding as of the
Closing Date (including for the avoidance of doubt borrowings pursuant
to Section 5.12) shall not exceed $3,000,000 and all such BRPA Borrowings in
excess of $3,000,000 will be forgiven or discharged prior to the
Closing Date.

 

 

 1.13 Registration Rights Agreement. On or prior to the Closing Date,
BRPA, the Company, certain BRPA Stockholders and certain
Company Stockholders who will receive BRPA Common Stock pursuant to
Article I, shall enter into a registration rights agreement to be
mutually agreed to between the parties thereto (the "Registration
Rights Agreement").

 

 

 

 

 

 

 

 

10

 

 

 

 

 

 

 

 

 

 

 

 1.14 Taking of Necessary Action; Further Action. If, at any time after the
Closing, any further action is necessary or desirable to carry out the
purposes of this Agreement, the officers and directors of BRPA and the
Surviving Corporation shall take all such lawful and necessary action.

 

 

 1.15 Tax Consequences. It is intended by the Parties that the Merger shall
constitute a reorganization within the meaning of Section 368 of the Code.
The Parties adopt this Agreement as a "plan of reorganization" within
the meaning of U.S. Income Tax Regulations Sections 1.368-2(g)
and 1.368-3(a).

 

 

 1.16 Payment of Expenses.

 

 

 (a) No sooner than five (5) nor later than two (2) Business Days prior
to the Closing Date, the Company shall provide to BRPA a written report
setting forth a list of all of the following fees and expenses incurred by or
on behalf of the Company in connection with the preparation, negotiation and
execution of this Agreement and the consummation of the Transactions
(together with written invoices and wire transfer instructions for the
payment thereof), solely to the extent such fees and expenses are incurred
and expected to remain unpaid as of the close of business on the Business
Day immediately preceding the Closing Date: (i) the fees and disbursements of
outside counsel to the Company incurred in connection with the Transactions
and (ii) the fees and expenses of any other agents, advisors, consultants,
experts, financial advisors and other service providers engaged by the
Company in connection with the Transactions (collectively,
the "Outstanding Company Transaction Expenses"). On the Closing Date,
following the Closing, BRPA shall pay or cause to be paid, by wire transfer
of immediately available funds, all such Outstanding Company Transaction
Expenses.

 

 

 (b) No sooner than five (5) nor later than two (2) Business Days prior
to the Closing Date, BRPA shall provide to the Company a written report
setting forth a list of all fees, expenses and disbursements incurred by or
on behalf of BRPA or Merger Sub for outside counsel, agents, advisors,
consultants, experts, financial advisors and other service providers engaged
by or on behalf of BRPA or Merger Sub in connection with the Transactions or
otherwise in connection with BRPA's operations (together with written
invoices and wire transfer instructions for the payment thereof)
(collectively, the "Outstanding BRPA Transaction Expenses"). On the Closing
Date, BRPA shall pay or cause to be paid, by wire transfer of immediately
available funds, all such Outstanding BRPA Transaction Expenses.

 

 

 1.17 Dissenting Shares. Notwithstanding anything in this Agreement to the
contrary, shares of Company Stock outstanding immediately prior to the
Effective Time and owned by a Company Stockholder who is entitled to demand
and has properly demanded appraisal for such shares in accordance with, and
who complies in all respects with, Section 262 of the DGCL (such shares,
"Dissenting Shares"), shall not be converted into the right to receive the
Per Share Merger Consideration and shall instead represent the right to
receive payment of the fair value of such Dissenting Shares in accordance
with and to the extent provided by Section 262 of the DGCL. At the Effective
Time, (i) all Dissenting Shares shall be cancelled, extinguished and cease
to exist and (ii) the holders of Dissenting Shares shall be entitled to only
such rights as may be granted to him, her or it under the DGCL. If any such
Company Stockholder fails to perfect or otherwise waives, withdraws or loses
such Company Stockholder's right to appraisal under Section 262 of the DGCL
or other applicable Legal Requirements, then the right of such holder to be
paid the fair value of such Dissenting Shares shall cease and
such Dissenting Shares shall be deemed to have been converted, as of
the Effective Time, into and shall be exchangeable solely for the right to
receive the Per Share Merger Consideration in accordance with this Article I.
The Company shall give BRPA prompt notice (and in any event within two (2)
Business Days) of any demands received by the Company for appraisal of shares
of Company Stock, attempted withdrawals of such demands and any other
instruments served pursuant to the DGCL and received by the Company relating
to rights to be paid the fair value of Dissenting Shares, and BRPA shall
have the right to participate in and direct all negotiations and proceedings
with respect to such demands. Prior to the Effective Time, the Company shall
not, except with the prior written consent of BRPA, make any payment with
respect to, or settle or compromise or offer to settle or compromise, any
such demands or waive any failure to timely deliver a written demand for
appraisal or otherwise comply with the provisions under Section 262 of
the DGCL, or agree or commit to do any of the foregoing.

 

 

 

 

 

 

 

 

11

 

 

 

 

 

 

 

 

 

 

 

  ARTICLE II

 

 

 REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

 

 Except as set forth in the Company's disclosure letter delivered by the
Company to BRPA and Merger Sub in connection with this Agreement (the
"Company Schedules") (each Schedule of which qualifies (a) the
correspondingly numbered representation, warranty or covenant specified
therein and (b) such other representations, warranties or covenants where its
relevance as an exception to (or disclosure for purposes of) such
other representation, warranty or covenant is reasonably apparent on
its face or cross-referenced), the Company hereby represents and warrants to
BRPA as follows:

 

 

 2.1 Organization and Qualification.

 

 

 (a) The Company is a corporation, duly incorporated validly existing and
in good standing under the laws of the State of Delaware, and has
the requisite corporate power and authority to own, lease, and operate its
assets and properties and to carry on its business as it is now being
conducted. The Company is in possession of all franchises, grants,
authorizations, licenses, permits, easements, consents, certificates,
approvals and orders of or from any Governmental Entity
("Approvals") necessary to own, lease, and operate the properties it purports
to own, operate, or lease and to carry on its business as it is now being
conducted. Complete and correct copies of the Charter Documents of the
Company, as amended and currently in effect, have been made available to BRPA
or BRPA's counsel.

 

 

 (b) The Company is duly qualified or licensed to do business as a
foreign corporation and is in good standing in each jurisdiction where
the character of the properties owned, leased, or operated by it or
the nature of its activities makes such qualification or
licensing necessary. Each jurisdiction in which the Company is so
qualified or licensed is listed in Schedule 2.1(b) of the
Company Schedules.

 

 

 2.2 Subsidiaries.

 

 

 (a) The Company has no direct or indirect Subsidiaries other than
those listed in Schedule 2.2 of the Company Schedules. Except as set forth
in Schedule 2.2 of the Company Schedules, the Company owns all of the
outstanding equity securities of the Subsidiaries, free and clear of all
Liens other than Permitted Liens, either directly or indirectly through one
or more other Subsidiaries. Except with respect to the Subsidiaries, the
Company does not own, directly or indirectly, any equity or voting interest
in any Person and does not have any agreement or commitment to purchase any
such interest, and has not agreed and is not obligated to make nor is bound
by any written or oral agreement, contract, subcontract, lease, binding
understanding, instrument, note, option, warranty, purchase order, license,
sublicense, insurance policy, benefit plan, commitment or undertaking of any
nature, as of the date hereof or as may hereafter be in effect, under which
it may become obligated to make any future investment in or capital
contribution to any other entity.

 

 

 

 

 

 

 

 

12

 

 

 

 

 

 

 

 

 

 

 

 (b) Each Subsidiary that is a corporation is duly incorporated,
validly existing and in good standing (or the equivalent thereof) under
the laws of its jurisdiction of incorporation (as listed
in Schedule 2.2 of the Company Schedules) and has the requisite corporate
power and authority to own, lease, and operate its assets and properties and
to carry on its business as it is now being conducted. Each Subsidiary that
is a limited liability company is duly organized or formed, validly existing,
and in good standing (or the equivalent thereof) under the laws of
its jurisdiction of organization or formation (as listed
in Schedule 2.2 of the Company Schedules) and has the requisite limited
liability company power and authority to own, lease and operate its assets
and properties and to carry on its business as it is now being conducted.
Each Subsidiary is in possession of all Approvals necessary to own, lease,
and operate the properties it purports to own, operate, or lease and to
carry on its business as it is now being conducted. Complete and
correct copies of the Charter Documents of each Subsidiary, as amended
and currently in effect, have been made available to BRPA or BRPA's counsel.

 

 

 (c) Each Subsidiary is duly qualified or licensed to do business as
a foreign corporation or foreign limited liability company and is in good
standing in each jurisdiction where the character of the properties owned,
leased, or operated by it or the nature of its activities makes such
qualification or licensing necessary.

 

 

 2.3 Capitalization.

 

 

 (a) The authorized capital stock of the Company as of the date of
this Agreement is as set forth on Schedule 2.3(a) of the Company
Schedules. Schedule 2.3(a) of the Company Schedules sets forth the issued
and outstanding Company Common Stock, Company Preferred Stock, Company
Warrants, and Company Stock Options, each holder thereof and the number and
type of securities beneficially held by each such Person, and each option,
warrant, purchase right, conversion, right, exchange right, or other Company
Contract exercisable for, exchangeable for, or convertible into
capital stock of the Company and the holders thereof as of the date of
this Agreement. All of the foregoing issued and outstanding equity interests
of the Company have been duly authorized, are validly issued, free and clear
of all Liens, in compliance in all respects with all Legal Requirements,
fully paid and non-assessable, have not been issued in violation of any
preemptive or subscription rights, and are not subject to any preemptive or
subscription rights that will survive the Closing Date. As of the date of
this Agreement, the Company has no issued or outstanding equity interests
other than the equity interests that are set forth on Schedule 2.3(a) of the
Company Schedules, and the Company does not hold any equity interests in its
treasury. All shares of Company Common Stock subject to issuance, upon
issuance on the terms and conditions specified in the instrument pursuant
to which they are issuable, will be duly authorized, validly issued, fully
paid, and nonassessable, free and clear of all Liens, and will have not been
issued in violation of any preemptive or subscription rights, and are not
subject to any preemptive or subscription rights that will survive the
Closing Date. All outstanding shares of Company Common Stock, Company
Preferred Stock and Company Warrants have been issued and granted in
compliance with (x) all applicable securities laws and (in all
material respects) other applicable Legal Requirements, and (y)
all requirements set forth in any applicable Company Contracts and Charter
Documents.

 

 

 

 

 

 

 

 

13

 

 

 

 

 

 

 

 

 

 

 

 (b) The shares of Company Common Stock and Company Preferred Stock are
the only outstanding classes of voting equity of the Company. The Company
Stockholders hold all of the outstanding Company Common Stock and Company
Preferred Stock.

 

 

 (c) Except as provided for in this Agreement or as set forth
on Schedule 2.3(c) of the Company Schedules, there are no subscriptions,
options, warrants, convertible notes, derivative securities, equity
securities, or other ownership interests, calls, rights (including
preemptive rights), commitments or agreements of any character to which
the Company is a party or by which it is bound obligating the Company to
issue, deliver, or sell, or cause to be issued, delivered, or sold, or
repurchase, redeem, or otherwise acquire, or cause the repurchase,
redemption, or acquisition of, any shares of capital stock or other ownership
interests of the Company or obligating the Company to grant, extend,
accelerate the vesting of, or enter into any such subscription, option,
warrant, equity security, call, right, commitment or agreement.

 

 

 (d) Except as set forth on Schedule 2.3(d) of the Company Schedules,
neither the Company nor any Subsidiary has any outstanding bonds,
debentures, notes or other obligations the holders of which have the right
to vote (or which are convertible into or exercisable or exchangeable for
securities having the right to vote) with the Company Stockholders on any
matter.

 

 

 (e) Except as contemplated by this Agreement or as set forth
on Schedule 2.3(e) of the Company Schedules, there are no registration
rights, and there is no voting trust, proxy, rights plan, anti-takeover plan,
or other agreements or understandings, to which the Company is a party or by
which the Company is bound with respect to any equity security of
the Company.

 

 

 (f) Except as contemplated by this Agreement, as a result of the
consummation of the Transactions, no shares of capital stock, warrants,
options, or other securities of the Company are issuable and no rights
in connection with any shares, warrants, options or other securities of the
Company accelerate or otherwise become triggered (whether as to vesting,
exercisability, convertibility, or otherwise).

 

 

 (g) Other than unvested Company Stock Options, no outstanding securities
of the Company are unvested or subjected to a repurchase option, risk of
forfeiture, or other condition under any applicable agreement with the
Company. Each outstanding Company Stock Option was granted at fair market
value on the date of grant.

 

 

 2.4 Authority Relative to this Agreement. The Company has all requisite
power and authority to enter into this Agreement and each Ancillary Agreement
to which the Company is (or with respect to Ancillary Agreements to be
entered into at or prior to the Closing, will be) a party and, subject to the
receipt of the Company Stockholder Approval, to consummate the Merger.
The execution and delivery of this Agreement and each Ancillary Agreement by
the Company has been (or with respect to Ancillary Agreements to be entered
into at the Closing, will be) duly authorized by all necessary corporate
action on the part of the Company, subject to the receipt of the Company
Stockholder Approval. This Agreement and each Ancillary Agreement to which
the Company is (or with respect to Ancillary Agreements to be entered into
at or prior to the Closing, will be) a party (a) has been (or, in the case of
Ancillary Agreements to be entered into at or prior to the Closing, will be
when executed and delivered) duly executed and delivered by the Company and
(b) assuming due authorization, execution and delivery thereof by each other
party hereto and thereto, is (or, in the case of Ancillary Agreements to be
entered into at the Closing, will be when executed and
delivered) enforceable against the Company in accordance with its
terms, except as may be limited by bankruptcy, insolvency, reorganization or
other similar laws affecting the enforcement of creditors' rights generally
and by general principles of equity.

 

 

 

 

 

 

 

 

 

 

14

 

 

 

 

 

 

 

 

 

 

 

 2.5 No Conflict; Required Filings and Consents. Except as set forth in
Schedule 2.5 of the Company Schedules:

 

 

 (a) The execution and delivery of this Agreement by the Company do not,
and the performance of this Agreement by the Company shall not, (i) conflict
with or violate the Charter Documents of the Company or any of its
Subsidiaries, or any of the Company Stockholder Agreements, (ii) to the
knowledge of the Company, conflict with or violate any applicable
Legal Requirements, (iii) result in any breach of or constitute a
default (or an event that with notice or lapse of time or both would
become a default) under, or materially impair the Company's or any of its
Subsidiaries' rights or alter the rights or obligations of any third party
under, or give to others any rights of termination, amendment, acceleration
or cancellation of, or result in the creation of a Lien on any of the
properties or assets of the Company or any of its Subsidiaries (other than
Permitted Liens) pursuant to, any Company Contracts, or (iv) result in
the triggering, acceleration or increase of any payment to any
Person pursuant to any Company Contract, including any "change in control"
or similar provision of any Company Contract; except, with respect to clauses
(ii), (iii) and (iv), for any such conflicts, violations, breaches,
defaults, impairments, alterations, triggerings, accelerations, increases
or other occurrences that would not, individually or in the aggregate, have
a Company Material Adverse Effect.

 

 

 (b) The execution and delivery of this Agreement by the Company does
not, and the performance of its obligations hereunder will not, require any
consent, approval, authorization or permit of, or filing with or notification
to, any Governmental Entity or other third party (including, without
limitation, lenders and lessors), except (i) the filing of any notifications
required under the HSR Act and the expiration of the required waiting period
thereunder, (ii) applicable requirements of the Securities Act, Exchange Act,
state securities laws, or Nasdaq, and the rules and regulations thereunder,
(iii) the consents, approvals, authorizations, and permits described
in Schedule 2.5(b) of the Company Schedules, and (iv) where the failure to
obtain such consents, approvals, authorizations, or permits, or to make such
filings or notifications, would not prevent the consummation of the Merger
or otherwise prevent the Company from performing its material obligations
under this Agreement on a timely basis.

 

 

 (c) No "fair price," "moratorium," "control share acquisition,"
"supermajority," "affiliate transactions," "business combination," or other
similar anti-takeover statute or regulation enacted under any federal, state,
local, or foreign laws applicable to the Company is applicable to this
Agreement, the Merger, or any of the other Transactions.

 

 

 2.6 Compliance. To the knowledge of the Company, the Company and each of
its Subsidiaries has materially complied with all, and is not in material
violation of any, and is conducting its business in material compliance with
all, applicable Legal Requirements. Neither the Company nor any of its
Subsidiaries is in default or violation of any term, condition or provision
of any applicable Charter Documents. No written notice of non-compliance with
any applicable Legal Requirements has been received by the Company or any of
its Subsidiaries (and the Company has no knowledge of any such notice
delivered to any other Person).

 

 

 

 

 

 

 

 

15

 

 

 

 

 

 

 

 

 

 

 

 2.7 Permits. (i) To the knowledge of the Company, the Company and
each Subsidiary, as applicable, collectively hold all permits necessary to
lawfully conduct the business of the Company and each Subsidiary as presently
conducted, or as currently contemplated, and to own, lease and operate its
assets and properties, including permits, approvals, clearances,
registrations, and listings required by any Governmental Entity, including
the FDA, or pursuant to any Health Care Regulatory Law (collectively, the
"Permits"), (ii) all such Permits are in full force and effect, and no
suspension or cancellation of any of the Permits is pending or, to
the Company's knowledge, threatened, and (iii) all Permits are renewable by
their terms in the ordinary course of business. The Company has made
available to BRPA or BRPA's counsel true, correct and complete copies of all
material Permits. Neither the Company nor any Subsidiary, as applicable, is
in material violation of the terms of any Permit. To the knowledge of the
Company, no event has occurred and is continuing which requires or permits,
or after notice or lapse of time or both would require or permit,
any modification or termination of any such Permits.

 

 

 2.8 Financial Matters.

 

 

 (a) Financial Statements. BRPA or its counsel has been furnished with each
of the following:

 

 

 (i) the audited and consolidated balance sheets of the Company as
of December 31, 2018 and 2019 and the related audited
consolidated statements of income, cash flow and changes in
stockholders' equity of the Company for the fiscal years then ended,
accompanied by any notes thereto (collectively, the "Company Annual
Financial Statements"); and

 

 

 (ii)  the unaudited consolidated balance sheet of the Company for
the three and nine month period ended as of September 30, 2020 (the "Most
Recent Balance Sheet" and the date thereof, the "Most Recent Balance
Sheet Date") and the related unaudited consolidated statement of income of
the Company for the quarter then ended (the "Company Interim Financial
Statements" and, together with the Company Annual Financial Statements, the
"Company Financial Statements").

 

 

 (b) Compliance with U.S. GAAP. The Company Financial Statements (including
any notes thereto) (i) accurately reflect in all material respects, (ii) have
been prepared, in all material respects, in accordance with U.S.
GAAP consistently applied, and (iii) fairly present, in all material
respects, the consolidated financial position and results of operations of
the Company and each of its Subsidiaries on the dates and for the periods
specified therein, all in accordance with U.S. GAAP (subject, in the case of
the Company Interim Financial Statements, to the absence of statements of
cash flows and shareholders' equity and footnotes and, in each case,
to normal year-end audit adjustments which are not expected to be material).
The Company and its Subsidiaries have never been subject to the reporting
requirements of Sections 13(a) and 15(d) of the Securities Exchange Act of
1934, as amended ("Exchange Act").

 

 

 

 

 

 

 

 

 

 

16

 

 

 

 

 

 

 

 

 

 

 

 (c) Absence of Undisclosed Liabilities. There is no liability, debt or
obligation against the Company or its Subsidiaries that would be required to
be set forth or reserved for on a balance sheet of the Company and its
Subsidiaries (and the notes thereto) prepared in accordance with U.S. GAAP
and in accordance with past practice, except for liabilities and obligations
(i) reflected or reserved for Most Recent Balance Sheet or disclosed in the
notes thereto, (ii) that have arisen since the date of the Most Recent
Balance Sheet in the ordinary course of the operation of business of the
Company and its Subsidiaries, (iii) disclosed in the Company Schedules
(including Section 2.8(c) of the Company Schedules), (iv) arising under
this Agreement or the performance by the Company of its obligations
hereunder, or (v) that would not, individually or in the aggregate,
reasonably be expected to be material to the Company and its Subsidiaries,
taken as a whole.

 

 

 (d) Controls. The Company has established and maintained a system of
internal accounting controls. Such internal controls are sufficient
to provide reasonable assurance regarding the reliability of the Company's
financial reporting and the preparation of the Company Financial Statements
for external purposes in accordance with U.S. GAAP.

 

 

 (e) Auditor. To the Company's knowledge, the auditor engaged by
the Company with respect to the Company Financial Statements has at
all required times since the date of the Sarbanes-Oxley Act been: (i)
a registered public accounting firm (as defined in Section 2(a)(12) of the
Sarbanes-Oxley Act); (ii) "independent" with respect to the Company within
the meaning of Regulation S-X under the Exchange Act; and (iii) in compliance
with subsections (g) through (l) of Section 10A of the Exchange Act and the
rules and regulations promulgated by the SEC and the Public
Company Accounting Oversight Board thereunder.

 

 

 (f) CARES Act. Schedule 2.8(f) of the Company Schedules sets forth all
Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act")
stimulus fund programs in which the Company or its Subsidiaries are
participating and the amount of funds received and/or requested for each
such program (the "Stimulus Funds"). The Company and each Subsidiary have
maintained accounting records associated with the Stimulus Funds in
compliance with applicable Legal Requirements and related guidance. The
Company and each Subsidiary have used reasonable best efforts to utilize all
such Stimulus Funds received in accordance with all applicable
Legal Requirements.

 

 

 (g) Off-Balance Sheet Arrangements. Except as set forth in Schedule
2.8(g) of the Company Schedules, neither the Company nor any Subsidiary has
entered into any material off-balance sheet transactions.

 

 

 2.9 Absence of Certain Developments. From the Most Recent Balance Sheet
Date to the date hereof, (a) there has not been a Company Material Adverse
Effect, (b) the business of the Company and its Subsidiaries has been
conducted in the ordinary course of business (aside from steps taken in
contemplation of the Merger), and (c) neither the Company nor its
Subsidiaries has taken any action that would have required the prior written
consent of BRPA under Section 4.1 if such action had been taken during the
Interim Period.

 

 

 

 

 

 

 

 

17

 

 

 

 

 

 

 

 

 

 

 

 2.10 Condition and Sufficiency of Assets. The Company or one of its
Subsidiaries has good and valid title to, or a valid leasehold interest in,
or adequate rights to use, all buildings, machinery, equipment, and other
tangible assets which are necessary for the conduct of its or their business
as currently conducted and are shown on the Interim Financial Statement or
acquired after the Most Recent Balance Sheet Date (the "Assets"). The Assets
are free and clear of all Liens, except for Permitted Liens, except
for Assets disposed of in the ordinary course of business since the Most
Recent Balance Sheet Date and except in the case of any non-owned Asset, for
Liens contained in the Company Contract to use such Asset. Each Asset has
been maintained in the ordinary course of business, is in good operating
condition, subject to normal wear and tear, and is suitable for the purposes
for which it is currently used.

 

 

 2.11 Litigation. Except as set forth in Schedule 2.11 of the
Company Schedules, there are no claims, suits, actions or
proceedings pending or, to the Company's knowledge, threatened against the
Company or any of its Subsidiaries before any court, governmental department,
commission, agency, instrumentality or authority, or any arbitrator, in each
case that would, individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect.

 

 

 2.12 Employee Benefit Plans.

 

 

 (a) Schedule 2.12(a) of the Company Schedules lists all material Plans.
"Plan" means any "employee benefit plan" as defined in Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended ("ERISA"), any
plan, fund (including any superannuation fund, or other similar program or
arrangement established or maintained outside of the United States primarily
for the benefit of employees residing outside of the United States), and any
other material employee compensation, deferred compensation, incentive,
severance, change in control, retirement, death, disability, medical, or
employee benefit plan, program, policy or other arrangement covering
any active or former employee, director or consultant of the Company or any
Subsidiary, in each case, with respect to which the Company or any Subsidiary
has liability, other than (i) standard employment or consulting agreements
that can be terminated at any time without severance or termination pay and
upon notice of not more than 60 calendar days or such longer period as may be
required by Legal Requirements, (ii) any plan, program, policy or other
arrangement that is sponsored or maintained by a Governmental Entity or (iii)
any plan, program, policy or other arrangement that covers only
former directors, officers, employees, independent contractors and
service providers and with respect to which the Company and the Subsidiaries
have no remaining liabilities. All Plans have been maintained and
administered in all material respects in compliance with their respective
terms and with the Legal Requirements which are applicable to such Plans, and
all contributions required to be made with respect to the Plans as of the
date of this Agreement have been made or, if not yet due, are reflected in
the Company Financial Statements. Except as would not, individually or in
the aggregate, be material to the Company and its Subsidiaries, taken as a
whole, (x) no suit, action or other litigation (excluding claims for benefits
incurred in the ordinary course) has been brought, or, to the knowledge of
the Company, is threatened, against or with respect to any Plan and
(y) there are no audits, inquiries or proceedings pending or, to
the knowledge of the Company, threatened by any Governmental Entity with
respect to any Plan. Except as disclosed in Schedule 2.12(a) of the
Company Schedules, each Plan can be amended, terminated or
otherwise discontinued after the Closing in accordance with its
terms, without material liability to BRPA (other than
ordinary administration expenses and amounts payable for benefits
accrued but not yet paid).

 

 

 

 

 

 

 

 

18

 

 

 

 

 

 

 

 

 

 

 

 (b) Except as disclosed in Schedule 2.12(b) of the Company Schedules,
neither the execution and delivery of this Agreement nor the consummation of
the Transactions will (i) result in any payment (including severance, bonus
or otherwise) becoming due to any shareholder, director, officer or employee
of the Company or any Subsidiary under any Plan or otherwise, (ii) materially
increase any benefits otherwise payable under any Plan, or (iii) result
in the acceleration of the time of payment or vesting of any such benefits.

 

 

 (c) None of the Company, the Subsidiary, or any other Person that would
be considered a single employer with the Company or a Subsidiary under the
Code or ERISA sponsors or maintains a plan subject to Title IV of ERISA or
Code Section 412, or contributes to or is obligated to contribute to a
"multiemployer plan" as defined in Section 4001(a)(3) of ERISA

 

 

 2.13 Labor Matters.

 

 

 (a) Except as set forth in Schedule 2.13(a) of the Company Schedules,
neither the Company nor any Subsidiary is a party to any collective
bargaining agreement or other labor union contract applicable to individuals
employed by the Company or the Subsidiary, as applicable, nor does the
Company have knowledge of any activities or proceedings of any labor union to
organize any such employees. There are no material pending grievances or
similar proceedings involving the Company or its Subsidiaries and any of its
employees subject to a collective bargaining agreement or other labor union
contract, or any continuing obligations of the Company or any Subsidiary
pursuant to the resolution of any such proceeding that is no longer pending.
No work stoppage, slowdown, strike, or lockout with respect to any employees
of the Company or its Subsidiaries has occurred, is pending, or, to the
knowledge of the Company, is threatened.

 

 

 (b) Other than as set forth in Schedule 2.13(b) of the Company Schedules,
each employee of the Company and its Subsidiaries is terminable "at will"
subject to applicable severance entitlements or notice periods as set forth
by applicable Legal Requirement or in any applicable employment agreement,
and there are no agreements between the Company or any Subsidiary and any
of its employees that their employment will be for any particular period.

 

 

 (c) To the knowledge of the Company, none of the officers of the
Company or any of its Subsidiaries presently intends to terminate his or her
employment with the Company. The Company and its Subsidiaries are in
compliance in all material respects and, to the Company's knowledge, each of
its employees and consultants is in compliance in all material respects, with
the terms of the respective employment and consulting agreements between the
Company or Subsidiary, as applicable, and such individuals.

 

 

 (d) To the knowledge of the Company, the Company and each of
its Subsidiaries is in compliance in all material respects with all Legal
Requirements applicable to its employees, respecting hiring, employment,
termination of employment, employment practices, terms and conditions of
employment, employment discrimination, harassment, retaliation, reasonable
accommodation, wages and hours, and employee health and safety and is not
liable for any arrears of wages or penalties with respect thereto. All
amounts that the Company or any Subsidiary is legally or contractually
required either (x) to deduct from its employees' salaries or to transfer to
such employees' pension or provident, life insurance, incapacity
insurance, continuing education fund or other similar funds or (y) to
withhold from its employees' salaries and benefits and to pay to
any Governmental Entity as required by applicable Legal Requirements have,
in each case, been duly deducted, transferred, withheld and paid, and neither
the Company nor any Subsidiary have any material outstanding obligation to
make any such deduction, transfer, withholding or payment. There are no
pending, or to the Company's knowledge, threatened material claims or
actions against the Company or the Subsidiary by any employee in
connection with such employee's employment or termination of employment by
the Company or any Subsidiary.

 

 

 

 

 

 

 

 

19

 

 

 

 

 

 

 

 

 

 

 

 (e) Except as would not, individually or in the aggregate, be material to
the Company and its Subsidiaries, taken as a whole, no employee or former
employee of the Company or any Subsidiary is owed any wages, benefits or
other compensation for past services that has not yet been paid or reimbursed
(other than wages, benefits and compensation accrued in the ordinary course
of business during the current pay period and any accrued benefits for
services, which by their terms or under applicable Legal Requirements, are
payable in the future, such as accrued vacation, recreation leave
and severance pay).

 

 

 2.14 Restrictions on Business Activities. Except as disclosed in Schedule
2.14 of the Company Schedules, there is no agreement, commitment,
exclusive license, judgment, injunction, order or decree binding upon
the Company or its Subsidiaries or their respective assets or to which the
Company or any of its Subsidiaries is a party which has had or would
reasonably be expected to have the effect of prohibiting or materially
impairing any business practice of the Company or its Subsidiaries, any
acquisition of property by the Company or its Subsidiaries or the conduct of
business by the Company or its Subsidiaries as currently conducted.

 

 

 2.15 Title to Property.

 

 

 (a) Except as set forth in Schedule 2.15(a) of the Company Schedules,
neither the Company nor any Subsidiary owns or leases any real property and
there are no options or other contracts under which the Company or any
Subsidiary has a right or obligation to acquire or lease any interest in real
property.

 

 

 (b) All material personal property and other material property and
assets of the Company and its Subsidiaries owned, used or held for use
in connection with the business of the Company and its Subsidiaries (the
"Personal Property"), are shown or reflected on the Most Recent Balance
Sheet, to the extent required by U.S. GAAP applied on a consistent basis in
accordance with past practice, other than those entered into or acquired on
or after the Most Recent Balance Sheet Date in the ordinary course of
business. The Company and its Subsidiaries have good and marketable title
to the Personal Property owned by them, and all such Personal Property is in
each case held free and clear of all Liens, except for Permitted Liens. The
Personal Property is structurally sound, in good operating condition,
ordinary wear and tear excepted, and is suitable for the uses to which it is
being put.

 

 

 (c) All material leases pursuant to which the Company and/or one of
its Subsidiaries leases from others real property or Personal Property are
valid and effective in accordance with their respective terms, and there is
not, under any of such leases, any existing material default or event of
default of the Company or its Subsidiaries or, to the Company's knowledge,
any other party (or any event which with notice or lapse of time, or both,
would constitute a material default).

 

 

 (d) Each of the Company and its Subsidiaries is in possession of, or
has good and valid title to, or a valid leasehold interest in, or adequate
rights to, all properties, assets and rights (other than Intellectual
Property Rights, which are governed exclusively by Section 2.19) which are
necessary for the effective conduct of its business, as it is currently
operated and expected to be operated in the future. Each such property,
asset, and right is shown on the Most Recent Balance Sheet, has been
maintained in the ordinary course of business, is in good operating condition
subject to normal wear and tear, and is suitable for the purposes for which
it is currently used.

 

 

 

 

 

 

 

 

20

 

 

 

 

 

 

 

 

 

 

 

 2.16 Taxes. Except as set forth in Schedule 2.16 of the Company
Schedules:

 

 

 (a) The Company and its Subsidiaries have timely filed all
material returns, estimates, information statements and reports relating
to Taxes ("Returns") required to be filed by them with any Tax authority
prior to the date hereof (after giving effect to any valid extensions of time
in which to make such filings). All such Returns are true, correct
and complete in all material respects. The Company and its Subsidiaries have
paid all material amounts of Taxes shown to be due and payable on such
Returns.

 

 

 (b) All material amounts of Taxes that the Company and its Subsidiaries
are required by applicable Legal Requirements to withhold or collect have
been duly withheld or collected and have been timely paid over to the proper
Governmental Entity to the extent due and payable.

 

 

 (c) The Company and its Subsidiaries have not been delinquent in
the payment of any material amount of Tax nor is there any material
Tax deficiency outstanding, proposed or assessed by a taxing
authority against the Company or any of its Subsidiaries (other than
any deficiencies that have since been resolved), nor has the Company or any
of its Subsidiaries executed any unexpired waiver of any statute of
limitations on or extending the period for the assessment or collection of
any material amount of Tax.

 

 

 (d) No material audit or other examination of any Return of the Company
or any of its Subsidiaries by any Tax authority is presently in progress,
nor has the Company or any of its Subsidiaries been notified of any request
for such an audit or other examination.

 

 

 (e) No material adjustment relating to any Returns filed by the Company
or any of its Subsidiaries has been formally proposed by any Tax authority
to the Company or any of its Subsidiaries or any representative thereof.

 

 

 (f) Neither the Company nor any of its Subsidiaries has taken any action or
is aware of any fact or circumstance that, to the Company's knowledge, would
reasonably be expected to prevent or impede, the Merger from qualifying as a
reorganization governed by Section 368 of the Code.

 

 

 (h) Schedule 2.16(h) of the Company Schedules sets forth the total
amount of Taxes the payment of which has been deferred under the
authority of Section 2302 of the CARES Act.

 

 

 2.17 Environmental Matters. Except as would not reasonably be expected,
individually or in the aggregate, to result in a material liability of the
Company and its Subsidiaries, taken as a whole: (i) the Company and its
Subsidiaries have complied with applicable Environmental Laws; (ii) none of
the Company or its Subsidiaries or, the knowledge of the Company, any third
party has caused any properties currently owned, leased or operated by the
Company or its Subsidiaries to be contaminated with any Hazardous Substances;
(iii) the properties formerly owned, leased or operated by the Company or its
Subsidiaries were not contaminated with Hazardous Substances during the
period of ownership, leasing or operation by the Company or its
Subsidiaries; (iv) as of the date hereof, none of the Company or its
Subsidiaries has received notice that it is potentially liable for any
Hazardous Substance disposal or contamination on any third party or
public property (whether above, on or below ground or in the atmosphere
or water); (v) as of the date hereof, none of the Company or
its Subsidiaries has received any written notice, demand, letter, claim or
request for information alleging that the Company or any Subsidiary may be in
material violation of or have material liability under any Environmental Law;
and (vi) none of the Company or its Subsidiaries is subject to any orders,
decrees, injunctions or other arrangements with any Governmental Entity or
subject to any contractual indemnity or other agreement with any third
party relating to a material liability under any Environmental
Law, including in relation to Hazardous Substances.

 

 

 

 

 

 

 

 

21

 

 

 

 

 

 

 

 

 

 

 

 2.18 Brokers. Except as set forth in Schedule 2.18 of the Company
Schedules, neither the Company nor any of its Subsidiaries has incurred, nor
will it incur, and has not entered into any contract, agreement,
understanding, arrangement, or commitment pursuant to which BRPA or the
Surviving Corporation, or any of its or their direct or in indirect
Subsidiaries, could incur, directly or indirectly, any liability for
brokerage, finders' fees, agent's commissions, or any similar charges in
connection with this Agreement or the Transactions.

 

 

 2.19 Intellectual Property.

 

 

 (a) Non-Infringement. Except as set forth on Schedule 2.19(a) of the
Company Schedules: (i) the use, practice or other exploitation of
the Company Intellectual Property owned, used, practiced or
otherwise commercially exploited by the Company or any Subsidiary, (ii)
the development, manufacturing, licensing, sublicensing,
marketing, importation, offer for sale, sale or use of any Company Product
as conducted and as proposed to be conducted, and (iii) any of the Company's
or its Subsidiaries' business practices and methods and proposed business
practices and methods, in each case, to the knowledge of the Company, (A)
have not infringed upon, misappropriated or otherwise constituted an
unauthorized use of or otherwise violated the Intellectual Property Rights of
any Person, (B) do not infringe upon, misappropriate, constitute
an unauthorized use of or otherwise violate the Intellectual Property Rights
of any Person, and (C) if any Company Products in development were to be
manufactured, licensed, marketed, imported, offered for sale, sold or used as
of the date hereof, would not infringe upon, misappropriate, constitute an
unauthorized use of or otherwise violate the Intellectual Property Rights of
any Person. Neither the Company nor any Subsidiary has received any
charge, complaint, claim, demand or notice alleging any
infringement, misappropriation, or violation of the Intellectual Property
Rights of any Person. Except as set forth on Schedule 2.19(a) of the
Company Schedules, (x) the Company IP Registrations are not the subject
of any challenge and (y) to the Company's knowledge, no Person is materially
infringing upon any of the Company Intellectual Property.

 

 

 (b) Scheduled Intellectual Property Rights. Schedule 2.19(b) of the
Company Schedules identifies all registered patents, trademarks,
and copyrights, and all applications, certificates, filings, provisionals,
or other documents relating to patents, trademarks, or copyrights, and domain
names owned by the Company or any Subsidiary (collectively, the "Company
IP Registrations"). Each of the Company IP Registrations is valid and
subsisting. The Company or one of its Subsidiaries exclusively owns and
possesses all right, title and interest in and to the Company IP
Registrations, free and clear of all Liens. All necessary fees and filings
with respect to any Company IP Registrations have been timely submitted to
the relevant intellectual property office or Governmental Entity and
Internet domain name registrars to maintain such Company IP Registration
in full force and effect. No issuance or registration obtained and
no application filed by the Company for any Company IP Registration has been
cancelled, abandoned, allowed to lapse or not renewed, except where the
Company has, in its reasonable business judgment, decided to cancel, abandon,
allow to lapse or not renew such issuance, registration or application and
where such decision would not have a Company Material Adverse Effect. There
are no pending proceedings by or before any Governmental Entity that relate
to the validity or enforceability of any of the Company IP
Registrations and, to the Company's knowledge, no such proceedings
are threatened by any Person. To the Company's knowledge, no current or
former officer, employee, or contractor of the Company or any Subsidiary has
misrepresented, or failed to disclose, and there have not been any
misrepresentations of or failures to disclose, any facts or circumstances in
any patent application for any Company IP Registrations that would constitute
fraud or a misrepresentation with respect to such patent application, or
that would otherwise affect the validity or enforceability of any Company IP
Registrations.

 

 

 

 

 

 

 

 

22

 

 

 

 

 

 

 

 

 

 

 

 (c) IP Contracts. Schedule 2.19(c) of the Company Schedules lists each
Company Contract (i) under which the Company or any of its Subsidiaries uses
or licenses Intellectual Property Rights that any third-party owns, other
than off-the-shelf software (the "Inbound IP Contracts") and (ii) under which
the Company or any Subsidiary has granted to any Person any right or interest
in any Company Intellectual Property, including settlement agreements and
covenants not to sue (the "Outbound IP Contracts", and together with the
Inbound IP Contracts, the "IP Contracts"). Except as set forth in Schedule
2.19(c) of the Company Schedules, neither the Company nor any Subsidiary is
(and with the passage of time, the giving of notice or both, will be)
required or obligated to make any payments by way of royalties, fees
or otherwise or provide any other consideration of any kind, to any owner or
licensor of, or other claimant to, any Intellectual Property Rights, or any
other Person, with respect to the use thereof or in connection with the
conduct of the business of the Company and its Subsidiaries as conducted or
proposed to be conducted (including the development, manufacturing,
licensing, sublicensing, marketing, importation, sale, offer for sale or
use, and future manufacturing, licensing, sublicensing,
marketing, importation, sale, offer for sale or use, of any Company
Products, including Company Products in development).

 

 

 (d) Company IP. Except as set forth on Schedule 2.19(d) of the
Company Schedules, the Company Intellectual Property includes all of
the Intellectual Property Rights used by the Company and each Subsidiary to
conduct its business and, to the Company's knowledge, includes all of the
Intellectual Property Rights used by the Company or any Subsidiary to conduct
its business in the manner proposed to be conducted (including the research,
manufacturing, licensing, marketing, importation, sale, offer for sale or use
and future research, manufacturing, licensing, marketing, importation, sale,
offer for sale or use, of any Company Product in development). Except as set
forth on Schedule 2.19(d) of the Company Schedules, the Company or a
Subsidiary (i) is the sole and exclusive owner of all right, title and
interest in and to or (ii) has valid, exclusive and continuing rights to
develop, manufacture, license, sublicense, market, import, sell, offer or use
as the case may be, the Company Intellectual Property, in each case, free
and clear of all Liens (other than Permitted Liens). No Company Intellectual
Property is subject to (i) any judicial or administrative action, suit,
litigation, arbitration, proceeding, Company Contract, or order of a
Governmental Entity that restricts the use, transfer or licensing thereof by
the Company or its Subsidiaries (other than restrictions contained in the IP
Contracts disclosed in Schedule 2.19(c) of the Company Schedules), or (ii)
which may affect the validity, use or enforceability of such Company
Intellectual Property.

 

 

 (e) Know-how. The Company and each Subsidiary, as appropriate, has
used reasonable best efforts to protect the secrecy and confidentiality of
all know-how included in the Intellectual Property Rights of the Company or
Subsidiary. To the Company's knowledge, neither the Company nor any of its
Subsidiaries has disclosed to any Person (including any employees,
contractors, and consultants) any such know-how except under a
confidentiality agreement or other legally binding confidentiality
obligation, and to the Company's knowledge, there has not been any breach by
any party to any such confidentiality agreement. The Company and each
Subsidiary has required all Persons (including any current or former
employees, contractors, and consultants) who create or develop or have
created or developed any material registered or applied for
Intellectual Property Rights for the benefit of the Company or such
Subsidiary to assign, and all such Persons have assigned, to the Company
or Subsidiary, as applicable, (by present assignment) all of such Person\'s
rights in such registered or applied for Intellectual Property Rights.

 

 

 

 

 

 

 

 

23

 

 

 

 

 

 

 

 

 

 

 

 (f) No Government or University Funding. Except as set forth in Schedule
2.19(f) of the Company Schedules, no (i) government funding or
governmental grants; (ii) facilities of a university, college, other
educational institution or research center; or (iii) funding from any
Person was used in the development of the Company Intellectual
Property. Except as set forth in Schedule 2.19(f) of the Company Schedules,
to the knowledge of the Company, no employee, consultant or independent
contractor of the Company who was involved in, or who contributed to, the
creation or development of any of the Company Intellectual Property, has
performed services for or otherwise was under restrictions resulting from
his/her relations with any government, university, college or other
educational institution or research center during a period of time during
which any of the Company Intellectual Property were created or during such
time that such employee, consultant or independent contractor was also
performing services for or for the benefit of the Company, nor has any such
person created or developed any of the Company Intellectual Property with any
governmental grant.

 

 

 (g) Data Privacy.

 

 

 (i) To the Company's knowledge, there has not been any "data breach" (as
defined by applicable Information Privacy and Security Laws), security
breach, "security incident" or "breach of unprotected health information" (as
such terms are defined by HIPAA), or material unauthorized access,
use, loss, disclosure, or publication of any Personal
Confidential Information or Protected Health Information owned,
used, maintained, received, or controlled by or on behalf of the Company or
any Subsidiary, including any unauthorized access, use, disclosure, or
publication of Personal Confidential Information or Protected Health
Information that would constitute a breach for which notification to
individuals and/or Governmental Entities is required under any applicable
Information Privacy and Security Laws to which the Company or such Subsidiary
is subject.

 

 

 (ii) The collection, maintenance, transmission, transfer, use,
disclosure, storage, disposal, and security of Personal
Confidential Information and Protected Health Information by the Company
and each Subsidiary has complied in all material respects with (i) HIPAA,
(ii) applicable Information Privacy and Security Laws, (iii) Material Company
Contracts that govern Personal Confidential Information or Protected Health
Information, and (iv) applicable privacy policies of the Company and each
Subsidiary. No judicial or administrative action, suit, litigation,
arbitration, proceeding is pending or, to the Company's knowledge, threatened
in writing against the Company or a Subsidiary relating to the Company's
or Subsidiary's non-compliance with Information Privacy and Security Laws or
laws concerning Protected Health Information.

 

 

 2.20 Product Warranties; Product Liability.

 

 

 (a) Neither the Company, any Subsidiary, nor, to the Company's
knowledge, any of its or their licensees, partners, collaborators or
joint venturers has developed, manufactured, commercialized,
produced, formulated, propagated, modified, customized,
processed, distributed or sold any Company Product that did not comply
with any express or implied warranty regarding such Company Product or that
contained any unintended Hazardous Substance or that was otherwise
adulterated, contaminated, mislabeled, defective, off-specification or
improperly packaged or transported.

 

 

 

 

 

 

 

 

24

 

 

 

 

 

 

 

 

 

 

 

 (b) To the extent any warranties are implied or imposed by any
Legal Requirements, no Company Product sold, distributed, delivered
or licensed by the Company, any Subsidiary, or any of its or
their licensees, partners, collaborators or joint venturers is subject
to any guaranty or warranty from or on behalf of the Company or
any Subsidiary. No claim has been made, or to the knowledge of the Company,
threatened against the Company or any Subsidiary by a customer or any other
Person alleging that (i) such Company Product (A) did not comply with any
express or implied warranty regarding such Company Product, (B) contained an
unintended Hazardous Substance, or (C) was otherwise contaminated,
adulterated, mislabeled, defective or improperly packaged or transported,
or (ii) the Company, any Subsidiary, or any licensee, partner, collaborator,
joint venturer, supplier, warehouse, distributor or seller of any Company
Product breached any duty to warn, test, inspect or instruct of the risks,
limitations, precautions or dangers related to the use, application, or
transport of any such Company Product.

 

 

 (c) Except as set forth in Schedule 2.20(c) of the Company Schedules,
there have been no recalls, market withdrawals or replacements (voluntary or
involuntary) with respect to any Company Product or any similar actions,
investigations, notices or threatened recalls by any Governmental Entity with
respect to any Company Product and, to the knowledge of the Company, no facts
or circumstances exist that are reasonably likely to (i) result in
the recall, market withdrawal or replacement of any Company Product sold or
intended to be sold, or (ii) cause, as a result of any regulatory action by
any Governmental Entity, (y) a material change in the labeling or packaging
of any Company Product or (z) a termination or suspension of the marketing,
distribution or sale of any Company Product.

 

 

 (d) Except as set forth in Schedule 2.20(d) of the Company Schedules, no
Person has claimed that the Company or any Subsidiary has committed any act,
or failed to commit any act, which would result in, and there has been no
occurrence which would reasonably give rise to, or form the basis of, whether
or not covered by insurance, any (i) product liability, (ii) liability for
injuries or damage to individuals or property (including without
limitation any crops, animals or livestock) or (iii) liability for
economic damages or losses.

 

 

 2.21 Agreements, Contracts and Commitments.

 

 

 (a) Schedule 2.21 of the Company Schedules sets forth a complete and
accurate list of all Material Company Contracts in effect on the date of this
Agreement, specifying the parties thereto. As used herein, the
term "Company Contracts" means all legally binding contracts, agreements,
leases, mortgages, indentures, notes, and bonds, whether written or oral, to
which the Company or any of its Subsidiaries is a party or by or to which
any of the properties or assets of the Company or any of its Subsidiaries
may be bound (including without limitation notes for borrowed money payable
to the Company or any of its Subsidiaries), and the term "Material
Company Contracts" means each of the following Company Contracts:

 

 

 (i) any Company Contract (or group of related Company Contracts) for
the sale of Company Products or for the purchase of products or services of
at least $1,000,000 per year or $1,000,000 in the aggregate;

 

 

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

 

 

 (ii)  any Company Contract with respect to a dealer,
distributor, referral, or similar agreement, or any Company Contract
providing for the grant by the Company of rights to market or sell
Company Products on behalf of the Company to any other Person;

 

 

 (iii)  any Company Contract pursuant to which a partnership or
joint venture was established.

 

 

 (iv)  any Company Contract made other than in the ordinary course
of business (x) providing for the grant of any preferential rights of first
offer or first refusal to purchase or lease any Asset or (y) providing for
any exclusive right to sell or distribute, or otherwise relating to the sale
or distribution of, any Company Product, or (z) pursuant to which any other
Person is granted "most favored nations" pricing or customer status
or similar with respect to any Company Product;

 

 

 (v)  any Company Contract under which clinical or non-clinical data
is generated that would need to be included in any regulatory approval (or
filing or application therefor);

 

 

 (vi)  any Company Contract (other than "shrink wrap" and similar generally
available commercial end user licenses to software that have an individual
acquisition cost of $100,000 or less per year) pursuant to which the Company
or any Subsidiary licenses any Intellectual Property Rights used in the
development, manufacturing, sale, or licensing of the Company Products, in
each case, that is material to the business of the Company and
its Subsidiaries, taken as a whole;

 

 

 (vii)  any Company Contract providing for outsourced development or
joint development of any of the Company Intellectual Property;

 

 

 (viii)  any Company Contract that (A) purports to limit either the type
of business in which the Company or any Subsidiary (or, after the Closing,
BRPA) may engage, the geographic area in which any of them may engage in
business, the solicitation of them of the employment of any Person or the
ability of any of them to sell or purchase from any Person, or (B) would
require the disposition of any Assets of the Company or any Subsidiary (or,
after the Closing, BRPA);

 

 

 (ix)  any Company Contract containing any indemnification,
warranty, support, maintenance, or service that represents a
material obligation of the Company or any Subsidiary;

 

 

 (x)  any Company Contract under which the Company or a Subsidiary
has permitted any Asset to become, or to become subject to, a Lien (other
than a Permitted Lien);

 

 

 (xi)  any Company Contract providing for the employment or consultancy
of any Person on a full-time, part-time, consulting or other basis
or otherwise providing compensation or other benefits equal to or in excess
of $250,000 per year;

 

 

 (xii)  any collective bargaining agreement with any labor union;

 

 

 

 

 

 

 

 

26

 

 

 

 

 

 

 

 

 

 

 

 (xiii)  any Company Contract that involves any joint venture,
profit sharing, partnership, limited liability company or similar agreement
or arrangement relating to the formation, creation, operation, management, or
control of any such partnership or joint venture;

 

 

 (xiv)  any Company Contract that evidences indebtedness, whether
incurred, assumed, guaranteed, or secured by any asset, of the Company or
any Subsidiary, having an outstanding principal amount in excess
of $1,000,000;

 

 

 (xv)  any Company Contract relating to the issuance of any capital
stock or other securities convertible into or exchangeable for
capital stock, or subscriptions, rights, warrants, or options to acquire any
capital stock or any securities convertible into or exchangeable for capital
stock;

 

 

 (xvi)  any Company Contract that involves the acquisition or
disposition, directly or indirectly, by merger or otherwise, of assets with
an aggregate value in excess of $1,000,000, other than in the
ordinary course of business consistent with past practice, or shares
or other equity interests of any other Person;

 

 

 (xvii)  any outstanding general or special powers of attorney executed
by or on behalf of the Company or a Subsidiary;

 

 

 (xviii)  any Company Contract under which the Company or a Subsidiary
has advanced or loaned an amount to, or received a loan, note, or
other instrument, agreement, or arrangement for or relating to the borrowing
of money from, any of its Affiliates, shareholders, members, officers,
managers, members of the board of directors or board of managers, or
employees, other than in the ordinary course of business;

 

 

 (xix)  any guaranty by the Company, a Subsidiary, or any Affiliate of
the foregoing, of any obligation of a third party in excess of $500,000;

 

 

 (xx)  any obligation to register any securities of the Company with
any Governmental Entity; and

 

 

 (xxi)  any Company Contract which is a "material contract," as such term
is defined in Item 601(b)(10) of Regulation S-K promulgated by the SEC.

 

 

 (b) The Company has made available to BRPA copies of each Material
Company Contract that are accurate and complete, in each case, as amended or
otherwise modified and in effect.

 

 

 (c) Each Material Company Contract is in full force and effect and
is enforceable against each party to such Material Company Contract, except
insofar as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, or similar laws affecting creditors'
rights generally or by principles governing the availability of equitable
remedies. Neither the Company, a Subsidiary, nor, to the Company's knowledge,
any other party to any Material Company Contract is in material breach or
violation of, or default under, or has repudiated any provision of, any
Material Company Contract and no event has occurred which, with notice or
lapse of time or both, would become a breach or default under a Material
Company Contract.

 

 

 

 

 

 

 

 

27

 

 

 

 

 

 

 

 

 

 

 

 2.22 Insurance. Schedule 2.22 of the Company Schedules sets forth the
Company's and its Subsidiaries' material Insurance Policies. With respect
to each such Insurance Policy required to be listed on Schedule 2.22 of the
Company Schedules: (i) all premiums due have been paid, (ii) the policy
is legal, valid, binding and enforceable in accordance with its terms and,
except for policies that have expired under their terms in the ordinary
course, is in full force and effect, (iii) neither the Company nor its
Subsidiaries is in material breach or default (including any such breach or
default with respect to the payment of premiums or the giving of notice),
and, to the Company's knowledge, no event has occurred which, with notice or
the lapse of time or both, would constitute such a material breach or
default, or permit termination or modification, under the policy, and to
the knowledge of the Company, no such action has been threatened, and (iv)
no written notice of cancellation, non-renewal, disallowance or reduction in
coverage or claim or termination has been received other than in connection
with ordinary renewals. The coverages provided by such Insurance Policies are
believed by the Company to be reasonably adequate in amount and scope for the
Company's and its Subsidiaries' business and operations

 

 

 2.23 Interested Party Transactions. Except as set forth in the Schedule
2.23 of the Company Schedules, (a) no Insider or a member of his or
her immediate family is indebted to the Company or any of its Subsidiaries,
nor is the Company or any of its Subsidiaries indebted (or committed to make
loans or extend or guarantee credit) to any of such Persons, other than (i)
for payment of salary for services rendered, (ii) advances or reimbursement
for reasonable expenses incurred on behalf of the Company or any of
its Subsidiaries, (iii) for other employee benefits made generally available
to all employees, or (iv) arms' length relationships between the Company or
any of its Subsidiaries, on the one hand, and an Affiliate of an Insider, on
the other hand and (b) to the Company's knowledge, no Insider has a
beneficial interest in any Company Contracts (other than such contracts
as relate to the acquisition of capital stock or other securities of the
Company or any Company Contract of employment).

 

 

 2.24 Registration Statement. None of the information relating to the
Company or its Subsidiaries to be supplied by the Company, or by any other
Person acting on behalf of the Company at its direction, in writing
specifically for inclusion in the Registration Statement will, as of the date
the Registration Statement (or any amendment or supplement thereto) is first
mailed to the BRPA Stockholders, at the time of the BRPA Special Meeting, or
at the Effective Time, contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading;
provided, however, notwithstanding the foregoing provisions of this Section
2.24, no representation or warranty is made by the Company with respect
to information or statements made or incorporated by reference in
the Registration Statement that were not supplied by or on behalf of the
Company for use therein.

 

 

 2.25 Certain Business Practices.

 

 

 (a) Neither the Company nor any of its Subsidiaries or Affiliates acting on
its behalf has (i) used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses relating to
political activity, (ii) made any unlawful payment to foreign or
domestic government officials or employees, to foreign or domestic
political parties or campaigns or violated any provision of the
Foreign Corrupt Practices Act of 1977 or similar anti-corruption or
bribery law of any other jurisdiction, or (iii) directly or indirectly given
or agreed to give any unlawful gift or similar benefit in any material amount
to any customer, supplier, government employee or other Person who is or may
be in a position to help or hinder the Company or any Subsidiary or assist
the Company or any Subsidiary in connection with any actual or proposed
transaction.

 

 

 

 

 

 

 

 

28

 

 

 

 

 

 

 

 

 

 

 

 (b) The operations of the Company and each Subsidiary are and have
been conducted at all times in compliance with money laundering statutes in
all applicable jurisdictions, the rules and regulations thereunder and any
related or similar rules, regulations or guidelines, issued, administered or
enforced by any Governmental Entity in all material respects, and no action
involving the Company with respect to the any of the foregoing is pending or,
to the knowledge of the Company, threatened.

 

 

 (c) Neither the Company, any Subsidiary, nor any of its or their directors
or officers, or, to the knowledge of the Company, any other Person acting on
behalf of the Company, (i) is currently identified on the specially
designated nationals or other blocked person list or otherwise currently
subject to any U.S. sanctions administered by or enforced by the United
States (including any administered or enforced by the Office of Foreign
Assets Control of the U.S. Department of the Treasury, the U.S. Department of
State, or the Bureau of Industry and Security of the U.S. Department
of Commerce), the United Nations Security Council, the European Union or any
member state of the European Union (collectively, "Sanctions"), (ii)
is located, organized, or resident in a country or territory that is, or
whose government is, the subject of Sanctions that broadly prohibit dealings
with that country or territory, (iii) has in the last five years, directly or
indirectly, used any funds or loaned, contributed, or otherwise made
available such funds to any Person in connection with any sales or operations
in any country targeted under Sanctions (including, but not limited to, the
Crimea region of Ukraine, Cuba, Iran, North Korea, and Syria), or for the
purpose of financing the activities of any Person the subject of
or otherwise in violation of, any Sanctions, in each case in violation of
applicable Sanctions.

 

 

 (d) The Company is currently in compliance with, and has complied with,
all Export Control Laws applicable to it. Without limiting the foregoing:
(i) the Company has obtained all material export licenses and other material
approvals required for its exports of products required by any Export Control
Law and all such approvals and licenses are in full force and effect; (ii)
the Company is in compliance with the terms of such applicable export
licenses or other approvals; and (ii) there are no claims pending or
threatened in writing against the Company with respect to such export
licenses or other approvals.

 

 

 2.26 FDA and EMEA Approval.

 

 

 (a) Schedule 2.26(a) of the Company Schedules sets forth the
development and testing phase for each Company Product. To the
Company's knowledge, all Company Products are being and have been
researched, developed, designed, manufactured, tested, prepared,
assembled, packaged, labeled, stored, processed, distributed, and marketed
in material compliance with all applicable Health Care Regulatory Laws,
including those rules and regulations enacted by any federal, state, or
foreign Governmental Entity relating to investigational use, premarket
clearance or approval, good laboratory practice, good tissue practice, good
clinical practice, good manufacturing practice, labeling, advertising,
promotion, recordkeeping, filing of reports, and security.

 

 

 

 

 

 

 

 

29

 

 

 

 

 

 

 

 

 

 

 

 (b) To the Company's knowledge, the preclinical and clinical testing,
manufacture, labeling, distribution, promotion and sale of the Company
Products, whether conducted by or on behalf of the Company, or sponsored by
the Company, are and were in material compliance with all Legal Requirements
including, but not limited to, FDA's good laboratory practice regulations at
21 C.F.R. Part 58 and good clinical practice regulations at 21 C.F.R.
Parts 50, 54, 56, 11, 312, and 314. The descriptions of the results of such
tests and trials provided to BRPA or BRPA's counsel are complete and accurate
in all material respects. The Company is not aware of any studies, tests, or
trials the results of which reasonably call into question the results of the
tests and trials conducted by or on behalf of the Company. There have been
no serious or unanticipated adverse effects associated with the Company
Products during clinical studies that have not been reported to the
applicable Governmental Entity as required by applicable Legal Requirements.
The Company has not received notice of adverse finding, warning letter, or
clinical hold notice from an IRB, IEC, FDA, EMEA, or similar Governmental
Entity, or any untitled letter or other correspondence or notice from the FDA
or any other Governmental Entity or any institutional or ethical review
board alleging or asserting noncompliance with any Health Care Regulatory
Laws applicable in any jurisdiction. No human clinical trial conducted or
sponsored by or on behalf of the Company or on the Company Products has been
terminated or suspended by an IRB or IEC, FDA, EMEA, or any other applicable
Governmental Entity or any review board.

 

 

 (c) Neither the Company, any Subsidiary, or, to the Company's
knowledge, any officer, director, employee or contractor thereof has made
any untrue statement of a material fact, or failed to disclose a material
fact required to be disclosed, to the FDA, EMEA, or other similar
Governmental Entity.

 

 

 (d) Except as set forth in Schedule 2.26(d) of the Company Schedules, the
Company has not received any written notices or statements from the FDA, the
EMEA, or any other Governmental Entity, and otherwise has no knowledge
or reason to believe, that (i) any Company Product is reasonably likely to
be rejected or determined to be non-approvable; (ii) a delay in time for
review or approval of a marketing authorization application or marketing
approval application in any jurisdiction for any Company Product is
reasonably likely to be required, requested or being implemented; or (iii)
any license, approval, permit or authorization to conduct any clinical trial
of, or market, any product or Company Product has been or is
reasonably likely to be suspended, revoked, modified or limited.

 

 

 (e) There are no citations, decisions, adjudications or statements, in
each case issued in writing, by any Governmental Entity, and neither
the Company nor any Subsidiary is subject to any order asserting that any
Company Product is defective or unsafe in any material respect, resulting
from design defects or otherwise, or fails in any material respect to meet
any standards promulgated by any rule or regulation promulgated by any
Governmental Entity.

 

 

 (f) Except as set forth in Schedule 2.26(f) of the Company Schedules, the
Company has not, either voluntarily or involuntarily, initiated, conducted
or issued, or caused to be initiated, conducted or issued, any recall, field
correction, market withdrawal or replacement, safety alert, warning or "dear
doctor" letter, investigator notice, or other notice or action relating to an
alleged or potential lack of safety or efficacy of any Company Product, any
alleged product defect in any Company Product, or any violation of any
Legal Requirements or any clinical trial or marketing Permit for any Company
Product, and the Company is not aware of any facts or information that would
cause it to initiate any such notice or action and has no knowledge or reason
to believe that the FDA, the EMEA or any other Governmental Entity or any IRB
or IEC or other non-governmental authority intends to impose, require,
request or suggest such notice or action.

 

 

 

 

 

 

 

 

30

 

 

 

 

 

 

 

 

 

 

 

 (g) Neither the Company nor any of its Subsidiaries is the subject of
any pending or, to the knowledge of the Company, threatened investigation in
respect of its business or products by the FDA pursuant to its "Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities" Final Policy
set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any
amendments thereto. Neither the Company nor any of its Subsidiaries
has committed any acts, made any statement, or failed to make any statement,
in each case in respect of its business or products that would violate the
FDA's "Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
Gratuities" Final Policy, and any amendments thereto. None of the Company,
any of its Subsidiaries or, to the knowledge of the Company, any of
their respective officers, employees or agents has been convicted of
any crime or engaged in any conduct that (i) could result in a debarment or
exclusion under 21 U.S.C.  335a, (ii) could result in disqualification under
FDA investigator disqualification proceedings, (iii) is subject to
FDA's Application Integrity Policy, (iv) is subject to any
enforcement proceeding arising from material false statements to FDA
pursuant to 18 U.S.C.  1001, or (v) any similar applicable
Legal Requirements. To the knowledge of the Company, no debarment
or exclusionary claims, actions, proceedings or investigations in respect of
their business or products are pending or threatened against the Company, any
of its Subsidiaries or any of their respective officers, employees or agents.

 

 

 2.27 Health Care Regulatory Compliance.

 

 

 (a) Except as set forth in Schedule 2.27(a) of the Company Schedules, the
Company and each Subsidiary is operating and has operated in material
compliance with the Health Care Regulatory Laws. Except as set forth
in Schedule 2.27(a) of the Company Schedules, neither the Company, any
Subsidiary, or any Affiliate thereof has received any written or oral notice
or complaint from a Governmental Entity or any other Person, that allege
that the Company or such Subsidiary is not in compliance with any such Health
Care Regulatory Laws and that have not been addressed to the satisfaction of
such Governmental Entity or complainant.

 

 

 (b) Neither the Company nor any Subsidiary, or its or their officers
or directors, nor, to the Company's knowledge, any employees or independent
contractors of the Company or the Subsidiary, has been excluded, debarred, or
suspended from, or otherwise determined to be or identified as ineligible to
participate in, any Health Care Program, or convicted of any crime relating
to any Health Care Program, and the Company has not received, and to
the Company's knowledge, no officer, director, employee, or independent
contractor of the Company has received, any written notice that the Company
or such Subsidiary is the subject of any investigation or review regarding
its participation in any Health Care Program. Neither the Company nor any
Subsidiary, or its or their officers or directors, nor, to the Company's
knowledge, any employees or independent contractors of the Company or
such Subsidiary is listed on the Office of Inspector General's exclusion
list, the General Services Administration's Lists of Parties Excluded from
Federal Procurement and Non-procurement Programs, any state Medicaid
exclusion list, or similar lists in any jurisdiction in which the Company or
a Subsidiary operates.

 

 

 (c) Neither the Company nor any Subsidiary has been the subject of or
received, or has knowledge of any pending or, to the Company's knowledge,
threatened: (i) compliance, disciplinary or enforcement action from any
Governmental Entity; (ii) any written notice of noncompliance with or alleged
violation of any Health Care Regulatory Laws; or (iii) material finding from
an inspection by a Governmental Entity. No Person has filed or, to the
Company's knowledge, has threatened to file against the Company or
any Subsidiary any claim under any federal or state whistleblower statute,
including without limitation, the Federal False Claims Act (31 U.S.C.  3729
et seq.).

 

 

 

 

 

 

 

 

31

 

 

 

 

 

 

 

 

 

 

 

 (d) Neither the Company nor any Subsidiary has offered, paid, solicited,
or received remuneration in return for referring an individual to or from
any customer for the furnishing of any item or service reimbursed under
Health Care Programs, subject to applicable safe harbors. All discounts or
rebates provided to customers satisfy the requirements of the safe harbor to
the Anti-Kickback Statute, 42 C.F.R.  1001.952(h).

 

 

 2.28 Board Approval. The board of directors of the Company (the "Company
Board") (including any required committee or subgroup thereof),
by resolutions duly adopted, has (a) determined that this Agreement and the
Transactions are advisable and in the best interest of the Company and the
Company Stockholders, (b) approved this Agreement and the Transactions in
accordance with the Company Certificate of Incorporation and declared their
advisability, and (c) resolved to recommend that the stockholders of the
Company approve and adopt each of the matters requiring Company Stockholder
Approval and directed that this Agreement and the Transactions be submitted
for consideration by the Company Stockholders in accordance
with Section 5.16.

 

 

 2.29 Company Stockholder Approval. The approval and adoption of this
Agreement and the approval of the Transactions by the Company Stockholders
requires the affirmative vote of (i) the holders of a majority of the
outstanding shares of Company Common Stock and Company Preferred Stock,
voting together as a single class on an "as-converted" to Company Common
Stock basis , (ii) two-thirds of the outstanding shares of Company Series A
Preferred Stock, voting as a separate class and (iii) a two-thirds of the
outstanding shares of Company Series B Preferred Stock, voting as a separate
class, in each case, given in writing or at a meeting in accordance with the
Company Certificate of Incorporation (collectively, the "Company
Stockholder Approval"). The Company Stockholder Approval is the only vote of
holders of securities of the Company necessary to approve the Merger.

 

 

 2.30 No Additional Representations and Warranties; No Reliance. Except
as provided in this Article II (as modified by the Company Schedules),
neither the Company, any Subsidiary, any of their respective Affiliates,
nor any of their respective directors, officers, employees, shareholders, or
representatives has made, or is making, any representation or warranty
whatsoever to BRPA or its Affiliates, and no such Party shall be liable in
respect of the accuracy or completeness of any information provided to BRPA
or its Affiliates. Without limiting the generality of the foregoing, except
as expressly set forth in this Agreement (as modified by the
Company Schedules), neither the Company nor any other person on behalf
of the Company has made or makes, any representation or warranty, whether
express or implied, with respect to any projections, forecasts, estimates or
budgets made available to BRPA, its Affiliates or any of their respective
Representatives of future revenues, future results of operations (or any
component thereof), future cash flows or future financial condition (or any
component thereof) of the Company (including the reasonableness of
the assumptions underlying any of the foregoing), whether or not included in
any management presentation or in any other information made available to
BRPA, its Affiliates or any of their respective Representatives or any other
person, and any such representations or warranties are expressly disclaimed.
The Company acknowledges and agrees (on its own behalf and on behalf of its
Affiliates and its Representatives) that: (i) it has conducted its own
independent investigation of the financial condition, results of
operations, assets, liabilities, properties and projected operations of
BRPA; (ii) it has been afforded satisfactory access to the books
and records, facilities and personnel of BRPA for purposes of conducting
such investigation; and (iii) except for the representations and warranties
set forth in Article III (as modified by the BRPA Schedules), it is not
relying on any representations and warranties from any Person in connection
with the Transactions. Neither BRPA nor Merger Sub nor any of its or their
respective stockholders, Affiliates or Representatives shall have
any liability to the Company or any of its stockholders, Affiliates
or Representatives resulting from the use of any information, documents or
materials made available to the Company or any of its Representatives,
whether orally or in writing, in any confidential information memoranda,
"data rooms," management presentations, due diligence discussions or in any
other form in expectation of the Transactions except as set forth in
this Agreement and the Ancillary Agreements.

 

 

 

 

 

 

 

 

32

 

 

 

 

 

 

 

 

 

 

 

  ARTICLE III

 

 

 REPRESENTATIONS AND WARRANTIES OF BRPA AND MERGER SUB

 

 

 Except as set forth in the BRPA's disclosure letter delivered by BRPA to
the Company in connection with this Agreement (the "BRPA Schedules") (each
Schedule of which qualifies (a) the correspondingly numbered representation,
warranty or covenant specified therein and (b) such other representations,
warranties or covenants where its relevance as an exception to (or disclosure
for purposes of) such other representation, warranty or covenant
is reasonably apparent on its face or cross-referenced), each of BRPA and
Merger Sub hereby represents and warrants to the Company as follows:

 

 

 3.1 Organization and Qualification.

 

 

 (a) Each of BRPA and Merger Sub (i) is a corporation duly
incorporated, validly existing and in good standing under the laws of the
State of Delaware and has the requisite corporate power and authority
to own, lease and operate its assets and properties and to carry on its
business as it is now being conducted; and (ii) is in possession of all
Approvals necessary to own, lease and operate the properties it purports to
own, operate or lease and to carry on its business as it is now being
conducted. Complete and correct copies of the Charter Documents of BRPA and
Merger Sub, as amended and currently in effect, have been made available to
the Company or Company's counsel.

 

 

 (b) BRPA is duly qualified or licensed to do business as a
foreign corporation and is in good standing in each jurisdiction where
the character of the properties owned, leased, or operated by it or
the nature of its activities makes such qualification or
licensing necessary. Each jurisdiction in which BRPA is so qualified
or licensed is listed in Schedule 3.1(b) of the BRPA Schedules.

 

 

 3.2 Subsidiaries. Other than as set forth in Schedule 3.2 of the
BRPA Schedules, BRPA has no direct or indirect Subsidiaries
or participations in joint ventures or other entities. BRPA does not own,
directly or indirectly, any equity or voting interest in any Person or has
any agreement or commitment to purchase any such interest, and has not agreed
and is not obligated to make nor is bound by any written or oral agreement,
contract, subcontract, lease, binding understanding, instrument, note,
option, warranty, purchase order, license, sublicense, insurance policy,
benefit plan, commitment or undertaking of any nature, as of the date hereof
or as may hereafter be in effect under which it may become obligated to make,
any future investment in or capital contribution to any other Person.

 

 

 

 

 

 

 

 

33

 

 

 

 

 

 

 

 

 

 

 

 3.3 Capitalization.

 

 

 (a) The authorized capital stock of BRPA as of the date of this
Agreement consists of 100,000,000 shares of BRPA Common Stock and
1,000,000 shares of BRPA Preferred Stock. No BRPA Preferred Stock is
issued and outstanding. Schedule 3.3(a) of the BRPA Schedules sets forth
the issued and outstanding BRPA Common Stock, BRPA Rights, BRPA Warrants,
BRPA Units, and BRPA unit purchase options and each other option, warrant,
purchase right, conversion, right, exchange right, or other BRPA Contract
exercisable for, exchangeable for, or convertible into capital stock of BRPA
as of the date of this Agreement. All of the foregoing issued and outstanding
equity interests of BRPA have been duly authorized, are validly issued, free
and clear of all Liens, in compliance in all respects with all Legal
Requirements, fully paid and non-assessable, have not been issued in
violation of any preemptive or subscription rights, and are not subject to
any preemptive or subscription rights that will survive the Closing Date.
BRPA has no issued or outstanding equity interests other than the equity
interests that are that set forth on Schedule 3.3(a) of the BRPA Schedules.
All shares of BRPA Common Stock subject to issuance, upon issuance on the
terms and conditions specified in the instrument pursuant to which they are
issuable, will be duly authorized, validly issued, fully paid, and
nonassessable, free and clear of all Liens, and will have not been issued in
violation of any preemptive or subscription rights, and are not subject to
any preemptive or subscription rights that will survive the Closing Date. All
outstanding shares of BRPA Common Stock, BRPA Warrants, and BRPA Rights have
been issued and granted in compliance with (x) all applicable securities
laws and (in all material respects) other applicable Legal Requirements, and
(y) all requirements set forth in any applicable BRPA Contracts and Charter
Documents.

 

 

 (b) Except as provided for in this Agreement or as set forth
in Schedule 3.3(b) of the BRPA Schedules, there are no subscriptions,
options, warrants, convertible notes, derivative securities, equity
securities, or other ownership interests, calls, rights (including preemptive
rights), commitments or agreements of any character to which BRPA is a party
or by which it is bound obligating BRPA to issue, deliver or sell, or cause
to be issued, delivered or sold, or repurchase, redeem or otherwise acquire,
or cause the repurchase, redemption or acquisition of, any shares of capital
stock or other ownership interests of BRPA or obligating BRPA to grant,
extend, accelerate the vesting of or enter into any such subscription,
option, warrant, equity security, call, right, commitment, or agreement. BRPA
does not have any outstanding bonds, debentures, notes or other obligations
the holders of which have or upon the happening of certain events would have
the right to vote (or which are convertible into or exercisable or
exchangeable for securities having the right to vote) with the BRPA
Stockholders on any matter.

 

 

 (c) Except as set forth in Schedule 3.3(c) of the BRPA Schedules or
as contemplated by this Agreement, there are no registration rights, and
there is no voting trust, proxy, rights plan, anti-takeover plan, or other
agreements or understandings to which BRPA or Merger Sub is a party or by
which BRPA or Merger Sub is bound with respect to any BRPA Securities.

 

 

 (d) Except as provided for in this Agreement or as set forth in Schedule
3.3(d) of the BRPA Schedules, as a result of the consummation of the Merger,
no shares of capital stock, warrants, options, or other securities of BRPA or
Merger Sub are issuable and no rights in connection with any shares,
warrants, options, or other securities of BRPA or Merger Sub accelerate
or otherwise become triggered (whether as to vesting,
exercisability, convertibility or otherwise).

 

 

 

 

 

 

 

 

34

 

 

 

 

 

 

 

 

 

 

 

 (e) Except as provided for in this Agreement or as set forth in Schedule
3.3(e) of the BRPA Schedules, no outstanding BRPA Securities are unvested or
subjected to a repurchase option, risk of forfeiture, or other condition
under any applicable agreement with BRPA.

 

 

 (f) The authorized and outstanding capital stock of Merger Sub is
1,000 shares of common stock, par value $0.0001 per share. BRPA owns all of
the outstanding common stock of Merger Sub, free and clear of all Liens.

 

 

 3.4 Authority Relative to this Agreement.

 

 

 (a) Each of BRPA and Merger Sub has all requisite power and authority
to enter into this Agreement and each Ancillary Agreement to which BRPA or
Merger Sub, respectively is (or with respect to Ancillary Agreements to be
entered into at or prior to the Closing, will be) a party and, subject to the
receipt of the BRPA Stockholder Approval, to consummate the Merger. The
execution and delivery of this Agreement and each Ancillary Agreement by BRPA
and Merger Sub, respectively, has been (or with respect to Ancillary
Agreements to be entered into at the Closing, will be) duly authorized by
all necessary corporate action on the part of BRPA and Merger Sub, subject
to the receipt of the BRPA Stockholder Approval. This Agreement and each
Ancillary Agreement to which BRPA or Merger Sub, respectively, is (or with
respect to Ancillary Agreements to be entered into at or prior to the
Closing, will be) a party (i) has been (or, in the case of Ancillary
Agreements to be entered into at or prior to the Closing, will be when
executed and delivered) duly executed and delivered by BRPA and Merger Sub
and (ii) assuming due authorization, execution and delivery thereof by each
other party hereto and thereto, is (or, in the case of Ancillary Agreements
to be entered into at the Closing, will be when executed and delivered)
enforceable against BRPA and Merger Sub in accordance with its terms, except
as may be limited by bankruptcy, insolvency, reorganization or other similar
laws affecting the enforcement of creditors' rights generally and by general
principles of equity.

 

 

 (b) The board of directors of BRPA (the "BRPA Board") has, as of the date
of this Agreement, unanimously (i) determined that this Agreement and the
Transactions are advisable and in the best interests of BRPA and its
stockholders, (ii) approved this Agreement and the Transactions in accordance
with the Charter Documents of BRPA and declared their advisability, (iii)
approved the Transactions as a Business Combination, (iv) determined
that the fair market value of the Company is equal to at least 80% of the
balance held in the Trust Fund (excluding taxes payable on the income earned
on the Trust Fund) as of the date hereof, and (v) resolved to recommend that
the stockholders of BRPA approve each of the matters requiring BRPA
Stockholder Approval and directed that this Agreement and the Transactions,
be submitted for consideration by the stockholders of BRPA at the BRPA
Special Meeting.

 

 

 (c) The board of directors of Merger Sub has approved and
declared advisable, this Agreement and the Transactions, and BRPA, in
its capacity as the sole stockholder of Merger Sub shall approve and adopt
this Agreement by written consent immediately following its execution.

 

 

 

 

 

 

 

 

35

 

 

 

 

 

 

 

 

 

 

 

 (d) The affirmative vote of (i) holders of a majority of the
outstanding shares of BRPA Common Stock present and entitled to vote at
the BRPA Special Meeting shall be required to approve the
Transaction Proposal, (ii) holders of a majority of the outstanding shares
of BRPA Common Stock cast at the BRPA Special Meeting shall be required to
approve the Nasdaq Proposal and the BRPA Plan Proposal and (iii) holders of a
majority of the outstanding shares of BRPA Common Stock shall be required to
approve the AandR Charter Proposal, in each case, assuming a quorum is present,
are the only votes of any of BRPA's capital stock necessary in
connection with the entry into this Agreement by BRPA, and the consummation
of the Transactions, including the Merger (the approval by BRPA Stockholders
of all of the foregoing, collectively, the "BRPA Stockholder Approval")

 

 

 3.5 No Conflict; Required Filings and Consents.

 

 

 (a) The execution and delivery of this Agreement and each
Ancillary Agreement to which BRPA and Merger Sub are party by BRPA and
Merger Sub does not and will not, and the consummation by BRPA and
Merger Sub of the transactions contemplated hereby and thereby does not and
will not, and the performance of this Agreement and each such Ancillary
Agreements by BRPA and Merger Sub shall not: (i) conflict with or violate
their respective Charter Documents, (ii) conflict with or violate
any applicable Legal Requirements, (iii) result in any breach of
or constitute a default (or an event that with notice or lapse of time or
both would become a default) under, or materially impair BRPA's or Merger
Sub's rights or alter the rights or obligations of any third party under, or
give to others any rights of termination, amendment, acceleration or
cancellation of, or result in the creation of a Lien on any of the properties
or assets of BRPA or Merger Sub (other than Permitted Liens) pursuant to,
any BRPA Contracts or (iv) result in the triggering, acceleration
or increase of any payment to any Person pursuant to any BRPA Contract,
including any "change in control" or similar provision of any BRPA Contract,
except, with respect to clauses (ii), (iii) and (iv), for any such conflicts,
violations, breaches, defaults, impairments, alterations triggerings,
accelerations, increases or other occurrences that would not, individually
and in the aggregate, have a BRPA Material Adverse Effect.

 

 

 (b) The execution and delivery of this Agreement and each
Ancillary Agreement by BRPA and Merger Sub do not and will not, and
the performance of their respective obligations hereunder and thereunder
will not, require any consent, approval, authorization or permit of, or
filing with or notification to, any Governmental Entity or other third party
(including, without limitation, lenders and lessors), except (i)
for applicable requirements, if any, of the Securities Act, the Exchange
Act, state securities laws, and the rules and regulations thereunder, and
appropriate documents with the relevant authorities of other jurisdictions in
which BRPA or Merger Sub is qualified to do business, (ii) the filing of any
notifications required under the HSR Act and the expiration of the required
waiting period thereunder, and (iii) where the failure to obtain such
consents, approvals, authorizations or permits, or to make such filings
or notifications, would not, individually or in the aggregate, reasonably be
expected to prevent the consummation of the Merger or otherwise prevent BRPA
or Merger Sub from performing its material obligations under this Agreement
on a timely basis.

 

 

 3.6 Compliance

 

 

 . Except as set forth in Schedule 3.6 of the BRPA Schedules, each of BRPA
and Merger Sub has complied with all, and is not in violation of any,
applicable Legal Requirements with respect to the conduct of its business, or
the ownership or operation of its business. The businesses and activities of
BRPA and Merger Sub have not been and are not being conducted in violation
of any applicable Legal Requirements. Neither BRPA nor Merger Sub is in
default or violation in any material respect of any term, condition or
provision of any applicable Charter Documents. Except as set forth in
Schedule 3.6 of the BRPA Schedules, no written notice of non-compliance with
any applicable Legal Requirements has been received by BRPA or Merger Sub
(and BRPA has no knowledge of any such notice delivered to any
other Person).

 

 

 

 

 

 

 

 

36

 

 

 

 

 

 

 

 

 

 

 

 3.7 BRPA SEC Reports and Financial Statements.

 

 

 (a) Except as set forth in Schedule 3.7(a) of the BRPA Schedules, BRPA has
timely filed all required registration statements, reports,
schedules, forms, statements and other documents filed by BRPA with the
SEC since its formation (collectively, as they have been amended since the
time of their filing and including all exhibits thereto, the "BRPA
SEC Reports"). None of the BRPA SEC Reports, as of their respective dates
(or, if amended or superseded by a filing prior to the date of this Agreement
or the Closing Date, then on the date of such filing), contained any untrue
statement of a material fact or omitted to state a material fact required to
be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading. As of the date
hereof, there are no outstanding or unresolved comments in comment letters
from the SEC staff with respect to BRPA or the BRPA SEC Reports. To
the knowledge of BRPA, as of the date hereof, (i) none of the BRPA
SEC Reports is the subject of ongoing SEC review or outstanding SEC comment
and (ii) neither the SEC nor any other Governmental Entity is conducting any
investigation or review of any BRPA SEC Report.

 

 

 (b) The audited financial statements of BRPA ("BRPA Audited
Financial Statements") and unaudited interim financial statements of
BRPA ("BRPA Unaudited Financial Statements" and, together with the BRPA
Audited Financial Statements, the "BRPA Financial Statements")
(including, in each case, the notes and schedules thereto) included in the
BRPA SEC Reports complied as to form in all material respects with
the published rules and regulations of the SEC with respect thereto, were
prepared in accordance with U.S. GAAP applied on a consistent basis in
accordance with past practice during the periods involved (except as may be
indicated therein or in the notes thereto and except with respect to
unaudited statements as permitted by Form 10-Q of the SEC) and Regulation S-X
or Regulation S-K, as applicable, and fairly present (subject, in the case of
the unaudited interim financial statements included therein, to normal year-
end adjustments, the effect of which are not, individually or in the
aggregate, material, and the absence of complete footnotes to the extent
permitted by Regulation S-X or Regulation S-K, as applicable) in all material
respects the financial position of BRPA as of the respective dates thereof
and the results of their operations and cash flows for the respective periods
then ended.

 

 

 (c) BRPA has established and maintains disclosure controls and
procedures (as defined in Rule 13a-15 or 15d-15(e) under the Exchange Act).
Such disclosure controls and procedures are designed to ensure that material
information relating to BRPA is made known to BRPA's principal executive
officer and its principal financial officer, particularly during the periods
in which the periodic reports required under the Exchange Act are
being prepared. To BRPA's knowledge, such disclosure controls and procedures
are effective in timely alerting BRPA's principal executive officer and
principal financial officer to material information required to be included
in BRPA's periodic reports required under the Exchange Act.

 

 

 (d) BRPA has established and maintained a system of internal
accounting controls. To BRPA's knowledge, such internal accounting controls
are effective and sufficient to provide reasonable assurance regarding the
reliability of BRPA's financial reporting and the preparation of the BRPA
Financial Statements for external purposes in accordance with U.S. GAAP.

 

 

 

 

 

 

 

 

37

 

 

 

 

 

 

 

 

 

 

 

 (e) There are no outstanding loans or other extensions of credit made by
BRPA to any executive officer (as defined in Rule 3b-7 under the Exchange
Act) or director of BRPA. BRPA has not taken any action prohibited by Section
402 of the Sarbanes-Oxley Act.

 

 

 (f) Except as otherwise noted in the BRPA Financial Statements, the
accounts and notes receivable of BRPA reflected in the BRPA
Financial Statements: (i) arose from bona fide sales transactions in the
ordinary course of business and are payable on ordinary trade terms, (ii) are
legal, valid and binding obligations of the respective debtors enforceable
in accordance with their terms, except as such may be limited by bankruptcy,
insolvency, reorganization, or other similar laws affecting creditors' rights
generally, and by general equitable principles, (iii) are not subject to any
valid set-off or counterclaim to which BRPA has been notified in writing as
of the date hereof except to the extent set forth in such balance
sheet contained therein, and (iv) are not the subject of any actions
or proceedings brought by or on behalf of BRPA as of the date hereof.

 

 

 3.8 No Undisclosed Liabilities. There is no liability, debt or obligation
against BRPA or its Subsidiaries that would be required to be set forth or
reserved for on a balance sheet of BRPA and its Subsidiaries (and the notes
thereto) prepared in accordance with U.S. GAAP and in accordance with past
practice, except for liabilities and obligations (a) reflected or
reserved for on the BRPA Financial Statements or disclosed in the
notes thereto, (b) that have arisen since the date of the BRPA
Financial Statements in the ordinary course of the operation of business
of BRPA and its Subsidiaries, (c) disclosed in the BRPA Schedules (including
Section 3.8 of the BRPA Schedules, (d) arising under this Agreement or the
performance by BRPA of its obligations hereunder, or (e) that would
not, individually or in the aggregate, reasonably be expected to be material
to BRPA and its Subsidiaries, taken as a whole.

 

 

 3.9 Absence of Certain Developments. Except as contemplated by this
Agreement, since the date of the most recent BRPA Financial Statement to the
date of this Agreement, there has not been a BRPA Material Adverse Effect,
the business of BRPA has been conducted in the ordinary course of business,
and BRPA has not taken any action that would have required the prior written
consent of the Company under Section 4.2 if such action had been taken
during the Interim Period.

 

 

 3.10 Litigation. Except as set forth in Schedule 3.10 of the
BRPA Schedules, there are no, and have never been any, claims,
suits, actions or proceedings pending or, to BRPA's knowledge, threatened
against BRPA or Merger Sub before any court, governmental department,
commission, agency, instrumentality or authority, or any arbitrator.

 

 

 3.11 Employee Benefit Plans. Neither BRPA nor Merger Sub maintains, and
neither have any liability under, any Plan, and neither the execution and
delivery of this Agreement nor the consummation of the Merger will (i) result
in any payment (including severance, unemployment compensation, golden
parachute, bonus, or otherwise) becoming due to any shareholder, director,
or employee of BRPA or Merger Sub, or (ii) result in the acceleration of the
time of payment or vesting of any such benefits.

 

 

 3.12 Labor Matters. Neither BRPA nor Merger Sub is a party to any
collective bargaining agreement or other labor union contract applicable to
persons employed by BRPA or Merger Sub and BRPA does not know of any
activities or proceedings of any labor union to organize any such
employees. Other than as described in the BRPA SEC Reports, neither BRPA
nor Merger Sub has ever had any employees.

 

 

 

 

 

 

 

 

38

 

 

 

 

 

 

 

 

 

 

 

 3.13 Business Activities. Since its organization, BRPA has not conducted
any business activities other than activities directed toward the
accomplishment of a Business Combination. Except as set forth in the BRPA
Charter Documents, there is no agreement, commitment, exclusive license,
judgment, injunction, order, or decree binding upon BRPA or to which BRPA
is a party which has or would reasonably be expected to have the effect of
prohibiting or materially impairing any business practice of BRPA, any
acquisition of property by BRPA, or the conduct of business by BRPA. Since
its organization, Merger Sub has not conducted any business activities other
than in connection with this Agreement. In addition, none of BRPA or Merger
Sub or any of their respective Subsidiaries or Associates has an interest of
five percent (5%) or greater in an entity that operate in the
same industries as or compete with the Company or any of its Subsidiaries.
For purposes of this Section 3.13, "Associate" is defined pursuant to 16
C.F.R.  801.1(d)(2).

 

 

 3.14 Title to Property. Neither BRPA nor Merger Sub owns or leases any
real property or personal property. Except as set forth in Schedule 3.14 of
the BRPA Schedules, there are no options or other contracts under which BRPA
or Merger Sub has a right or obligation to acquire or lease any interest in
real property or personal property.

 

 

 3.15 Intellectual Property. Neither BRPA nor Merger Sub owns, licenses, or
otherwise has any right, title or interest in any material Intellectual
Property Rights.

 

 

 3.16 Taxes. Except as set forth in Schedule 3.16 of the BRPA Schedules:

 

 

 (a) BRPA has timely filed all material Returns required to be filed by
BRPA with any Tax authority prior to the date hereof (after giving effect to
any valid extensions of time in which to make such filings). All such Returns
are true, correct, and complete in all material respects. BRPA has paid all
material amounts of Taxes shown to be due and payable on such Returns.

 

 

 (b) All material amounts of Taxes that BRPA is required by applicable
Legal Requirements to withhold or collect have been duly withheld
or collected and have been timely paid over to the proper
Governmental Entity to the extent due and payable.

 

 

 (c) BRPA has not been delinquent in the payment of any material amount
of Tax, nor is there any material Tax deficiency outstanding, proposed or
assessed by a taxing authority against BRPA (other than any deficiencies that
have since been resolved), nor has BRPA executed any unexpired waiver of any
statute of limitations on or extending the period for the assessment or
collection of any material amount of Tax.

 

 

 (d) No material audit or other examination of any Return of BRPA by
any Tax authority is presently in progress, nor has BRPA been notified of
any request for such an audit or other examination.

 

 

 (e) No material adjustment relating to any Returns filed by BRPA has
been formally proposed by any Tax authority to BRPA or any representative
thereof.

 

 

 (f) BRPA has not taken any action, nor is it aware of any fact
or circumstance that would reasonably be expected to prevent or impede, the
Merger from qualifying as a reorganization governed by Section 368 of the
Code.

 

 

 

 

 

 

 

 

39

 

 

 

 

 

 

 

 

 

 

 

 3.17 Brokers. Except as set forth in Schedule 3.17 of the BRPA Schedules,
neither BRPA nor Merger Sub has incurred liability for or is obligated
to make any payments with respect to, and neither BRPA nor Merger Sub will
incur liability for or will be obligated to make any payments with respect
to, any brokerage, investment banking fees or finders' fees or agent's
commissions or any similar charges in connection with this Agreement or any
of the Transactions. Except as set forth in Schedule 3.17 of the BRPA
Schedules, neither BRPA nor Merger Sub has entered into any
contract, agreement, understanding, arrangement or commitment of any
sort pursuant to which BRPA or the Surviving Corporation or any of
its direct or indirect Subsidiaries could, directly or indirectly, incur any
liability for or be obligated to make any payments with respect to, any
brokerage, investment banking fees or finders' fees or agent's commissions or
any similar charges in connection with this Agreement or any of
the Transactions.

 

 

 3.18 Agreements, Contracts and Commitments.

 

 

 (a) Except as set forth in the BRPA SEC Reports filed prior to the date
of this Agreement or as set forth on Schedule 3.18(a) of the BRPA
Schedules, other than confidentiality and non-disclosure agreements, there
are no contracts, agreements, leases, mortgages, indentures, notes,
bonds, Liens, license, permit, franchise, purchase orders, sales orders
or other understandings, commitments or obligations (including
without limitation outstanding offers or proposals) of any kind,
whether written or oral, to which BRPA or Merger Sub is a party or by or
to which any of the properties or assets of BRPA or Merger Sub may be bound,
subject or affected, which may not be cancelled without penalty or liability
by BRPA on less than 30 days' or less prior notice ("BRPA Contracts"). All
BRPA Contracts are listed in Schedule 3.18(a) of the BRPA Schedules other
than those that are exhibits to the BRPA SEC Reports.

 

 

 (b) Except as set forth in the BRPA SEC Reports filed prior to the date
of this Agreement, each BRPA Contract was entered into at arms' length and
in the ordinary course, is in full force and effect, and is valid and binding
upon and enforceable against each of the parties thereto, except insofar as
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, or similar laws affecting creditors' rights
generally or by principles governing the availability of equitable remedies.
True, correct, and complete copies of all BRPA Contracts (or
written summaries in the case of oral BRPA Contracts) have been
made available to the Company or Company counsel.

 

 

 (c) Neither BRPA, Merger Sub, nor, to the knowledge of BRPA, any other
party thereto is in breach of or in default under, and no event has occurred
which with notice or lapse of time or both would become a breach of or
default under, any BRPA Contract, and no party to any BRPA Contract has given
any written notice of any claim of any such breach, default or event under a
BRPA Contract.

 

 

 3.19 Insurance. Except for directors' and officers' liability insurance,
neither BRPA nor Merger Sub maintains any Insurance Policy.

 

 

 

 

 

 

 

 

40

 

 

 

 

 

 

 

 

 

 

 

 3.20 Interested Party Transactions. Except as set forth on Schedule 3.20
of the BRPA Schedules or in the BRPA SEC Reports, none of BRPA or
its Subsidiaries is a party to any transaction, agreement, arrangement or
understanding with any (i) present or former executive officer or director of
any of BRPA or its Subsidiaries, (ii) beneficial owner (within the meaning of
Section 13(d) of the Exchange Act) of 5% or more of the capital stock or
equity interests of any of BRPA or its Subsidiaries or (iii)
Affiliate, "associate" or member of the "immediate family" (as such terms
are respectively defined in Rules 12b-2 and 16a-1 of the Exchange Act) of any
of the foregoing (each of the foregoing, an "BRPA Affiliate Agreement").

 

 

 3.21 BRPA Listing. The BRPA Common Stock, BRPA Warrants, BRPA Rights, and
BRPA Units are listed for trading on the Nasdaq Capital Market ("Nasdaq").
Except as set forth in the BRPA SEC Reports or Schedule 3.21 of the
BRPA Schedules, there is no, and there has not been any, action
or proceeding pending or, to BRPA's knowledge, threatened against BRPA by
Nasdaq with respect to any intention by such entity to prohibit or terminate
the listing of BRPA Common Stock on Nasdaq. None of BRPA, Merger Sub, or any
of its or their Affiliates has taken any action in an attempt to terminate
the registration of the BRPA Common Stock under the Exchange Act.

 

 

 3.22 Trust Fund. As of the date hereof, BRPA has no less than five million
nine hundred thousand dollars ($5,900,000) in a trust account administered
by Continental, such monies being invested in United States
Government securities or money market funds meeting the conditions under
Rule 2a-7(d) promulgated under the Investment Company Act of 1940,
as amended (the "Trust Fund"), held in trust pursuant to that
certain Investment Management Trust Agreement, dated as of November
20, 2017, between BRPA and Continental (the "Trust Agreement"). The Trust
Agreement is valid and in full force and effect and enforceable in accordance
with its terms and has not been amended or modified. There are no separate
contracts, side letters or other arrangements or understandings (whether
written or unwritten, express or implied) that would cause the description of
the Trust Agreement in the BRPA SEC Reports to be inaccurate or that
would entitle any Person (other than pursuant to valid redemptions by BRPA
Stockholders) to any portion of the proceeds in the Trust Fund. There are no
proceedings pending or, to the knowledge of BRPA, threatened with respect to
the Trust Fund. The Trust Fund will be utilized in accordance with Section
5.13.

 

 

 3.23 Registration Statement. None of the information relating to BRPA and
Merger Sub to be included in the Registration Statement will, as of the date
the Registration Statement (or any amendment or supplement thereto) is first
mailed to the BRPA Stockholders, at the time of the BRPA Special Meeting, or
at the Effective Time, contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading;
provided, however, notwithstanding the foregoing provisions of this Section
3.23, no representation or warranty is made by BRPA with respect
to information or statements made or incorporated by reference in
the Registration Statement that were not supplied by or on behalf of BRPA
for use therein.

 

 

 3.24 No Additional Representations and Warranties; No Reliance. Except
as provided in this Article III (as modified by the BRPA Schedules), neither
BRPA, Merger Sub, any of its or their Affiliates, nor any of
their respective directors, officers, employees, shareholders,
partners, members or representatives has made, or is making,
any representation or warranty whatsoever to the Company, any Subsidiary, or
their Affiliates, and no such Party shall be liable in respect of the
accuracy or completeness of any information provided to the Company, any
Subsidiary or their Affiliates. BRPA and Merger Sub each acknowledges and
agrees (on its own behalf and on behalf of its Affiliates and its respective
Representatives) that: (i) it has conducted its own independent investigation
of the financial condition, results of operations, assets,
liabilities, properties and projected operations of the Company and
its Subsidiaries; (ii) it has been afforded satisfactory access to the books
and records, facilities and personnel of the Company and its Subsidiaries for
purposes of conducting such investigation; (iii) except for the
representations and warranties set forth in Article II (as modified by the
Company Schedules), it is not relying on any representations and warranties
from any Person in connection with the Transactions, and (iv) neither the
Company nor any of its stockholders, Affiliates or Representatives is making,
directly or indirectly, any representation or warranty with respect to
any estimates, projections or forecasts involving the Company. Neither the
Company nor any of its stockholders, Affiliates or Representatives shall have
any liability to BRPA or Merger Sub or any of their respective stockholders,
Affiliates or Representatives resulting from the use of any information,
documents or materials made available to BRPA, Merger Sub or any of their
Representatives, whether orally or in writing, in any confidential
information memoranda, "data rooms," management presentations, due diligence
discussions or in any other form in expectation of the Transactions except as
set forth in this Agreement and the Ancillary Agreements.

 

 

 

 

 

 

 

41

 

 

 

 

 

 

 

 

 

 

 

  ARTICLE IV

 

 

 CONDUCT PRIOR TO CLOSING

 

 

 4.1 Conduct of Business by the Company. During the period from the date of
this Agreement and continuing until the earlier of the termination of this
Agreement pursuant to its terms and the Closing (the "Interim Period"), each
of the Company and the Company's Subsidiaries shall, except to the extent
that BRPA shall otherwise consent in writing (which consent shall not be
unreasonably withheld, conditioned or delayed) or as set forth in Schedule
4.1 of the Company Schedules or as contemplated by this Agreement, carry
on its business in the usual, regular and ordinary course consistent with
past practices, in substantially the same manner as heretofore conducted and
in compliance with all applicable Legal Requirements (except as expressly
contemplated by Schedule 4.1 of the Company Schedules) and use its
commercially reasonable efforts consistent with past practices and policies
to (i) preserve substantially intact its present business organization, (ii)
keep available the services of its present key officers and employees, and
(iii) preserve its relationships with key customers, suppliers, distributors,
licensors, licensees, and others with which it has significant business
dealings; provided, that, in the case of each of the preceding clauses
(i)-(iii), during any period of full or partial suspension of operations
related to COVID-19 or SARS-CoV-2 virus (or any mutation or variation
thereof), the Company may, in connection with the COVID-19 pandemic (or
any mutation or variation thereof), take such actions as are
reasonably necessary (A) to protect the health and safety of the Company's
or its Subsidiaries' employees and other individuals having business dealings
with the Company or its Subsidiaries or (B) to reasonably respond to third-
party supply or service disruptions caused by the COVID-19 pandemic, COVID-19
or SARS-CoV-2 virus (or any mutation or variation thereof), shall provide
prompt notice to BRPA of the taking of any action permitted by this proviso.
In addition, except as required or permitted or contemplated by the terms of
this Agreement or as set forth in Schedule 4.1 of the Company Schedules,
without the prior written consent of BRPA, which consent shall not be
unreasonably withheld, conditioned or delayed, during the Interim Period, the
Company and the Company's Subsidiaries shall not do any of the following:

 

 

 (a) Waive any stock repurchase rights, accelerate, amend or (except
as specifically provided for herein) change the period of exercisability of
options or restricted stock, or reprice options granted under any Plan or
authorize cash payments in exchange for any options granted under any Plan;

 

 

 (b) Grant any material severance or termination pay to (i) any officer or
(ii) any employee, except pursuant to applicable Legal Requirements, written
agreements outstanding, or Plans or policies existing on the date hereof
and as previously or concurrently disclosed or made available to the other
Party, or in the case of the Company and its Subsidiaries except in
connection with the promotion, hiring or firing of any employee in the
ordinary course of business consistent with past practice;

 

 

 (c) Abandon, dispose of, allow to lapse, transfer, sell, assign, or
exclusively license to any Person or otherwise extend, amend or modify
any existing or future Intellectual Property Rights;

 

 

 

 

 

 

 

 

42

 

 

 

 

 

 

 

 

 

 

 

 (d) Fail to pay its accounts payable or collect its accounts receivable
in accordance with past practices;

 

 

 (e) Declare, set aside or pay any dividends on or make any other
distributions (whether in cash, stock, equity securities or property) in
respect of any capital stock or other equity securities (other than any such
dividend or distribution by a Subsidiary of the Company to the Company or
another such Subsidiary), or split, combine or reclassify any capital stock
or other equity securities or issue or authorize the issuance of any other
securities in respect of, in lieu of or in substitution for any
capital stock;

 

 

 (f) Purchase, redeem or otherwise acquire, directly or indirectly, any
shares of capital stock or other equity securities or ownership interests;

 

 

 (g) Issue, deliver, sell, authorize, pledge or otherwise encumber, or agree
to any of the foregoing with respect to, any shares of capital stock or
other equity securities or ownership interests or any securities convertible
into or exchangeable for shares of capital stock or other equity securities
or ownership interests, or subscriptions, rights, warrants or options to
acquire any shares of capital stock or other equity securities or ownership
interests or any securities convertible into or exchangeable for shares of
capital stock or other equity securities or other ownership interests, or
enter into other agreements or commitments of any character obligating it
to issue any such shares, equity securities or other ownership interests or
convertible or exchangeable securities at an implied equity valuation of the
Company of less than $500,000,000; provided that this clause (g) shall
not prohibit the issuances of shares in respect of any exercise of Company
Stock Options, which shares, for the avoidance of doubt, will be converted
into the Per Share Merger Consideration pursuant to Section 1.3(b);
provided, further, that the Company may grant equity compensation awards in
respect of shares of Company Common Stock in connection with the hiring of
new employees or promotions of employees or pursuant to Plans existing as of
the date hereof, which equity awards shall be treated for all purposes of
this Agreement as Company Stock Options;

 

 

 (h) Amend its Charter Documents in any material respect;

 

 

 (i) Acquire or agree to acquire by merging or consolidating with, or
by purchasing any equity interest in or a material portion of the assets of,
or by any other manner, any business or any corporation, partnership,
association, or other business organization or division thereof, or otherwise
acquire or agree to acquire outside the ordinary course of business any
assets which are material, individually or in the aggregate, to the business
of such Party or enter into any joint ventures, strategic partnerships or
alliances, or other arrangements that provide for exclusivity of territory
or otherwise restrict such Party's ability to compete or to offer or sell
any products or services to other Persons. For purposes of this paragraph,
"material" includes the requirement that, as a result of such transaction,
financial statements of the acquired, merged, or consolidated entity
be included in the Registration Statement;

 

 

 (j) Sell, lease, license, encumber or otherwise dispose of any properties
or assets, except the sale, lease or disposition of property or assets in
the ordinary course of business consistent with past practices that are not
material, individually or in the aggregate, to the business of the Company;

 

 

 

 

 

 

 

 

43

 

 

 

 

 

 

 

 

 

 

 

 (k) Except as contemplated by Section 5.15 hereunder, or as otherwise
required by applicable Legal Requirements or pursuant to an existing
Plan, policy or Company Contract, (i) adopt or materially amend any Plan
(including any Plan that provides for severance) or collective bargaining
agreement (in each case, other than in the ordinary course of business
consistent with past practice), (ii) pay any special bonus or special
remuneration to any director or employee, except in the ordinary course
of business consistent with past practices, or (iii) materially increase the
salaries or wage rates or fringe benefits (including rights to severance or
indemnification) of its directors, officers, employees or consultants, except
in the ordinary course of business consistent with past practices;

 

 

 (l) (i) Pay, discharge, settle or satisfy any material claims,
liabilities or obligations (absolute, accrued, asserted or
unasserted, contingent or otherwise), or litigation (whether or not
commenced prior to the date of this Agreement) other than the
payment, discharge, settlement or satisfaction of any claims, liabilities
or obligations in the ordinary course of business consistent with
past practices or in accordance with their terms, or recognized or disclosed
in the most recent Company Financial Statements, as applicable, or incurred
since the date of such financial statements, (ii) settle any material
litigation where the consideration given by the Party is other than monetary
or to which an officer, director or employee of such Person is a party in
his or her capacity as such, or (iii) waive the benefits of, agree to modify
in any material manner, terminate, release any Person from or knowingly fail
to enforce any material confidentiality or similar agreement to which the
Company or any of its Subsidiaries is a party or of which the Company any of
its Subsidiaries is a beneficiary (other than with customers and other
counterparties in the ordinary course of business consistent with
past practices);

 

 

 (m) Except in the ordinary course of business consistent with past
practices, modify in any material respect or terminate (other than
in accordance with its terms) any Material Company Contract or waive, delay
the exercise of, release or assign any material rights or claims thereunder;

 

 

 (n) Except as required by law or U.S. GAAP, revalue any of its assets in
any manner or make any change in accounting methods, principles
or practices;

 

 

 (o) Except (i) in the ordinary course of business consistent with
past practices, or (ii) in connection with the promotion, hiring or firing
of any employee, incur or enter into any agreement, contract or commitment
requiring such Party to pay in excess of $500,000 in any 12-month period;

 

 

 (p) Make, revoke, amend, or rescind any material Tax elections
that, individually or in the aggregate, would be reasonably likely
to adversely affect the Tax liability or Tax attributes of such
Party, settle or compromise any material income Tax liability outside
the ordinary course of business or, except as required by applicable
Legal Requirements, change any material method of accounting for Tax
purposes or prepare or file any material Return in a manner inconsistent with
past practice;

 

 

 (q) Form or establish any Subsidiary except in the ordinary course
of business consistent with prior practice or as contemplated by
this Agreement;

 

 

 

 

 

 

 

 

44

 

 

 

 

 

 

 

 

 

 

 

 (r) Make capital expenditures in excess of $500,000;

 

 

 (s) Enter into any material transaction with or distribute or advance
any assets or property to any of its officers, directors,
partners, stockholders, managers, members or other Affiliates other than (i)
the payment of salary and benefits and the advancement of expenses in the
ordinary course of business consistent with prior practice or (ii)
such distributions or advancements by a Subsidiary of the Company to
the Company or another such Subsidiary;

 

 

 (t) Close any facility or discontinue any material line of business or
any material business operations; or

 

 

 (u) Agree in writing or otherwise agree or commit to take any of the
actions described in Section 4.1(a) through (t) above.

 

 

 4.2 Conduct of Business by BRPA and Merger Sub. During the Interim Period,
each of BRPA and Merger Sub shall, except to the extent that the Company
shall otherwise consent in writing (which consent shall not be unreasonably
withheld, conditioned or delayed) or as set forth in  Schedule 4.2 of the
BRPA Schedules or as contemplated by this Agreement, carry on its business in
the usual, regular and ordinary course consistent with past practices, in
substantially the same manner as heretofore conducted and in compliance with
all applicable Legal Requirements (except as expressly contemplated by
 Schedule 4.2 of the BRPA Schedules) and use its reasonable best efforts
consistent with past practices and policies to (i) preserve substantially
intact its present business organization and (ii) keep available the services
of its present key officers. In addition, except as required or permitted or
contemplated by the terms of this Agreement or as set forth in  Schedule 4.2
of the BRPA Schedules, without the prior written consent of the Company,
which consent shall not be unreasonably withheld, conditioned or delayed,
during the Interim Period, BRPA and Merger Sub shall not do any of
the following:

 

 

 (a) Waive any stock repurchase rights;

 

 

 (b) Grant any severance or termination pay to, or hire, any (i) officer
or (ii) any employee;

 

 

 (c) Abandon, dispose of, allow to lapse, transfer, sell, assign, or
exclusively license to any Person or otherwise extend, amend or modify
any existing or future Intellectual Property Rights;

 

 

 (d) Fail to pay its accounts payable or collect its accounts receivable
in accordance with past practices;

 

 

 (e) Declare, set aside or pay any dividends on or make any other
distributions (whether in cash, stock, equity securities or property) in
respect of any capital stock or other equity securities, or split,
combine or reclassify any capital stock or other equity securities or
issue or authorize the issuance of any other securities in respect of,
in lieu of or in substitution for any capital stock;

 

 

 

 

 

 

 

 

45

 

 

 

 

 

 

 

 

 

 

 

 (f) Purchase, redeem or otherwise acquire, directly or indirectly, any
shares of capital stock or other equity securities or ownership
interests, except with respect to redemptions of BRPA Common Stock by
BRPA Stockholders in connection with the Offer;

 

 

 (g) Issue, deliver, sell, authorize, pledge or otherwise encumber, or agree
to any of the foregoing with respect to, any shares of capital stock or
other equity securities or ownership interests or any securities convertible
into or exchangeable for shares of capital stock or other equity securities
or ownership interests, or subscriptions, rights, warrants or options to
acquire any shares of capital stock or other equity securities or ownership
interests or any securities convertible into or exchangeable for shares of
capital stock or other equity securities or other ownership interests, or
enter into other agreements or commitments of any character obligating it
to issue any such shares, equity securities or other ownership interests or
convertible or exchangeable securities;

 

 

 (h) Amend its Charter Documents in any respect, other than (1) to
effectuate the BRPA AandR Charter and the BRPA AandR Bylaws or (2) make any
necessary amendments to the BRPA's Amended and Restated Certificate of
Incorporation solely in connection with the Extension;

 

 

 (i) Acquire or agree to acquire by merging or consolidating with, or
by purchasing any equity interest in or a portion of the assets of, or by
any other manner, any business or any corporation, partnership, association,
or other business organization or division thereof, or otherwise acquire or
agree to acquire any assets or enter into any joint ventures, strategic
partnerships or alliances, or other arrangements that provide for exclusivity
of territory or otherwise restrict such Party's ability to compete or to
offer or sell any products or services to other Persons;

 

 

 (j) Sell, lease, license, encumber or otherwise dispose of any properties
or assets;

 

 

 (k) Except for BRPA Borrowings, incur any indebtedness for borrowed money
or guarantee any such indebtedness of another Person or Persons (other than
Affiliates), issue or sell any debt securities or options, warrants, calls or
other rights to acquire any debt securities, enter into any "keep well" or
other agreement to maintain any financial statement condition or enter into
any arrangement having the economic effect of any of the foregoing;

 

 

 (l) (i) Adopt or materially amend any Plan (including any Plan
that provides for severance), or enter into any employment contract
or collective bargaining agreement (other than in the ordinary course of
business consistent with past practice), (ii) pay any special bonus or
special remuneration to any director or employee, or (iii) increase the
salaries or wage rates or fringe benefits (including rights to severance or
indemnification) of its directors, officers, employees or consultants;

 

 

 (m) (i) Pay, discharge, settle or satisfy any claims, liabilities
or obligations (absolute, accrued, asserted or unasserted, contingent or
otherwise), or litigation (whether or not commenced prior to the date of this
Agreement), or (ii) waive the benefits of, agree to modify in any material
manner, terminate, release any Person from or knowingly fail to enforce any
material confidentiality or similar agreement to which the BRPA or any of its
Subsidiaries is a party or of which BRPA or any of its Subsidiaries is
a beneficiary;

 

 

 

 

 

 

 

 

46

 

 

 

 

 

 

 

 

 

 

 

 (n) Except in the ordinary course of business consistent with past
practices, modify in any respect or terminate (other than in accordance
with its terms) any BRPA Contract, as applicable, or waive, delay
the exercise of, release or assign any material rights or claims thereunder;

 

 

 (o) Except as required by law or U.S. GAAP, revalue any of its assets in
any manner or make any change in accounting methods, principles
or practices;

 

 

 (p) Incur or enter into any agreement, contract or commitment requiring
such Party to pay in excess of $10,000 in any 12-month period;

 

 

 (q) Make, revoke, amend, or rescind any Tax elections that, individually
or in the aggregate, would be reasonably likely to adversely affect the Tax
liability or Tax attributes of such Party, settle or compromise any income
Tax liability outside the ordinary course of business or, except as
required by applicable Legal Requirements, change any method of accounting
for Tax purposes or prepare or file any Return in a manner inconsistent with
past practice;

 

 

 (r) Form or establish any Subsidiary except as contemplated by
this Agreement;

 

 

 (s) Make capital expenditures;

 

 

 (t) Enter into any transaction with or distribute or advance any assets
or property to any of its officers, directors, partners,
stockholders, managers, members or other Affiliates;

 

 

 (u) enter into, renew or amend in any material respect, any BRPA
Affiliate Agreement (or any contract, that if existing on the date
hereof, would have constitute an BRPA Affiliate Agreement); or

 

 

 (v) Agree in writing or otherwise agree or commit to take any of the
actions described in Section 4.2(a) through (v) above.

 

 

 4.3 Confidentiality; Access to Information.

 

 

 (a) Confidentiality. BRPA acknowledges that the information being provided
to it in connection with this Agreement and the consummation of
the Transactions is subject to the terms of the Confidentiality Agreement,
the terms of which are incorporated herein by reference. At the Effective
Time, the Confidentiality Agreement shall terminate with respect to
information relating to the Company and its Subsidiaries.

 

 

 

 

 

 

 

 

47

 

 

 

 

 

 

 

 

 

 

 

 (b) Access to Information.

 

 

 (i) Subject to the terms of the Confidentiality Agreement and any
other confidentiality obligations and similar restrictions that may
be applicable to information furnished to the Company or its Subsidiaries by
third parties that may be in the Company's or its Subsidiaries' possession
from time to time, and except for any information which (x) in the opinion of
legal counsel of the Company would result in the loss of attorney-client
privilege or other privilege from disclosure or would conflict with
any applicable law, or (y) relates to interactions with prospective buyers
of the Company or the negotiation of this Agreement and the Transactions, the
Company will afford BRPA and its Representatives (subject to the execution of
customary access letters) reasonable access during normal business hours,
upon reasonable notice, in such manner as to not interfere with the normal
operation of the Company and its Subsidiaries, to the properties, books,
records and management personnel of the Company during the Interim Period
to obtain all information concerning the business, including the status of
business development efforts, properties, results of operations and personnel
of the Company, as BRPA may reasonably request; provided, that such access
shall not include any invasive or intrusive investigations or other testing,
sampling or analysis of any properties, facilities or equipment of the
Company or its Subsidiaries without the prior written consent of the Company.
The Parties shall use reasonable best efforts to make
alternative arrangements for such disclosure where the restrictions in
the preceding sentence apply. No information or knowledge obtained by BRPA
in any investigation pursuant to this Section 4.3(b)(i) will affect or be
deemed to modify any representation or warranty contained herein or the
conditions to the obligations of the Parties to consummate the Merger.

 

 

 (ii) Subject to the terms of the Confidentiality Agreement and any
other confidentiality obligations and similar restrictions that may
be applicable to information furnished to BRPA by third parties that may be
in BRPA's possession from time to time, and except for any information which
(x) in the opinion of legal counsel of BRPA would result in the loss of
attorney-client privilege or other privilege from disclosure or would
conflict with any applicable law, or (y) relates to interactions with
prospective targets for a Business Combination or the negotiation of this
Agreement and the Transactions, BRPA will afford the Company and its
Representatives (subject to the execution of customary access letters)
reasonable access during normal business hours, upon reasonable notice,
in such manner as to not interfere with the normal operation of BRPA, to the
properties, books, records and personnel of BRPA during the Interim Period to
obtain all information concerning the business, including properties, results
of operations and personnel of BRPA, as the Company may reasonably request.
The Parties shall use reasonable best efforts to make alternative
arrangements for such disclosure where the restrictions in the preceding
sentence apply. No information or knowledge obtained by the Company in
any investigation pursuant to this Section 4.3(b)(ii) will affect or be
deemed to modify any representation or warranty contained herein or the
conditions to the obligations of the Parties to consummate the Merger.

 

 

 

 

 

 

 

 

48

 

 

 

 

 

 

 

 

 

 

 

 4.4 Exclusivity.

 

 

 (a) During the Interim Period, to the extent not inconsistent with
the fiduciary duties of the BRPA Board, BRPA shall not, shall cause
its Subsidiaries not to, and shall use its reasonable best efforts to cause
its and their Representatives not to, directly or indirectly, solicit,
initiate, enter into, or continue discussions, negotiations, or transactions
with, or encourage or respond to any inquiries or proposals by, or provide
any information to any Person relating to, or enter into or consummate any
transaction relating to, (i) any Business Combination, merger, or sale of
ownership interests or material assets of BRPA, or a recapitalization,
share exchange, or similar transaction with respect to BRPA or any of
its Subsidiaries or (ii) any financing, investment, acquisition, purchase,
merger, sale or any other similar transaction that would restrict, prohibit
or inhibit the Company's or BRPA's ability to consummate the Merger and the
other Transactions, in each case, other than the Merger and the other
Transactions (the transactions in subsections (i) and (ii),
collectively "BRPA Competing Transactions"). In addition, BRPA will, and
will cause its Subsidiaries and use reasonable best efforts to cause its and
their Representatives to, promptly cease any and all existing discussions or
negotiations with any Person conducted heretofore with respect to any
BRPA Competing Transaction. BRPA will promptly (and in any event within two
(2) Business Days) notify the Company if BRPA or any of its Subsidiaries, or,
to BRPA's knowledge, any of BRPA's Representatives receives any inquiry,
proposal, offer or submission with respect to a BRPA Competing Transaction
(including the identity of the Person making such inquiry or submitting
such proposal, offer or submission), after the execution and delivery
of this Agreement, and will provide the Company with a copy of such inquiry,
proposal, offer or submission.

 

 

 (b) During the Interim Period, to the extent not inconsistent with
the fiduciary duties of the Company Board, the Company shall not,
shall cause its Subsidiaries not to, and shall use its reasonable
best efforts to cause its and their Representatives not to, directly
or indirectly, solicit, initiate, enter into, or continue
discussions, negotiations, or transactions with, or encourage or respond to
any inquiries or proposals by, or provide any information to any
Person relating to, or enter into or consummate any transaction relating to,
(i) any merger or sale of ownership interests or material assets of the
Company, or a recapitalization, share exchange, or similar transaction with
respect to the Company or any of its Subsidiaries or (ii) any financing,
investment, acquisition, purchase, merger, sale or any other similar
transaction that would restrict, prohibit or inhibit the Company's or
BRPA's ability to consummate the Merger and the other Transactions, in each
case, other than the Merger and the other Transactions (the transactions in
subsections (i) and (ii), collectively "Company Competing Transactions").
In addition, the Company will, and will cause its Subsidiaries and
use reasonable best efforts to cause its and their Representatives
to, promptly cease any and all existing discussions or negotiations with any
Person conducted heretofore with respect to any Company Competing
Transaction. The Company will promptly (and in any event within two (2)
Business Days) notify BRPA if the Company or any of its Subsidiaries, or, to
the Company's knowledge, any of the Company's Representatives receives any
inquiry, proposal, offer or submission with respect to a Company Competing
Transaction (including the identity of the Person making such inquiry
or submitting such proposal, offer or submission), after the execution and
delivery of this Agreement, and will provide BRPA with a copy of such
inquiry, proposal, offer or submission.

 

 

 

 

 

 

 

 

49

 

 

 

 

 

 

 

 

 

 

 

 (c) Notwithstanding anything in this Agreement to the contrary, nothing
contained in this Agreement shall restrict or limit the ability of the
Company Board or the BRPA Board from exercising or acting in accordance with
their respective fiduciary duties under applicable law. The Parties agree
that the rights and remedies for noncompliance with this Section 4.4 include
specific performance, it being acknowledged and agreed that any breach or
threatened breach will cause irreparable injury to the non-breaching Party
and that money damages would not provide an adequate remedy for such injury.

 

 

 (d) Notwithstanding anything in this Agreement to the contrary, if, at any
time prior to obtaining the Company Stockholder Approval, the Company
Board determines in good faith, after consultation with its outside
legal counsel, in response to any proposal or offer from any Person
or "group" (as defined in the Exchange Act) to the Company or the Company
Board with respect to a Company Competing Transaction (such proposal or
offer, an "Acquisition Proposal") that such Acquisition Proposal constitutes
a Superior Proposal and that the failure to terminate this Agreement pursuant
to Section 7.1(h) to enter into a definitive agreement with respect to such
Superior Proposal would be inconsistent with its fiduciary duties under
applicable law, the Company or the Company Board may, prior to obtaining the
Company Stockholder Approval, terminate this Agreement pursuant to Section
7.1(h) to enter into a definitive agreement with respect to such Superior
Proposal; provided, that the Company pays to BRPA the Termination Fee
required to be paid pursuant Section 7.2(b)(i) at or after the time of such
termination in accordance with Section 7.2(b)(i); provided, further, that
the Company will not be entitled to terminate this Agreement in accordance
with Section 7.1(h) unless the Company delivers to BRPA a written notice
advising BRPA that the Company Board proposes to take such action. For
purposes of this Agreement, "Superior Proposal" means a bona fide and
written Acquisition Proposal made after the date hereof that the Company
Board in good faith determines (after consultation with its outside legal
counsel) is reasonably likely to be consummated in accordance with its terms
and would, if consummated, result in a transaction that is more favorable
from a financial point of view to the stockholders of the Company (solely in
their capacity as such) than the transactions contemplated hereby
after taking into account all such factors and matters deemed relevant
in good faith by the Company Board, including legal, financial (including
the financing terms of any such proposal), regulatory, timing or other
aspects of such proposal and this Agreement and the transactions contemplated
hereby.

 

 

 4.5 Reasonable Best Efforts. Upon the terms and subject to the conditions
set forth in this Agreement, each of the Parties agrees to use its reasonable
best efforts to take, or cause to be taken, all actions, and to do, or cause
to be done, and to assist and cooperate with the other parties in doing, all
things reasonably necessary, proper or advisable to consummate and
make effective, in the most expeditious manner practicable, the
Merger, including using reasonable best efforts to accomplish the following:
(i) the taking of such reasonable acts necessary to cause the conditions
precedent set forth in Article VI to be satisfied, (ii) the obtaining of such
reasonably necessary actions, waivers, consents, approvals, orders and
authorizations from Governmental Entities and the making of such
reasonably necessary registrations, declarations and filings
(including registrations, declarations and filings with Governmental
Entities, if any) and the taking of such reasonable steps as may
be reasonably necessary to avoid any suit, claim, action, investigation or
proceeding by any Governmental Entity, (iii) the obtaining of such material
consents, approvals or waivers from third parties required as a result of the
Merger, including the consents referred to in Schedule 2.5 of the Company
Schedules, (iv) the defending of any suits, claims, actions, investigations
or proceedings, whether judicial or administrative, challenging this
Agreement or the consummation of the Merger, including seeking to have any
stay or temporary restraining order entered by any court or other
Governmental Entity vacated or reversed, and (v) the execution or delivery of
any additional instruments reasonably necessary to consummate
the transactions contemplated by, and to fully carry out the purposes of,
this Agreement. Notwithstanding anything herein to the contrary, nothing in
this Agreement shall be deemed to require BRPA or the Company to agree to any
divestiture by itself or any of its Affiliates of shares of capital stock or
of any business, assets or property, or the imposition of any material
limitation on the ability of any of them to conduct their business or to own
or exercise control of such assets, properties and stock.

 

 

 

 

 

 

 

 

50

 

 

 

 

 

 

 

 

 

 

 

  ARTICLE V

 

 

 ADDITIONAL AGREEMENTS

 

 

 5.1 Registration Statement; BRPA Special Meeting.

 

 

 (a) As promptly as practicable after the execution of this Agreement,
BRPA (with the assistance and cooperation of the Company as
reasonably requested by BRPA) shall use reasonable best efforts to prepare
and file with the SEC a registration statement on Form S-4 (as amended or
supplemented from time to time, and including the Proxy Statement and the
Consent Solicitation Statement contained therein, the
"Registration Statement") in connection with the registration under the
Securities Act of the BRPA Common Stock to be issued under this Agreement,
which Registration Statement will also contain the Proxy Statement and the
Consent Solicitation Statement. The Registration Statement shall include for
registration all shares of BRPA Common Stock issued under this Agreement,
including the Earnout Shares.

 

 

 (b) BRPA agrees to include provisions in the Proxy Statement and to
take reasonable action related thereto, with respect to (i) the approval of
the Business Combination and the adoption and approval of this Agreement (the
"Transaction Proposal"), (ii) the approval of the BRPA AandR Charter
(the "AandR Charter Proposal") and each change to the BRPA AandR Charter that
is required to be separately approved, (iii) the approval of amended and
restated bylaws of BRPA ("AandR Bylaws Proposal"); (iv) to the extent
required by the Nasdaq listing rules, the approval of the issuance of the
aggregate Per Share Merger Consideration, the Earnout Shares, and any BRPA
Common Stock issued in a Financing, if any (the "Nasdaq Proposal"), (v)
the approval of the election of each of the directors nominated to comprise
the board of directors of BRPA (the "Election of Directors Proposal"), (vi)
the approval and adoption of the BRPA Plan (the "BRPA Plan Proposal"),
(vii) adjournment of the BRPA Special Meeting, if necessary, to
permit further solicitation of proxies because there are not
sufficient votes to approve and adopt any of the foregoing proposals or
if BRPA and the Company mutually determine that the Merger cannot
be consummated for any reason, and (viii) the approval of any
other proposals reasonably agreed by BRPA and the Company to be necessary or
appropriate in connection with the transaction contemplated hereby (the
"Additional Proposal" and together with the Transaction Proposal, the AandR
Charter Proposal, the AandR Bylaws Proposal, the Nasdaq Proposal, the Election
of Directors Proposal and the BRPA Plan Proposal, the "BRPA
Stockholder Matters"). Without the prior written consent of the Company, the
BRPA Stockholder Matters shall be the only matters (other than procedural
matters) that BRPA shall propose to be acted on by BRPA's stockholders at
the BRPA Special Meeting.

 

 

 (c) The Company shall provide to BRPA all financial and other
information relating to the Company as BRPA may reasonably request for
the preparation of the Registration Statement. BRPA, with the assistance of
the Company, shall promptly respond to any SEC comments on the Registration
Statement and shall otherwise use reasonable best efforts to cause the
Registration Statement to be approved by the SEC as promptly as practicable.
BRPA shall also take any and all actions required to satisfy the requirements
of the Securities Act and the Exchange Act. BRPA will advise the Company
promptly after it receives notice of: (i) the time when the preliminary
Registration Statement has been filed; (ii) in the event the preliminary
Registration Statement is not reviewed by the SEC, the expiration of the
waiting period in Rule 14a-6(a) under the Exchange Act; (iii) in the event
the preliminary Registration Statement is reviewed by the SEC, receipt of
oral or written notification of the completion of the review by the SEC; (iv)
the filing of any supplement or amendment to the Registration Statement; (v)
any request by the SEC for amendment of the Registration Statement; (vi) any
comments from the SEC relating to the Registration Statement and responses
thereto; and (vii) requests by the SEC for additional information.

 

 

 

 

 

 

 

 

51

 

 

 

 

 

 

 

 

 

 

 

 (d) As soon as practicable following the SEC declaring the
Registration Statement effective (the "SEC Approval Date"), (x) BRPA
shall (i) distribute the Registration Statement to the BRPA
Stockholders, (ii) having, prior to the SEC Approval Date, established the
record date therefor (which record date shall be mutually agreed with
the Company), duly call, give notice of, convene and hold the BRPA Special
Meeting in accordance with the DGCL and subject to the other provisions of
this Agreement, and (iii) subject to the other provisions of this Agreement,
solicit proxies from such holders to vote in favor of the BRPA Stockholder
Matters in compliance with the DGCL and (y) the Company shall distribute the
Consent Solicitation Statement to the Company Stockholders in
accordance with Section 5.16. Notwithstanding the foregoing provisions of
this Section 5.1(d), if on a date for which the BRPA Special Meeting is
scheduled, BRPA and the Company mutually determine that the Merger cannot
be consummated for any reason, BRPA shall have the right (subject
to obtaining the Company's prior written consent, which shall not be
unreasonably withheld, conditioned, or delayed) to make one or more
successive postponements or adjournments of the BRPA Special Meeting,
provided that BRPA continues to satisfy its obligations under Section
5.1(f) below.

 

 

 (e) BRPA and the Company shall each use their reasonable best efforts
to comply with all applicable provisions of and rules under the Securities
Act, Exchange Act, all applicable provisions of the DGCL, as applicable, in
the preparation, filing and distribution of the Registration Statement. BRPA
shall use its reasonable best efforts to comply with all applicable
provisions of and rules under the Securities Act, Exchange Act, all
applicable provisions of the DGCL, as applicable, in the solicitation of
proxies thereunder, and the calling and holding of the BRPA Special Meeting.
Without limiting the foregoing, BRPA and the Company shall each use
their reasonable best efforts to cause the Registration Statement when filed
with the SEC to comply in all material respects with all Legal Requirements
applicable thereto and to not contain any untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements
made in light of the circumstances under which they were made, not misleading
(provided that no Party shall be responsible for the accuracy or
completeness of any information relating to another Party or any
other information furnished by another Party for inclusion in
the Registration Statement).

 

 

 (f) BRPA, acting through the BRPA Board, shall recommend to its
stockholders that they approve the BRPA Stockholder Matters (the "BRPA
Board Recommendation") and shall include the BRPA Board Recommendation in
the Proxy Statement, subject to the provisions of this Section
5.1(f). Neither the BRPA Board nor any committee or agent or representative
thereof shall withhold, withdraw or modify, or publicly propose or resolve to
withhold, withdraw or modify in a manner adverse to the Company the
BRPA Board Recommendation (any such event, a "BRPA Change in
Recommendation"); provided, that the BRPA Board may make a BRPA Change in
Recommendation if it determines in good faith, after consultation with its
outside legal counsel, that a failure to make a BRPA Change in Recommendation
would be inconsistent with its fiduciary duties under applicable
Legal Requirements.

 

 

 5.2 Directors and Officers of BRPA After Transactions. The Parties
shall take all necessary action so that the persons listed on Schedule 5.2
of the Company Schedules are elected and appointed to the positions
of officers and directors of BRPA as set forth therein, to serve in such
positions effective immediately after the Closing. If any Person listed on
Schedule 5.2 of the Company Schedules is unable to serve, the
Party appointing such Person shall designate a successor. Except
as otherwise agreed in writing by the Company and BRPA prior to the Closing,
the Parties shall take all necessary action so that all of the members of the
board of directors of BRPA and all officers of BRPA resign effective as of
the Closing unless such member or officer is included on Schedule 5.2 of the
Company Schedules.

 

 

 

 

 

 

 

 

52

 

 

 

 

 

 

 

 

 

 

 

 5.3 HSR Act.

 

 

 (a) If required pursuant to the HSR Act, as promptly as practicable,
BRPA and the Company shall use reasonable best efforts to (a) each prepare
and file the notification required of it thereunder in connection with the
Merger as soon as reasonably practicable but no later than twenty (20)
Business Days following January 14, 2021, (b) promptly and in good faith
respond to all information requested of it by the Federal Trade Commission
and Department of Justice in connection with such notification and otherwise
cooperate in good faith with each other and such Governmental Entities, (c)
each request early termination of any waiting period under the HSR Act, and
(d) submit, as soon as practicable, any other required applications or
filings pursuant to any Antitrust Laws and furnish to the other Party as
promptly as reasonably practicable all information required for any
application or other filing required to be made pursuant to any Antitrust
Law. BRPA and the Company shall substantially comply with any information or
document requests by the Federal Trade Commission or the Department
of Justice in connection with the Merger. BRPA and the Company shall (i)
promptly inform the other of any substantive communication to or from the
Federal Trade Commission, the Department of Justice or any other Governmental
Entity regarding the Merger and permit counsel to the other Party an
opportunity to review in advance, and each Party shall consider in good faith
the views of such counsel in connection with, any proposed written
communications by such Party to any Governmental Entity concerning the
Merger, (ii) give the other prompt notice of the commencement of any judicial
or administrative action, suit, litigation, arbitration, proceeding by or
before any Governmental Entity with respect to such transactions, and (iii)
keep the other reasonably informed as to the status of any such action. Each
Party agrees to provide, to the extent permitted by the applicable
Governmental Entity, the other Party and its counsel the opportunity, on
reasonable advance notice, to participate in any substantive meetings or
discussions, either in person or by telephone, between such Party and/or any
of its Affiliates, agents or advisors, on the one hand, and any Governmental
Entity, on the other hand, concerning or in connection with the Merger;
provided, neither Party shall extend any waiting period or comparable period
under the HSR Act or enter into any agreement with any Governmental Entity
without the written consent of the other Party. Any materials exchanged in
connection with this Section 5.3 may be redacted or withheld as necessary
to address reasonable privilege or confidentiality concerns of legal counsel
of the Company, and to remove references concerning the valuation of the
Company or other competitively sensitive material; provided, that the
Company may, as it deems advisable and necessary, designate any materials
provided to the BRPA under this Section 5.3 as "outside counsel
only." Filing fees with respect to the notifications required under the HSR
Act shall be paid by the Company.

 

 

 (b) BRPA shall not, and shall cause its Subsidiaries not to, acquire
or agree to acquire, by merging with or into or consolidating with, or by
purchasing a portion of the assets of or equity in, or by any other manner,
any business or any corporation, partnership, association or other business
organization or division thereof, or otherwise acquire or agree to acquire
any assets, or take any other action, if the entering into of a definitive
agreement relating to, or the consummation of such acquisition, merger or
consolidation, or the taking of any other action, would reasonably be
expected to (i) impose any material delay in the obtaining of, or
materially increase the risk of not obtaining, any authorizations,
consents, orders or declarations of any Governmental Entities or
the expiration or termination of any applicable waiting period;
(ii) materially increase the risk of any Governmental Entity entering
an order prohibiting the consummation of the transaction
contemplated hereby; (iii) materially increase the risk of not being able
to remove any such order on appeal or otherwise; or (iv) materially delay or
prevent the consummation of the transactions contemplated hereby.
Notwithstanding anything in this Agreement to the contrary, the restrictions
and obligations set forth in this Section 5.3(b) shall not apply to or be
binding upon BRPA's Affiliates, the Sponsor, their respective Affiliates or
any investment funds or investment vehicles affiliated with, or managed or
advised by, BRPA's Affiliates, the Sponsor, or any portfolio company (as such
term is commonly understood in the private equity industry) or investment of
BRPA's Affiliates, the Sponsor, or of any such investment fund or
investment vehicle.

 

 

 

 

 

 

 

 

53

 

 

 

 

 

 

 

 

 

 

 

 5.4 Public Announcements. Promptly after the execution of this Agreement,
BRPA and the Company shall issue a joint press release announcing the
execution of this Agreement, the text of which has been agreed to by each of
BRPA and the Company (the "Signing Press Release"). Prior to Closing, BRPA
and the Company shall prepare a press release announcing the consummation of
the Merger hereunder ("Closing Press Release").

 

 

 5.5 Required Information.

 

 

 (a) In connection with the preparation of the Registration Statement,
the Signing Press Release, the Closing Press Release, each Current Report on
Form 8-K proposed to be filed or furnished by BRPA under the Exchange Act
relating to or in connection with the Transactions, each document required to
be filed with the SEC pursuant to Rule 425 promulgated under the Securities
Act or Rule 14a-12 promulgated under the Exchange Act, or any other
statement, filing, notice, or application (other than pursuant to the HSR
Act, for which Section 5.3 applies) made by or on behalf of BRPA or the
Company to any Governmental Entity or other third party in connection with
Merger or otherwise, or any press release or Form 8-K relating to the
business or financial condition of BRPA or the Company (other than regularly
released factual, non-forward-looking business information of the Company)
(each, a "Reviewable Document"), each of BRPA and the Company shall, upon
request by the other, use reasonable best efforts (subject to applicable
Legal Requirements and contractual restrictions) to promptly furnish the
other with all information concerning themselves, their Subsidiaries, and
each of their and their Subsidiaries' respective directors, officers, and
stockholders (including the directors of BRPA to be elected effective as of
the Closing pursuant to Section 5.1(f) hereof) and such other matters as
may be reasonably necessary or advisable in connection with the Merger and
the preparation of such Reviewable Document.

 

 

 (b) At a reasonable time prior to the filing, furnishing, issuance,
or other submission or public disclosure of a Reviewable Document by BRPA or
the Company, the other Parties shall each be given a reasonable opportunity
to review and comment upon such Reviewable Document and give its consent to
the form thereof, such consent not to be unreasonably withheld, conditioned,
or delayed, and each Party shall accept and incorporate all reasonable
comments from the other Party to any such Reviewable Document prior to
filing, furnishing, issuance, submission or disclosure thereof.

 

 

 (c) Any language included in a Reviewable Document that reflects
the comments of the reviewing Party, as well as any text as to which the
reviewing Party has not commented upon after being given a reasonable
opportunity to comment, shall be deemed to have been approved by the
reviewing Party and may henceforth be used by the other Party in other
Reviewable Documents and in other documents distributed by the other Party in
connection with the Merger without further review or consent of the
reviewing Party.

 

 

 (d) Prior to the Closing Date, the Company and BRPA shall notify each
other as promptly as reasonably practicable (i) upon becoming aware of any
event or circumstance which should be described in an amendment of,
or supplement to, a Reviewable Document that has been filed with
or submitted to any Governmental Entity, and (ii) after the receipt by it of
any written or oral comments of any Governmental Entity on, or of any written
or oral request by any Governmental Entity for amendments or supplements to,
any such Reviewable Document, and shall promptly supply the other with copies
of all correspondence between it or any of its representatives and such
Governmental Entity with respect to any of the foregoing filings or
submissions, in each case, to the extent permitted by applicable
Legal Requirements. BRPA and the Company shall use their
respective reasonable best efforts, after consultation with each other,
to resolve all such requests or comments with respect to any Reviewable
Document as promptly as reasonably practicable after receipt of any comments
of any Governmental Entity. All correspondence and communications to any
Governmental Entity made by BRPA or the Company with respect to the Merger or
any agreement ancillary hereto shall, to extent permitted by applicable
Legal Requirements, be considered to be Reviewable Documents subject to the
provisions of this Section 5.5.

 

 

 

 

 

 

 

 

54

 

 

 

 

 

 

 

 

 

 

 

 5.6 No Securities Transactions. Neither the Company nor any of its
Affiliates, directly or indirectly, shall engage in any purchases or sales of
the securities of BRPA prior to the Effective Time without the consent of
BRPA, except as contemplated by this Agreement.

 

 

 5.7 No Claim Against Trust Fund. Notwithstanding anything else in this
Agreement, the Company acknowledges that it has read BRPA's final prospectus
dated November 20, 2017 and understands that BRPA has established the Trust
Fund for the benefit of BRPA's public shareholders and that BRPA
may disburse monies from the Trust Fund only (a) to BRPA's public
shareholders in the event they elect to convert their shares into cash in
accordance with BRPA's Charter Documents and/or the liquidation of BRPA or
(b) to BRPA after, or concurrently with, or in connection with the
consummation of a Business Combination. The Company further acknowledges
that, if the Merger, or, upon termination of this Agreement, another Business
Combination, is not consummated by December 23, 2020, or such later date as
shall be set forth in an amendment to BRPA's Amended and
Restated Certificate of Incorporation for the purpose of extending the
date by which BRPA must complete a Business Combination, BRPA will
be obligated to return to its shareholders the amounts being held in the
Trust Fund. Accordingly, the Company, for itself and the Company
Stockholders, directors, officers, employees, Representatives, Subsidiaries,
and Affiliates, hereby waives all rights, title, interest or claim of any
kind against BRPA to collect from the Trust Fund any monies that may be owed
to them by BRPA for any reason whatsoever, including but not limited to
a breach of this Agreement by BRPA or any negotiations, agreements
or understandings with BRPA (whether in the past, present or future), and
will not seek recourse against the Trust Fund at any time for any reason
whatsoever; provided that nothing herein shall amend, limit, alter, change,
supersede or otherwise modify the right of the Company to bring any action
or actions for specific performance, injunctive and/or other
equitable relief (including, without limitation, the right to compel
specific performance by BRPA and Merger Sub of their respective
obligations under this Agreement). This paragraph will survive
this Agreement and will not expire and will not be altered in any
way without the express written consent of BRPA.

 

 

 5.8 Disclosure of Certain Matters. Each of BRPA and the Company will
provide the other with prompt written notice of any event, development or
condition of which it obtains knowledge during the Interim Period that (a)
gives such Party any reasonable basis to believe that any of the conditions
to the obligations of the other Party set forth in Article VI will not
be satisfied;  provided,  however, that no such notice shall be deemed to
cure breach of this Agreement or (b) would require any amendment or
supplement to the Registration Statement.

 

 

 5.9 Securities Listing. BRPA shall use its reasonable best efforts to keep
the BRPA Common Stock listed for trading on Nasdaq from the date hereof and
through the Closing. BRPA shall use its reasonable best efforts to cause the
BRPA Common Stock to be issued in connection with the Transactions (including
the Earnout Shares) to have been approved for listing on Nasdaq as promptly
as practicable following the issuance thereof, subject only to official
notice of issuance thereof and the requirement to have a sufficient number
of round lot holders, prior to the Closing Date.

 

 

 

 

 

 

 

 

55

 

 

 

 

 

 

 

 

 

 

 

 5.10 Charter Protections; Directors' and Officers' Liability Insurance.

 

 

 (a) From and after the Effective Time, BRPA and the Surviving
Corporation shall indemnify and hold harmless each present and former
director and officer of BRPA, the Company and each of the
Company's Subsidiaries against any costs or expenses (including
reasonable attorneys' fees), judgments, fines, losses, claims, damages or
liabilities incurred in connection with any Action, whether civil, criminal,
administrative or investigative, arising out of or pertaining to matters
existing or occurring at or prior to the Effective Time, whether asserted or
claimed prior to, at or after the Effective Time, to the fullest extent that
BRPA, the Company or its Subsidiaries, as the case may be, would have been
permitted under applicable Legal Requirements and its Charter Documents
in effect on the date of this Agreement to indemnify such Person (including
the advancing of expenses as incurred to the fullest extent permitted under
applicable Legal Requirements).

 

 

 (b) For a period of six (6) years from the Effective Time, BRPA shall,
or shall cause one or more of its Subsidiaries to, maintain in
effect directors' and officers' liability insurance covering those Persons
who are currently covered by BRPA's, on the one hand, and the Company's or
its Subsidiaries', on the other hand, directors' and officers'
liability insurance policies on terms not less favorable than the terms
of such current insurance coverage, except that in no event shall BRPA or
its Subsidiaries be required to pay an annual premium for such insurance in
excess of 300% of the aggregate annual premium payable by the Company and its
Subsidiaries for such insurance policy for the year ended December 31, 2019;
 provided,  however, that (i) BRPA may cause coverage to be extended under
the current directors' and officers' liability insurance by obtaining a six-
year "tail" policy containing terms not materially less favorable than the
terms of such current insurance coverage with respect to claims existing or
occurring at or prior to the Effective Time and (ii) if any claim is asserted
or made within such six-year period, any insurance required to be maintained
under this  Section 5.10 shall be continued in respect of such claim until
the final disposition thereof.

 

 

 (c) Prior to the Closing, BRPA shall obtain directors' and officers'
liability insurance that shall be effective as of Closing and will cover
those Persons who will be the directors and officers of BRPA and its
Subsidiaries (including the directors and officers of the Company and its
Subsidiaries) at and after the Closing on terms not less favorable than the
better of (i) the terms of the current directors' and officers'
liability insurance in place for the Company's and its Subsidiaries'
directors and officers and (ii) the terms of a typical directors' and
officers' liability insurance policy for a company whose equity is listed on
Nasdaq which policy has a scope and amount of coverage that is reasonably
appropriate for a company of similar characteristics (including the line
of business and revenues) as BRPA and its Subsidiaries (including
the Company and its Subsidiaries).

 

 

 (d) Notwithstanding anything contained in this Agreement to the contrary,
this  Section 5.10 shall survive the consummation of the Merger
indefinitely and shall be binding, jointly and severally, on BRPA and the
Surviving Corporation and all successors and assigns of BRPA and the
Surviving Corporation. In the event that BRPA, the Surviving Corporation or
any of their respective successors or assigns consolidates with or merges
into any other Person and shall not be the continuing or
surviving corporation or entity of such consolidation or merger or
transfers or conveys all or substantially all of its properties and assets
to any Person, then, and in each such case, BRPA and the
Surviving Corporation shall ensure that proper provision shall be made
so that the successors and assigns of BRPA or the Surviving Corporation, as
the case may be, shall succeed to the obligations set forth in this  Section
5.10. The obligations of BRPA and the Surviving Corporation under this
 Section 5.10 shall not be terminated or modified in such a manner as to
materially and adversely affect any present and former director and officer
of BRPA, the Company and each of the Company's Subsidiaries to whom
this  Section 5.10 applies without the consent of the affected Person.

 

 

 

 

 

 

 

 

56

 

 

 

 

 

 

 

 

 

 

 

 5.11 Insider Loans. The Company shall cause each Insider of the Company or
its Subsidiaries to, at or prior to Closing (i) repay to the Company any loan
by the Company to such Insider and any other amount owed by such Insider to
the Company; and (ii) cause any guaranty or similar arrangement pursuant to
which the Company has guaranteed the payment or performance of any
obligations of such Insider to a third party to be terminated.

 

 

 5.12 BRPA Borrowings. Until the Closing, BRPA shall be allowed to borrow
funds from the BRPA Lenders, the Sponsor, its directors, officers,
shareholders, and each of their Affiliates to meet its reasonable
capital requirements, with any such loans to be made only as
reasonably required by the operation of BRPA in due course on a non-
interest bearing basis (such aggregate amount of outstanding borrowings,
the "BRPA Borrowings"). Schedule 5.12 of the BRPA Schedules sets forth the
amount of BRPA Borrowings outstanding as of the date hereof. At the Closing,
the outstanding principal and unpaid accrued interest on BRPA Borrowings
shall be repaid pursuant to Section 5.13(e), with all amounts not so repaid
to be converted or forgiven and discharged in accordance with Section 1.12.

 

 

 5.13 Trust Fund Disbursement. Upon satisfaction or waiver of the
conditions set forth in Article VI and provision of notice to Continental in
accordance with the Trust Agreement, at the Closing, BRPA shall instruct
Continental to distribute the Trust Fund as follows: (a) first, for the
redemption of any shares of BRPA Common Stock by BRPA Stockholders in
connection with the Offer, (b) second, for income Tax or other Tax
obligations of BRPA prior to Closing, (c) third, for the payment of the
Outstanding Company Transaction Expenses and the Outstanding BRPA
Transaction Expenses pursuant to Section 1.16, (d) fourth, in reimbursement
of expenses paid by directors, officers, and stockholders of BRPA, (e) fifth,
to the extent the sum of (x) the amount remaining in of the Trust Fund after
the disbursement provided by Section 5.13(a) plus (y) the Financing, if any,
exceeds $5,000,000, for the payment of BRPA Borrowings, and (f) sixth, to
distribute to BRPA the balance of the assets in the Trust Fund and net
proceeds of any financing of BRPA or for the benefit of BRPA, if any,
after payment of the amounts required under the foregoing clauses
(a) through (e).

 

 

 5.14 Tax Matters.

 

 

 (a) It is intended by the Parties that the Merger shall constitute
a reorganization within the meaning of Section 368 of the Code. The Parties
adopt this Agreement as a "plan of reorganization" within the meaning of U.S.
Income Tax Regulations Sections 1.368-2(g) and 1.368-3(a).

 

 

 (b) On or after the date hereof, none of the Parties shall take
any action, or fail to take any action, and following the Merger, BRPA shall
prevent the Surviving Corporation from taking any action or failing to take
any action, which action or failure to act would reasonably be expected to
prevent or impede the Merger from qualifying as a reorganization governed by
Section 368 of the Code. The Parties will in all Returns report the Merger in
a manner consistent with such tax treatment, and no Party will take
a position inconsistent with that treatment, unless required to do otherwise
pursuant to a final determination as defined in Section 1313(a) of the Code
(or pursuant to any similar provision of applicable state, local or foreign
Legal Requirements).

 

 

 

 

 

 

 

 

57

 

 

 

 

 

 

 

 

 

 

 

 (c) Each of BRPA and the Company shall, and BRPA shall cause the
Surviving Corporation to, use their respective reasonable best efforts
and cooperate with one another and Tax Opinion Counsel in order for (i) the
Company to obtain the Tax Opinion and (ii) any Tax opinions required to be
filed with the SEC in connection with the Registration Statement to be
obtained. Each of BRPA and the Company shall use reasonable best efforts to
deliver to Tax Opinion Counsel customary representation letters, in form and
substance reasonably acceptable to Tax Opinion Counsel, dated as of the
Closing Date or such time or times as may be reasonably requested by Tax
Opinion Counsel. The Company shall reasonably promptly notify BRPA if the
Company becomes aware of any fact or circumstance indicating that Tax Opinion
Counsel will not deliver the Tax Opinion. If Tax Opinion Counsel will not
deliver the Tax Opinion, the Company and BRPA shall cooperate and use good
faith efforts to consider and negotiate such amendments to this Agreement as
may be reasonably required in order for Tax Opinion Counsel to deliver the
Tax Opinion (it being understood that no party shall be required to agree to
any such amendment which, in the good faith judgment of such party, would
subject it to any material economic, legal, regulatory, reputational or other
cost or detriment).

 

 

 (d) On or prior to the Closing Date, the Company shall deliver to BRPA
a certificate or certificates, duly executed and acknowledged, certifying
certain facts reasonably sufficient to establish that the Merger is not
subject to withholding under Section 1445 of the Code.

 

 

 5.15 Incentive Equity Plan. Prior to the Closing Date, BRPA shall cause to
be adopted an equity incentive plan (the "BRPA Plan"), the proposed form and
terms of which shall be prepared and delivered by the Company and which shall
be reasonably acceptable to BRPA. The BRPA Plan shall provide for the
reservation by BRPA for the issuance pursuant to the BRPA Plan of a number
of shares of BRPA Common Stock as mutually agreed by BRPA and the Company
and set forth on Schedule 5.15 of the BRPA Schedules. BRPA shall file with
the SEC a registration statement on Form S-8 (or any successor form or
comparable form in another relevant jurisdiction) relating to BRPA Common
Stock issuable pursuant to the BRPA Plan. Such registration statement shall
be filed no later than sixty (60) days after the date of the Closing Form
8-K (or as soon as reasonably practicable after the expiration of such sixty
(60)-day period that registration of shares on Form S-8 (or any successor
form or comparable form in another relevant jurisdiction) first becomes
available to BRPA), and BRPA shall use reasonable best efforts to maintain
the effectiveness of such registration statement for so long as any awards
issued under the BRPA Plan remain outstanding.

 

 

 5.16 Company Stockholder Approval. As promptly as practicable after the
SEC Approval Date, the Company shall (i) seek the Company Stockholder
Approval via written consent (the "Written Consent") and (ii) in the event
the Company determines it is not able to obtain the Written Consent, the
Company shall call and hold a meeting of holders of Company Common Stock
and Company Preferred Stock for the purpose of voting solely upon
the Company Stockholder Approval (the "Company Stockholders Meeting") as
soon as reasonably practicable after the SEC Approval Date, provided that the
Company Stockholders Meeting will occur no later than the date of the BRPA
Special Meeting. In connection therewith, the Company shall use reasonable
best efforts to, as promptly as practicable, (A) establish the record
date (which record date shall be mutually agreed with BRPA) for determining
the Company Stockholders entitled to provide such Written Consent or vote in
such Company Stockholders Meeting, (B) cause the Consent Solicitation
Statement to be disseminated to the Company Stockholders in compliance with
applicable Legal Requirements and (C) solicit written consents or votes or
proxies for use at the Company Stockholders Meeting, as applicable, from the
Company Stockholders to give the Company Stockholder Approval. The Company,
acting through the Company Board, shall recommend that the Company
Stockholders approve and adopt this Agreement and the Transactions, including
the Merger (the "Company Board Recommendation") and shall include the Company
Board Recommendation in the Consent Solicitation Statement, subject to the
Company Board's compliance with its fiduciary duties under applicable law. If
the Company Stockholder Approval is obtained by written consent, then
promptly following the receipt of the Written Consent, the Company will
prepare and deliver to its stockholders who have not consented the notice
required by Section 228(e) of the DGCL.

 

 

 

 

 

 

 

 

58

 

 

 

 

 

 

 

 

 

 

 

 5.17 Third Party Consents. Each Party shall, and shall cause its
Subsidiaries and Affiliates to (a) use reasonable best efforts to assemble,
prepare, and file any information (and, as needed, to supplement such
information) as may be reasonably necessary to obtain as promptly as
practicable all governmental and regulatory consent required to be obtained
in connection with the Merger, (b) use reasonable best efforts to obtain all
consents and approvals of third parties that such Party or its Subsidiaries
or Affiliates is required to obtain in order to consummate the Merger, and
(c) take such other action as may reasonably be necessary or as the other
Party may reasonably request to satisfy the conditions set forth in Article
VI or otherwise to comply with this Agreement and to consummate the Merger as
soon as practicable.

 

 

 5.18 BRPA Financing. If the BRPA Board determines it is reasonably
necessary solely to meet Nasdaq listing standards or the SEC net tangible
asset test (as determined in accordance with Rule 3a51-1(g)(1) of the
Exchange Act), BRPA may, upon the written consent of the Company (such
consent not to be unreasonably withheld, conditioned, or delayed), arrange
and obtain up to a maximum of Ten Million Dollars ($10,000,000) in
financing from the sale of BRPA Common Stock at a price per share of no
less than $10.00 ("Financing"). Such Financing may be made contingent upon
Closing. If BRPA elects to arrange and obtain Financing, upon reasonable
advance notice to the Company, the Company shall (i) furnish, or cause to be
furnished, to any Financing sources such information regarding the Company
as may be reasonably requested, (ii) cause the Company's management team,
with appropriate seniority and expertise, to participate in meetings,
presentations, due diligence sessions, drafting sessions, road shows and
meetings with prospective Financing sources, (iii) prepare offering documents
and other marketing materials of a type customarily used for the type
of financing proposed and cooperate with marketing efforts for the Financing
as reasonably requested, and (iv) execute and deliver definitive documents
related to the Financing; provided, in each case in clauses (i) through (iv)
above, that nothing in this Section 5.18 shall require any efforts to the
extent that such efforts would reasonably be expected to conflict with or
violate any Legal Requirement, or result in the material contravention
of, or result in a material violation or breach of, or material
default under, any Material Company Contract.

 

 

 5.19 Employment Agreements. Prior to the Closing, BRPA shall enter into
employment agreements with the Company executives listed on Schedule 5.19 of
the Company Schedules, in a form which is reasonably acceptable to the
Company and such executives.

 

 

 5.20 Termination of Company Stockholder Agreements. Prior to the Closing,
the Company shall terminate each Company Stockholder Agreement.

 

 

 5.21 Section 16 of the Exchange Act. Prior to the Closing, the BRPA Board
or an appropriate committee thereof shall take all such steps as may be
required to adopt a resolution consistent with the interpretive guidance of
the SEC so that the acquisition of BRPA Common Stock pursuant to this
Agreement by any officer or director of BRPA or any person who is expected to
become a director or officer (as defined under Rule 16a-1(f) of the Exchange
Act) of BRPA for purposes of Section 16 of the Exchange Act and the rules and
regulations thereunder will be an exempt transaction under such rules and
regulations.

 

 

 5.22 Extension. BRPA shall take all actions necessary to obtain the
approval of the BRPA Stockholders to extend the deadline for BRPA to
consummate its initial Business Combination beyond December 23, 2020 to April
23, 2021 (such extension, the "Extension", and such approval of the BRPA
Stockholders of the Extension, the "Extension Approval").

 

 

 

 

 

 

 

 

59

 

 

 

 

 

 

 

 

 

 

 

 5.23 Company Support Agreements. On or before the earlier to occur of (x)
one day prior to the date the Registration Statement is filed with the SEC or
(y) January 14, 2021, the Company shall deliver to BRPA the Support
Agreements, pursuant to which each of the Supporting Stockholders party
thereto has agreed to, among other things, vote all of the shares of Company
Stock beneficially owned by such Supporting Stockholder in favor of the
Merger and the other Transactions including the conversion of the
Supporting Stockholder's Company Preferred Stock, if any, contemplated by
Section 1.3(a) (which vote may be accomplished by executing a written
consent) (all of the Supporting Stockholders that are party to the Support
Agreements delivered in accordance with this Section 5.23,
the "Requisite Stockholders"). The affirmative vote of the Requisite
Stockholders to approve and adopt this Agreement and to approve the
Transactions will be sufficient to obtain the Company Stockholder Approval.

 

 

  ARTICLE VI

 

 

 CONDITIONS TO THE TRANSACTION

 

 

 6.1 Conditions to Obligations of Each Party to Effect the Merger. The
respective obligations of each Party to this Agreement to effect the
Merger shall be subject to the satisfaction as of the Closing Date of
the following conditions, any one or more of which may be waived (if legally
permitted) in writing by all of such parties:

 

 

 (a) BRPA Stockholder Approval. The BRPA Stockholder Approval shall have
been obtained.

 

 

 (b) BRPA Net Tangible Assets. BRPA shall have at least $5,000,001 of net
tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the
Exchange Act) remaining after the Offer.

 

 

 (c) HSR Act; No Order. All specified waiting periods (or any extensions
thereof) under the HSR Act shall have expired and no Governmental Entity
shall have enacted, issued, promulgated, enforced or entered any statute,
rule, regulation, executive order, decree, injunction or other order
(whether temporary, preliminary or permanent) which is in effect and
which has the effect of making the Merger illegal or otherwise prohibiting
consummation of the Merger, substantially on the terms contemplated by this
Agreement.

 

 

 (d) Registration Statement. The Registration Statement shall have become
effective in accordance with the provisions of the Securities Act, no stop
order shall have been issued by the SEC which remains in effect with respect
to the Registration Statement, and no proceeding seeking such a stop
order shall have been threatened or initiated by the SEC which
remains pending.

 

 

 (e) Company Stockholder Approval. The Company Stockholder Approval shall
have been obtained.

 

 

 (f) Closing Ancillary Agreements. Each Closing Ancillary Agreement shall
have been executed and delivered by the parties thereto and shall be in full
force and effect.

 

 

 

 

 

 

 

 

60

 

 

 

 

 

 

 

 

 

 

 

 (g) Nasdaq Listing. BRPA shall be and remain listed on Nasdaq, and the
shares of BRPA Common Stock to be issued in connection with the Transactions
(including the Earnout Shares) shall have been approved for listing on
Nasdaq, subject only to official notice of issuance thereof and the
requirement to have a sufficient number of round lot holders.

 

 

 (h) Offer Completion. The Offer shall have been completed in accordance
with the terms hereof and the Proxy Statement.

 

 

 6.2 Additional Conditions to Obligations of the Company. The
obligations of the Company to consummate and effect the Merger shall be
subject to the satisfaction as of the Closing Date of each of the
following conditions, any of which may be waived, in writing, exclusively
by the Company:

 

 

 (a) Representations and Warranties.

 

 

 (i) Each representation and warranty of BRPA contained in Section
3.1 (Organization and Qualification), Section 3.4 (Authority Relative to
this Agreement) and Section 3.17 (Brokers), in each case, shall be true and
correct in all respects as of the date of this Agreement and as of the
Closing Date, as if made anew at and as of that time (except to the
extent such representation and warranty expressly relates to an
earlier date, and in such case, shall be true and correct as of such date).

 

 

 (ii) Each of the representations and warranties of BRPA contained
in Section 3.3 (Capitalization) shall be true and correct other than de
minimis inaccuracies, as of the date hereof and as of the Closing Date, as if
made anew at and as of that time (except to the extent such representation
and warranty expressly relates to an earlier date, and in such case, shall be
true and correct as of such date).

 

 

 (iii) Each representation and warranty of BRPA contained in this
Agreement (other than the representations and warranties of BRPA
described in Section 6.2(a)(i) and Section 6.2(a)(ii)), shall be true and
correct (without giving any effect to any limitation as to "materiality" or
"BRPA Material Adverse Effect" or any similar limitation set forth
therein) in all material respects as of the date hereof and as of
the Closing Date, as if made anew at and as of that time (except to
the extent such representation and warranty expressly relates to an earlier
date, and in such case, shall be true and correct as of such date).

 

 

 (b) Agreements and Covenants. BRPA shall have performed or complied with
all agreements and covenants required by this Agreement to be performed or
complied with by it on or prior to the Closing Date in all material respects.

 

 

 (c) Secretary Certificate. The Company shall have received a certificate
of the secretary or equivalent officer of BRPA certifying that attached
thereto are true and complete copies of all resolutions adopted by the BRPA
Board authorizing the execution, delivery, and performance of this Agreement
and the Transactions, and that all such resolutions are in full force
and effect.

 

 

 

 

 

 

 

 

61

 

 

 

 

 

 

 

 

 

 

 

 (d) No BRPA Material Adverse Effect. No BRPA Material Adverse Effect shall
have occurred since the date of this Agreement.

 

 

 (e) SEC Compliance. Immediately prior to Closing, BRPA shall be in
compliance with the reporting requirements under the Securities Act and
Exchange Act.

 

 

 (f) BRPA Closing Certificate. BRPA shall have delivered to the Company a
certificate signed by an authorized officer of BRPA, dated the Closing Date,
certifying as to the satisfaction of the conditions specified in
Sections 6.2(a)(i), 6.2(a)(ii), 6.2(a)(iii), 6.2(b), 6.2(d) and (e).

 

 

 (g) Tax Opinion. The Company shall have received the Tax Opinion.

 

 

 (h) Resignations. The directors and executive officers of BRPA listed
on Schedule 6.2(g) of the BRPA Schedules shall have been removed from their
respective positions or tendered their irrevocable resignations, in each case
effective as of the Effective Time.

 

 

 (i) BRPA AandR Charter. BRPA shall have adopted the BRPA AandR Charter.

 

 

 (j) Extension Approval. The Extension Approval shall have been obtained.

 

 

 (k) BRPA Borrowings. The amount of all BRPA Borrowings outstanding
(including, for the avoidance of doubt, borrowings pursuant to Section 5.12)
that are due and payable as of the Closing Date or at any time after the
Closing, shall not exceed, in the aggregate, three million
dollars ($3,000,000).

 

 

 6.3 Additional Conditions to the Obligations of BRPA. The obligations of
BRPA to consummate and effect the Merger shall be subject to the satisfaction
as of the Closing Date of each of the following conditions, any of which may
be waived, in writing, exclusively by BRPA:

 

 

 (a) Representations and Warranties.

 

 

 (i) Each representation and warranty of the Company contained in Section
2.1 (Organization and Qualification), Section 2.4 (Authority Relative to
this Agreement) and Section 2.18 (Brokers), in each case, shall be true and
correct in all respects as of the date hereof and as of the Closing Date, as
if made anew at and as of such time (except to the extent
such representation and warranty expressly relates to an earlier date, and
in such case, shall be true and correct as of such date).

 

 

 (ii) The representations and warranties of the Company contained
in Section 2.3 (Capitalization) shall be true and correct other than de
minimis inaccuracies as of the date hereof and as of the Closing Date, as if
made anew at and as of that time (except to the extent such representation
and warranty expressly relates to an earlier date, and in such case, shall be
true and correct as of such date).

 

 

 (iii) Each representation and warranty of the Company contained in
this Agreement (other than the representations and warranties of the Company
described in Section 6.3(a)(i) and Section 6.3(a)(ii)), shall be true
and correct (without giving any effect to any limitation as to "materiality"
or "Company Material Adverse Effect" or any similar limitation set forth
therein) shall be true and correct (without giving any effect to any
limitation as to "materiality" or "Company Material Adverse Effect" or any
similar limitation set forth therein) as of the date hereof and as of the
Closing Date, as if made anew at and as of that time (except to the extent
such representations and warranties expressly relate to an earlier date, and
in such case, shall be true and correct on and as of such earlier date),
except, in either case, where the failure of such representations
and warranties to be so true and correct, individually or in the aggregate,
has not had, and would not reasonably be expected to result in, a Company
Material Adverse Effect.

 

 

 

 

 

 

 

 

62

 

 

 

 

 

 

 

 

 

 

 

 (b) Agreements and Covenants. The Company shall have performed or complied
with all agreements and covenants required by this Agreement to be performed
or complied with by it at or prior to the Closing Date in all
material respects.

 

 

 (c) Secretary Certificate. BRPA shall have received a certificate of the
secretary or equivalent officer of the Company certifying that attached
thereto are true and complete copies of all resolutions adopted by the
Company Board authorizing the execution, delivery, and performance of this
Agreement and the Transactions, and that all such resolutions are in full
force and effect.

 

 

 (d) No Company Material Adverse Effect. No Company Material Adverse Effect
shall have occurred since the date of this Agreement.

 

 

 (e) Insider Loans. All outstanding loans or other indebtedness by the
Company to any Insider shall have been repaid in full and all outstanding
guaranties and similar arrangements pursuant to which the Company has
guaranteed the payment or performance of any obligations of any Insider to a
third party shall have been terminated.

 

 

 (f) Company Closing Certificate. The Company shall have delivered to BRPA
a certificate signed by an authorized officer of the Company, dated the
Closing Date, certifying as to the satisfaction of the conditions
specified in Sections 6.3(a)(i), 6.3(a)(ii), 6.3(a)(iii), 6.3(b) and
6.3(d).

 

 

  ARTICLE VII

 

 

 TERMINATION

 

 

 7.1 Termination. This Agreement may be terminated at any time prior to
the Closing:

 

 

 (a) by mutual written agreement of BRPA and the Company at any time;

 

 

 (b) by written notice from either BRPA or the Company to the other if
the Merger shall not have been consummated by April 23, 2021
(the "Outside Date"); provided, however, that the right to terminate this
Agreement under this Section 7.1(b) shall not be available to any
Party whose failure to fulfill any obligation under this Agreement has been
the primary cause of, or primarily resulted in, the failure of the Closing to
occur on or before such date;

 

 

 (c) by written notice from either BRPA or the Company to the other if
a Governmental Entity shall have issued an order, decree, judgment or ruling
or taken any other action, in any case having the effect of permanently
restraining, enjoining or otherwise prohibiting the Merger, which order,
decree, ruling or other action is final and nonappealable;

 

 

 (d) by written notice from the Company to BRPA if there is any breach
of any representation, warranty, covenant or agreement on the part of BRPA
set forth in this Agreement, such that the conditions set forth in Section
6.02(a) and Section 6.02(b) would not be satisfied at the Closing (a
"Terminating BRPA Breach"), except that, if any such Terminating BRPA Breach
is curable by BRPA through the exercise of its commercially reasonable
efforts, then, for a period of up to 30 days (or any shorter period of the
time that remains between the date the Company provides written notice of
such violation or breach and the Outside Date) after receipt by BRPA
of notice from the Company of such breach, but only as long as
BRPA continues to exercise such commercially reasonable efforts to cure such
Terminating Company Breach (the "BRPA Cure Period"), such termination shall
not be effective, and such termination shall become effective only if the
Terminating BRPA Breach is not cured within the BRPA Cure Period (it being
understood that the Company may not terminate this Agreement pursuant to
this Section 7.1(d) if it shall have materially breached this Agreement or
if such Terminating BRPA Breach is cured during such thirty
(30)-day period);

 

 

 

 

 

 

 

 

63

 

 

 

 

 

 

 

 

 

 

 

 (e) by written notice from BRPA to the Company if there is any breach
of any representation, warranty, covenant or agreement on the part of the
Company set forth in this Agreement, such that the conditions set forth in
Section 6.03(a) and Section 6.03(b) would not be satisfied at the
Closing (a "Terminating Company Breach"), except that, if any such
Terminating Company Breach is curable by the Company through the exercise of
its commercially reasonable efforts, then, for a period of up to 30 days (or
any shorter period of the time that remains between the date the Company
provides written notice of such violation or breach and the Outside Date)
after receipt by the Company of notice from BRPA of such breach, but only as
long as the Company continues to exercise such commercially
reasonable efforts to cure such Terminating Company Breach (the "Company
Cure Period"), such termination shall not be effective, and such termination
shall become effective only if the Terminating Company Breach is not cured
within the Company Cure Period (it being understood that BRPA may not
terminate this Agreement pursuant to this Section 7.1(e) if it shall
have materially breached this Agreement or if such Terminating
Company Breach is cured during such thirty (30)-day period);

 

 

 (f) by written notice from either BRPA or the Company to the other, if
the BRPA Stockholder Approval is not obtained at the BRPA Special Meeting
(including any adjournments thereof);

 

 

 (g) by written notice from either BRPA or the Company to the other if
the Company Stockholder Approval has not been obtained within thirty (30)
days following the date that the Consent Solicitation Statement is
disseminated to the Company Stockholders pursuant to Section 5.16;

 

 

 (h) by written notice from the Company to BRPA prior to obtaining
the Company Stockholder Approval, in order to enter into a
definitive agreement with respect to a Superior Proposal, subject to the
terms and conditions of Section 4.4(d);

 

 

 (i) by written notice from the Company to BRPA if the Extension
Approval is not obtained by December 24, 2020; or

 

 

 (j) by written notice from either BRPA or the Company to the other if
the shares of BRPA Common Stock are delisted from Nasdaq.

 

 

 7.2 Notice of Termination; Effect of Termination.

 

 

 (a) Any termination of this Agreement under Section 7.1 above will be
effective immediately upon (or, if the termination is pursuant to Section
7.1(d) or Section 7.1(e) in accordance with the terms thereof) the delivery
of written notice of the terminating Party to the other Parties.

 

 

 (b) Termination Fee.

 

 

 (i) In the event that this Agreement is validly terminated by the
Company pursuant to Section 7.1(h), then the Company shall pay, within
three (3) Business Day of the notice of such termination of this Agreement, a
termination fee to BRPA in an amount equal to Ten Million Dollars
($10,000,000) ("Termination Fee") in immediately available funds as
liquidated damages and not as a penalty.

 

 

 

 

 

 

 

 

64

 

 

 

 

 

 

 

 

 

 

 

 (ii) The Parties acknowledge and hereby agree that the Termination Fee,
if, as and when required pursuant to Section 7.2(b), shall not constitute a
penalty but will be liquidated damages, in a reasonable amount that will
compensate BRPA in the circumstances in which it is payable for the efforts
and resources expended and opportunities foregone while negotiating this
Agreement and in reliance on this Agreement and on the expectation of
the consummation of the Merger, which amount would otherwise be impossible
to calculate with precision. The Parties acknowledge and hereby agree that in
no event shall the Company be required to pay the Termination Fee on more
than one (1) occasion. Each of the Company, BRPA and Merger Sub acknowledges
that the agreements contained in this Section 7.2 are an integral part of
the transactions contemplated by this Agreement and that, without
these agreements, the parties hereto would not enter into this Agreement.

 

 

 (iii) Notwithstanding anything to the contrary in this Agreement, in any
circumstance in which this Agreement is terminated and BRPA is paid the
Termination Fee pursuant to this Section 7.2(b), the Termination Fee shall
be the sole and exclusive monetary remedy of BRPA, Merger Sub or any of the
BRPA Related Parties against the Company or any other Company Related Party
for any loss or damage suffered as a result of the failure of the Merger and
the other transactions contemplated by this Agreement to be consummated
or for a breach of, or failure to perform under, this Agreement or
any certificate or other document delivered in connection herewith
or otherwise or in respect of any oral representation made or alleged to
have been made in connection herewith or therewith, and upon payment of such
amounts, none of the Company Related Parties shall have any further liability
or obligation relating to or arising out of this Agreement or in respect of
representations made or alleged to be made in connection herewith, whether in
equity or at law, in contract, in tort or otherwise.

 

 

 (c) In the event of the termination of this Agreement as provided in
Section 7.1, this Agreement shall be of no further force or effect and
the Merger shall be abandoned, except for and subject to the following:
(i) Sections 4.3(a), 5.7, 7.2 and 7.3, and Article VIII, shall survive
the termination of this Agreement, and (ii) nothing herein shall relieve any
Party from liability for any intentional and willful breach of this Agreement
by such Party occurring prior to such termination.

 

 

 7.3 Fees and Expenses. Except as otherwise set forth herein, all fees and
expenses incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the Party incurring such expenses.

 

 

  ARTICLE VIII

 

 

 GENERAL PROVISIONS

 

 

 8.1 Notices. All notices and other communications among the Parties shall
be in writing and shall be deemed to have been duly given (i) when delivered
in person, (ii) when delivered after posting in the United States mail having
been sent registered or certified mail return receipt requested, postage
prepaid, (iii) when delivered by FedEx or other nationally recognized
overnight delivery service or (iv) when e-mailed during normal business hours
(and otherwise as of the immediately following Business Day), addressed
as follows:

 

 

 

 

 

 

 

 

65

 

 

 

 

 

 

 

 

 

 

 

 if to BRPA, to:

 

 

 Big Rock Partners Acquisition Corp.

 

 2645 N. Federal Highway, Suite 230

 

 Delray Beach, FL 33483

 

 Attn: Richard Ackerman

 

 Email: rackerman@bigrockpartners.com

 

 

 with a copy to:

 

 

 Graubard Miller

 

 The Chrysler Building

 

 405 Lexington Avenue, 11th Floor

 

 New York, New York 10174

 

 Attention: David Alan Miller / Jeffrey M. Gallant

 

 Email: dmiller@graubard.com / jgallant@graubard.com

 

 

 if to the Company to:

 

 

 NeuroRx, Inc.

 

 1201 N. Market Street, Suite 111

 

 Wilmington, Delaware 19801

 

 Attention: Jonathan Javitt

 

 Email: jjavitt@neurorxpharma.com

 

 

 

 with a copy to:

 

 

 

 Alessandra Daigneault

 

 Email: adaigneault@neurorxpharma.com

 

 

 8.2 Interpretation. The definitions of the terms herein shall apply equally
to the singular and plural forms of the terms defined. Whenever the context
shall require, any pronoun shall include the corresponding masculine,
feminine and neuter forms. When a reference is made in this Agreement to an
Exhibit or Schedule, such reference shall be to an Exhibit or Schedule to
this Agreement unless otherwise indicated. When a reference is made in this
Agreement to Sections or subsections, such reference shall be to a Section or
subsection of this Agreement. Unless otherwise indicated the
words "include," "includes" and "including" when used herein shall be deemed
in each case to be followed by the words "without limitation." The table of
contents and headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this
Agreement. Reference to the Subsidiaries of an entity shall be deemed to
include all direct and indirect Subsidiaries of such entity.

 

 

 8.3 Counterparts; Electronic Delivery. This Agreement and each other
document executed in connection with the Merger, and the consummation
thereof, may be executed in one or more counterparts, all of which shall be
considered one and the same document and shall become effective when one or
more counterparts have been signed by each of the Parties and delivered to
the other Parties, it being understood that all Parties need not sign
the same counterpart. Delivery by electronic transmission to counsel for the
other Party of a counterpart executed by a Party shall be deemed to meet the
requirements of the previous sentence.

 

 

 

 

 

 

 

 

66

 

 

 

 

 

 

 

 

 

 

 

 8.4 Entire Agreement; Third Party Beneficiaries. This Agreement and the
documents and instruments and other agreements among the Parties as
contemplated by or referred to herein, including the Ancillary Agreements and
the Exhibits and Schedules hereto, and the Confidentiality Agreement (which
will terminate at the Closing) (a) constitute the entire agreement among the
Parties with respect to the subject matter hereof and supersede all prior
agreements and understandings, both written and oral, among the Parties and
any of their respective Affiliates with respect to the Merger; and (b)
are not intended to confer upon any other Person any rights or
remedies hereunder (except as specifically provided in this
Agreement, including Section 5.10). No representations, warranties,
covenants, understandings, agreements, oral or otherwise, relating to the
Merger exist between the Parties except as expressly set forth or referenced
in this Agreement, the Ancillary Agreements, and the
Confidentiality Agreement.

 

 

 8.5 Severability. In the event that any provision of this Agreement, or
the application thereof, becomes or is declared by a court of
competent jurisdiction to be illegal, void or unenforceable, the remainder
of this Agreement will continue in full force and effect and the application
of such provision to other Persons or circumstances will be interpreted so as
reasonably to effect the intent of the Parties. The Parties further agree to
replace such void or unenforceable provision of this Agreement with a valid
and enforceable provision that will achieve, to the extent possible, the
economic, business and other purposes of such void or unenforceable
provision.

 

 

 8.6 Other Remedies; Specific Performance. Except as otherwise provided
herein, any and all remedies herein expressly conferred upon a Party will be
deemed cumulative with and not exclusive of any other remedy conferred
hereby, or by law or equity upon such Party, and the exercise by a Party of
any one remedy will not preclude the exercise of any other remedy. The
Parties agree that irreparable damage would occur in the event that any of
the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached. It is accordingly agreed that the
Parties shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions hereof
in any court of the United States or any state having jurisdiction, this
being in addition to any other remedy to which they are entitled at law
or in equity. Each Party agrees that it will not oppose the granting of
specific performance and other equitable relief on the basis that the other
parties have an adequate remedy at law or that an award of specific
performance is not an appropriate remedy for any reason at law or equity. The
Parties acknowledge and agree that any Party seeking an injunction to prevent
breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement in accordance with this Section 8.6 shall not be
required to provide any bond or other security in connection with any
such injunction.

 

 

 8.7 Governing Law. This Agreement, and all claims or causes of action
based upon, arising out of, or related to this Agreement or the transactions
contemplated hereby, shall be governed by, and construed in accordance with,
the laws of the State of Delaware, without giving effect to principles or
rules of conflict of laws to the extent such principles or rules
would require or permit the application of laws of another jurisdiction.

 

 

 

 

 

 

 

 

67

 

 

 

 

 

 

 

 

 

 

 

 8.8 Consent to Jurisdiction; WAIVER OF TRIAL BY JURY. Any Action based
upon, arising out of or related to this Agreement, or the transactions
contemplated hereby, shall be brought in the Court of Chancery of the State
of Delaware; provided, that if jurisdiction is not then available in the
Delaware Chancery Court, then any such legal Action may be brought in any
federal court located in the State of Delaware or any other Delaware state
court. The parties hereto hereby (a) irrevocably submit to the
exclusive jurisdiction of the aforesaid courts for themselves and
with respect to their respective properties for the purpose of any Action
arising out of or relating to this Agreement brought by any party hereto, and
(b) agree not to commence any Action relating thereto except in the courts
described above in Delaware, other than Actions in any court of competent
jurisdiction to enforce any judgment, decree or award rendered by any such
court in Delaware as described herein. Each of the parties further agrees
that notice as provided herein shall constitute sufficient service of process
and the parties further waive any argument that such service
is insufficient. Each of the parties hereby irrevocably and unconditionally
waives, and agrees not to assert, by way of motion or as a defense,
counterclaim or otherwise, in any Action arising out of or relating to this
Agreement or the transactions contemplated hereby, (i) any claim that it is
not personally subject to the jurisdiction of the courts in Delaware as
described herein for any reason, (ii) that it or its property is exempt
or immune from jurisdiction of any such court or from any legal process
commenced in such courts (whether through service of notice, attachment prior
to judgment, attachment in aid of execution of judgment, execution of
judgment or otherwise) and (iii) that (A) the Action in any such court is
brought in an inconvenient forum, (B) the venue of such Action is improper or
(C) this Agreement, or the subject matter hereof, may not be enforced in or
by such courts. EACH OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO
TRIAL BY JURY IN ANY ACTION BASED UPON, ARISING OUT OF OR RELATED TO THIS
AGREEMENT, THE MERGER, OR THE OTHER TRANSACTIONS CONTEMPLATED HEREBY.

 

 

 8.9 Rules of Construction. The Parties agree that they have been
represented by counsel during the negotiation and execution of this Agreement
and, therefore, waive the application of any law, regulation, holding or rule
of construction providing that ambiguities in an agreement or other document
will be construed against the Party drafting such agreement or document.

 

 

 8.10 Assignment. No Party may assign either this Agreement or any of its
rights, interests, or obligations hereunder without the prior
written approval of the other Parties. Subject to the first sentence of this
Section 8.10, this Agreement shall be binding upon and shall inure to the
benefit of the Parties and their respective successors and
permitted assigns.

 

 

 8.11 Amendment. This Agreement and, prior to the Closing, each of the
Ancillary Agreements, may be amended by the Parties at any time only
by execution of an instrument in writing signed on behalf of each of the
Parties. The approval of this Agreement by the shareholders of any Party
shall not restrict the ability of the board of directors of such Party to
terminate this Agreement in accordance with Section 7.1 or to cause such
Party to enter into an amendment to this Agreement pursuant to this
Section 8.11.

 

 

 8.12 Extension; Waiver. At any time prior to the Closing, any party hereto
may, to the extent legally allowed, (i) extend the time for the performance
of any of the obligations or other acts of the other Parties, (ii) waive
any inaccuracies in the representations and warranties made to such Party
contained herein or in any document delivered pursuant hereto and (iii) waive
compliance with any of the agreements or conditions for the benefit of such
Party contained herein. Any agreement on the part of a Party to any such
extension or waiver shall be valid only if set forth in an instrument in
writing signed on behalf of such Party. Delay in exercising any right under
this Agreement shall not constitute a waiver of such right.

 

 

 

 

 

 

 

 

68

 

 

 

 

 

 

 

 

 

 

 

 8.13 Currency. Unless otherwise specified, all references to currency
amounts in this Agreement shall mean United States dollars.

 

 

 8.14 Schedules. The information furnished in the Schedules is arranged in
sections corresponding to the Sections of this Agreement, and
the disclosures in any section of the Schedules shall qualify (a)
the corresponding Section of this Agreement and (b) other Sections of this
Agreement to the extent (notwithstanding the absence of a specific cross-
reference), that it is reasonably apparent on its face that such disclosure
is also applicable to such other Sections of this Agreement. The Schedules
and the information and disclosures contained in such Schedules are intended
only to qualify and limit the representations and warranties of the
parties contained in this Agreement and shall not be deemed to expand in any
way the scope of any such representation or warranty. The inclusion of any
information in the Schedules shall not be deemed to be an admission or
acknowledgment that such information is material or outside the ordinary
course of business. The inclusion of any fact or information in a Schedule is
not intended to be construed as an admission or concession as to the legal
effect of any such fact or information in any proceeding between any
party and any Person who is not a party.

 

 

 8.15 Nonsurvival of Representations, Warranties and Covenants. None of
the representations, warranties, covenants, obligations or other agreements
in this Agreement or in any certificate, statement or instrument delivered
pursuant to this Agreement, including any rights arising out of any breach of
such representations, warranties, covenants, obligations, agreements and
other provisions, shall survive the Closing and shall terminate and expire
upon the occurrence of the Effective Time (and there shall be no liability
after the Closing in respect thereof), except for (a) those covenants and
agreements contained herein that by their terms expressly apply in whole or
in part after the Closing and then only with respect to any breaches
occurring after the Closing and (b) this Article VIII.

 

 

 8.16 Non-Recourse. This Agreement may only be enforced against, and any
claim or cause of action based upon, arising out of, or related to this
Agreement or the Transactions may only be brought against, the entities
that are expressly named as Parties hereto, and then only with respect to
the specific obligations set forth herein with respect to such Party. Except
to the extent a named Party to this Agreement (and then only to the extent of
the specific obligations undertaken by such named Party in this Agreement),
(a) no past, present or future director, officer, employee, incorporator,
member, partner, stockholder, Affiliate, agent, attorney, advisor or
Representative or Affiliate of any named Party to this Agreement and (b) no
past, present or future director, officer, employee, incorporator, member,
partner, stockholder, Affiliate, agent, attorney, advisor or Representative
or Affiliate of any of the foregoing shall have any liability (whether in
contract, tort, equity or otherwise) for any one or more of the
representations, warranties, covenants, agreements or other obligations or
liabilities of any one or more of the Company, BRPA or Merger Sub under this
Agreement of or for any claim based on, arising out of, or related to this
Agreement or the transactions contemplated hereby.

 

 

 

 

 

 

69

 

 

 

 

 

 

 

 

 

 

 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
as of the date first written above.

 

 

    

 

  |  

BIG ROCK PARTNERS ACQUISITION CORP.

  |  

 

   
---|---|--- 
  

 

  |  

 

  |  

 

  |  

 

   
   
 |  

By:

  |  

/s/ Richard Ackerman

  |  

 

   
  
 |  

 

  |  

Name: Richard Ackerman

  |  

 

   
  

 

  |  

 

  |  

 Title: Chief Executive Officer

  |  

 

   
 

 

 

 

    

 

  |  

NEURORX, INC.

  |  

 

   
---|---|--- 
  
 |  

 

  |  

 

  |  

 

   
   
 |  

By:

  |  

/s/  Jonathan Javitt

  |  

 

   
  
 |  

 

  |  

Name: Jonathan Javitt

  |  

 

   
  
 |  

 

  |  

 Title: Chief Executive Officer

  |  

 

   
 

 

 

 

    

 

  |  

BIG ROCK MERGER CORP.

  |  

 

   
---|---|--- 
  
 |  

 

  |  

 

  |  

 

   
   
 |  

By:

  |  

/s/ Richard Ackerman

  |  

 

   
  
 |  

 

  |  

Name: Richard Ackerman

  |  

 

   
  
 |  

 

  |  

 Title: Chief Executive Officer

  |  

 

   
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

  Exhibit A

 

 Certain Definitions

 

 

 

 "Action" means any claim, action, suit, assessment, arbitration or
proceeding, in each case that is by or before any Governmental Entity.

 

 

 "Affiliate" means, as applied to any Person, any other Person directly or
indirectly controlling, controlled by or under direct or indirect
common control with, such Person. For purposes of this definition, "control"
(including with correlative meanings, the terms "controlling," "controlled
by" and "under common control with"), as applied to any Person, means the
possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through the
ownership of voting securities, by contract or otherwise.

 

 

 "Ancillary Agreements" means the Sponsor Agreement, Support Agreements,
BCMA Amendment Agreement, Note Amendment, Stock Escrow Amendment, and
the Registration Rights Agreement.

 

 

 "Antitrust Law" means the HSR Act, the Federal Trade Commission Act, as
amended, the Sherman Act, as amended, the Clayton Act, as amended, and any
applicable foreign antitrust Legal Requirements and all other applicable
Legal Requirements that are designed or intended to prohibit, restrict
or regulate actions having the purpose or effect of monopolization
or restraint of trade or lessening of competition through merger
or acquisition.

 

 

 "BRPA Closing Price" means the closing sale price of BRPA Common Stock on
Nasdaq (as reported on Nasdaq.com) on the last complete trading day
immediately prior to the Effective Time.

 

 

 "BRPA Common Stock" means the common stock of BRPA, par value $0.001 per
share.

 

 

 "BRPA Lenders" means BRAC Lending Group LLC ("BRAC"), A/Z Property
Partners, LLC, and the other lenders to BRPA.

 

 

 "BRPA Material Adverse Effect" means any change, event, occurrence,
effect, circumstance or development that has a materially adverse effect
on (x) financial condition, assets, business, or results of operations of
BRPA or (y) the ability of BRPA to timely consummate the Closing (including
the Merger) on the terms set forth in this Agreement; provided that, in the
case of clause (x) only, in no event would any of the following (or the
effect of any of the following), alone or in combination, be deemed to
constitute, or be taken into account in determining whether there has been or
will be, a "BRPA Material Adverse Effect": (i) changes or developments in
general U.S. or global economic conditions, including changes in interest
rates or economic, political, business, financial, commodity, currency or
market conditions generally, (ii) changes in applicable Legal Requirements,
U.S. GAAP, or authoritative interpretations thereof, (iii) any geopolitical
conditions, outbreak of hostilities, acts of war, sabotage, terrorism,
cyberterrorism, civil unrest, military actions, natural or man-made
disasters, weather conditions, epidemics, pandemics (including COVID-19 or
SARS-CoV-2 virus (or any mutation or variation thereof)) or other outbreaks
of illness or public health events and other force majeure events (including
any escalation or general worsening of any of the foregoing), (iv) any
change, event, occurrence, effect, circumstance or development attributable
to the announcement, pendency, negotiation or consummation of the Merger or
any other Transactions or the execution or performance of this Agreement, (v)
any action taken or omitted to be taken by BRPA at the Company's direction
or written request, any action required or permitted to be taken or omitted
to be taken by this Agreement or any Ancillary Agreement or any action to
which the Company has consented in writing, (vi) any change generally
affecting any of the industries or markets in which BRPA operate or the
economy as a whole, or (vii) the failure, in and of itself, of BRPA to meet,
or changes to, any budget, projection, forecast, estimate, or prediction (it
being understood that the underlying facts and circumstances giving rise to
or contributing to such failure or change may be taken into account
in determining whether there has been a BRPA Material Adverse Effect, unless
such underlying facts and circumstances would otherwise be excepted from
this definition); provided, however, in the case of each of the foregoing
clauses (i), (ii), (iii) and (vii), in the event that BRPA is materially and
disproportionately affected by such change, event, occurrence, effect,
circumstance or development relative to other participants in the business
and industries in which they operate, the extent (and only the extent) of
such material and disproportionate affect, relative to such other
participants, on BRPA may be taken into account in determining whether there
has been a BRPA Material Adverse Effect.

 

 

 

 

 

 

A-1

 

 

 

 

 

 

 

 

 

 

 

 "BRPA Preferred Stock" means the preferred stock of BRPA, par value $0.001
per share.

 

 

 "BRPA Related Parties" means any of BRPA's or Merger Sub's respective
former, current or future general or limited partners,
stockholders, controlling Persons, direct or indirect equityholders,
managers, members, directors, officers, employees, Affiliates, affiliated
(or commonly advised) funds, representatives, agents or any their respective
assignees or successors or any former, current or future general or limited
partner, stockholder, controlling Person, direct or indirect equityholder,
manager, member, director, officer, employee, Affiliate, affiliated (or
commonly advised) fund, representative, agent, assignee or successor of any
of the foregoing; provided, "BRPA Related Parties" shall not be deemed to
include BRPA or Merger Sub.

 

 

 "BRPA Securities" means the (i) BRPA Common Stock, (ii) warrants, each
whole warrant exercisable for one share of BRPA Common Stock at an exercise
price of $11.50 per share ("BRPA Warrants"), (iii) rights, exchangeable for
one-tenth of one share of BRPA Common Stock upon the Closing ("BRPA Rights"),
(iv) units, each consisting of one share of BRPA Common Stock, one BRPA
Right, and one-half of one BRPA Warrant ("BRPA Units"), unit purchase
options of BRPA, and each other equity security of BRPA issued and
outstanding immediately prior to the Effective Time.

 

 

 "BRPA Special Meeting" means a meeting of the holders of BRPA Common Stock
held for the purpose of approving the BRPA Stockholder Matters.

 

 

 "BRPA Stockholders" means the holders of BRPA Common Stock.

 

 

 "Business Combination" has the meaning ascribed to such term in BRPA's
Charter Documents.

 

 

 "Business Day" means a day other than a Saturday, Sunday or other day on
which commercial banks in New York, New York are authorized or required by
law to close.

 

 

 "Cash and Cash Equivalents" shall mean the cash and cash
equivalents, including checks, money orders, marketable securities, short-
term instruments, negotiable instruments, funds in time and demand deposits
or similar accounts on hand, in lock boxes, in financial institutions or
elsewhere, together with all accrued but unpaid interest thereon, and all
bank, brokerage or other similar accounts.

 

 

 "Charter Documents" means the certificate of incorporation, bylaws,
memorandum and articles of association, articles of organization, other
comparable governing instruments with different names.

 

 

 "Closing Ancillary Agreements" means the Ancillary Agreements other
than the Support Agreements.

 

 

 "Company Antidepressant Drug Regimen" means NRX-100/NRX-101, a single
infusion of NRX-100 (ketamine) followed by sequential weeks of daily
oral treatment with NRX-101, a proprietary, oral fixed-dose
combination capsule of d-cycloserine and Lurasidone.

 

 

 

 

 

 

A-2

 

 

 

 

 

 

 

 

 

 

 

 "Company Certificate of Incorporation" means that certain Second Amended
and Restated Certificate of Incorporation of the Company, filed with the
Secretary of State of the State of Delaware on October 20, 2016, as amended.

 

 

 "Company Common Stock" means the common stock of the Company, par value
$0.001 per share.

 

 

 "Company COVID-19 Drug" means RLF-100 for the treatment of critical
COVID-19 with respiratory failure (or similar).

 

 

 "Company Intellectual Property" means any Intellectual Property Rights
owned by the Company and/or its Subsidiaries.

 

 

 "Company Material Adverse Effect" means any change, event, occurrence,
effect, circumstance or development that has a materially adverse effect
on (x) financial condition, assets, business, or results of operations of
the Company and its Subsidiaries, taken as a whole, or (y) the ability of the
Company and its Subsidiaries to timely consummate the Closing (including the
Merger) on the terms set forth in this Agreement; provided that, in the case
of clause (x) only, in no event would any of the following (or the effect of
any of the following), alone or in combination, be deemed to constitute, or
be taken into account in determining whether there has been or will be, a
"Company Material Adverse Effect": (i) changes or developments in general
U.S. or global economic conditions, including changes in interest rates or
economic, political, business, financial, commodity, currency or market
conditions generally, (ii) changes in applicable Legal Requirements,
U.S. GAAP, or authoritative interpretations thereof, (iii) any geopolitical
conditions, outbreak of hostilities, acts of war, sabotage, terrorism,
cyberterrorism, civil unrest, military actions, natural or man-made
disasters, weather conditions, epidemics, pandemics (including COVID-19 or
SARS-CoV-2 virus (or any mutation or variation thereof)) or other outbreaks
of illness or public health events and other force majeure events (including
any escalation or general worsening of any of the foregoing), (iv) any
change, event, occurrence, effect, circumstance or development attributable
to the announcement, pendency, negotiation or consummation of the Merger or
any other Transactions or the execution or performance of this Agreement,
including the impact thereof on relationships, contractual or otherwise, with
customers, suppliers, licensors, distributors, partners, providers
and employees or the Company or any of its Subsidiaries, (vi) any action
taken or omitted to be taken by the Company or its Subsidiaries at BRPA's
direction or written request, any action required or permitted to be taken or
omitted to be taken by this Agreement or any Ancillary Agreement or any
action to which BRPA has consented in writing, (vii) any change generally
affecting any of the industries or markets in which the Company or
its Subsidiaries operate or the economy as a whole, or (viii) the failure,
in and of itself, to meet, or changes to, any budget, projection, forecast,
estimate, or prediction (it being understood that the underlying facts and
circumstances giving rise to or contributing to such failure or change may be
taken into account in determining whether there has been a Company Material
Adverse Effect, unless such underlying facts and circumstances would
otherwise be excepted from this definition); provided, however, in the case
of each of the foregoing clauses (i), (ii), (iii) and (vii), in the event
that the Company and its Subsidiaries, taken as a whole are materially
and disproportionately affected by such change, event, occurrence, effect,
circumstance or development relative to other participants in the business
and industries in which they operate, the extent (and only the extent) of
such material and disproportionate affect, relative to such other
participants, on the Company and its Subsidiaries, taken as a whole, may be
taken into account in determining whether there has been a Company Material
Adverse Effect.

 

 

 

 

 

 

A-3

 

 

 

 

 

 

 

 

 

 

 

 "Company Preferred Stock" means the Company Series A Preferred Stock,
Company Series B-1 Preferred Stock, Company Series B-1A Preferred Stock, and
Company Series B-2 Preferred Stock.

 

 

 "Company Products" means all products or service offerings of the Company
and its Subsidiaries, including but not limited to the Company
COVID-19 Drug, Company Antidepressant Drug Regimen, and any future
product candidates developed by or on behalf of the Company.

 

 

 "Company Related Parties" means the Company, its Subsidiaries and any of
their respective former, current or future general or limited
partners, stockholders, controlling Persons, managers, members,
directors, officers, employees, Affiliates, representatives, agents or any
of their respective assignees or successors or any former, current or future
general or limited partner, stockholder, controlling Person, manager, member,
director, officer, employee, Affiliate, representative, agent, assignee or
successor of any of the foregoing.

 

 

 "Company Series A Preferred Stock" means the Series A preferred stock of
the Company, par value $0.001 per share.

 

 

 "Company Series B Preferred Stock" means, collectively, the Company Series
B-1 Preferred Stock, the Company Series B-1A Preferred Stock and the Company
Series B-2 Preferred Stock.

 

 

 "Company Series B-1 Preferred Stock" means the Series B-1 preferred stock
of the Company, par value $0.001 per share.

 

 

 "Company Series B-1A Preferred Stock" means the Series B-1A preferred stock
of the Company, par value $0.001 per share.

 

 

 "Company Series B-2 Preferred Stock" means the Series B-2 preferred stock
of the Company, par value $0.001 per share.

 

 

 "Company Stock" means, collectively, the Company Common Stock and the
Company Preferred Stock.

 

 

 "Company Stockholder Agreements" means the (i) First Refusal and Co-
Sale Agreement dated as of November 10, 2016, among the Company and
the Company Stockholders party thereto, (ii) Voting Agreement dated as of
November 10, 2016, among the Company and the Company Stockholders party
thereto, (iii) Investors' Rights Agreement dated as of November 10, 2016,
among the Company and the Company Stockholders party thereto, (iv)
Stockholders Agreement dated as of June 1, 2015, by and among the Company and
the Company Stockholders party thereto, and (v) Registration Rights Agreement
dated as of July 1, 2015, among the Company and the Company Stockholders
party thereto.

 

 

 "Company Stockholder" means a holder of Company Common Stock and/or Company
Preferred Stock.

 

 

 "Company Warrants" means all warrants to purchase shares of Company
Common Stock.

 

 

 

 

 

 

A-4

 

 

 

 

 

 

 

 

 

 

 

 "Confidentiality Agreement" means that certain Mutual Non-Disclosure
Agreement, dated as of December 3, 2020, between BRPA and the Company.

 

 

 "Consent Solicitation Statement" means the consent solicitation
statement included as part of the Registration Statement with respect to
the solicitation by the Company of the Company Stockholder Approval.

 

 

 "Copyrights" means all copyrights, copyrights registrations and
applications therefor, and all other rights corresponding thereto throughout
the world.

 

 

 "Earnout Cash Post-Earnout Share Equivalent" means the quotient of (i) the
aggregate amount, if any, of the Earnout Cash actually distributed to
Company Stockholders in accordance with Section 1.8 divided by (ii) the BRPA
Closing Price.

 

 

 "Earnout Cash Share Equivalent" means the quotient of (i)
$100,000,000 divided by (ii) the BRPA Closing Price.

 

 

 "Earnout Pro Rata Portion" means, with respect to each holder of
outstanding shares of Company Common Stock as of immediately prior to the
Effective Time (including holders of shares of Company Common Stock resulting
from the Preferred Stock Conversion), a fraction expressed as a percentage
equal to (i) the number of shares of BRPA Common Stock into which such
holder's shares of Company Common Stock are converted into in
accordance with Section 1.3(b) divided by (ii) the sum of (x) the total
number of shares of BRPA Common Stock into which all outstanding shares of
Company Common Stock (including all shares of Company Common Stock resulting
from the Preferred Stock Conversion) are converted into in accordance with
Section 3.01(b), plus (y) total shares of BRPA Common Stock that would have
been underlying the Substitute Options had the number of shares underlying
such Substitute Options been determined pursuant Section 1.3(c)(i) based
on the Exchange Ratio instead of the Option Exchange Ratio (for
the avoidance of doubt, without reflecting any subsequent Option Post-
Earnout Adjustments).

 

 

 "EMEA" means the European Medicines Agency.

 

 

 "Environmental Law" means any federal, state, local or foreign law,
regulation, order, decree, permit, authorization, opinion, common law or
agency requirement relating to: (i) the protection, investigation
or restoration of the environment, health and safety (in relation
to exposure to Hazardous Substances), or natural resources; (ii)
the handling, use, presence, disposal, release or threatened release of any
Hazardous Substance or (iii) noise, odor, wetlands, pollution, contamination
or any injury or threat of injury to persons or property, including but not
limited to the United States federal statutes known as the Clean Air Act,
Clean Water Act, Comprehensive Environmental Response, Compensation, and
Liability Act, Emergency Planning and Community Right to Know Act, Endangered
Species Act, Hazardous Materials Transportation Act, Migratory Bird Treaty
Act, National Environmental Policy Act, Operational Safety and Health Act,
Oil Pollution Act of 1990, Resource Conservation and Recovery Act, Safe
Drinking Water Act, Toxic Substances Control Act, or any similar law in any
jurisdiction in which the Company or a Subsidiary conducts business or
provides or offers goods or services.

 

 

 

 

 

 

A-5

 

 

 

 

 

 

 

 

 

 

 

 "Exchange Ratio" means the quotient of (i) 50,000,000 divided by (ii) the
total number of issued and outstanding shares of Company Common Stock and
the Company Preferred Stock (on an "as-converted" to Company Common Stock
basis) on a fully diluted basis as of the Closing Date using the treasury
method of accounting, including, without duplication, the number of shares of
Company Common Stock issuable pursuant to the conversions or exercises
provided for in Section 1.3(a), the number of shares of Company Common Stock
issued or issuable upon the exercise of all Company Stock Options and the
shares of Company Common Stock underlying the Company Warrants.

 

 

 "Export Control Laws" means (i) all U.S. import and export laws, including
those laws under the authority of U.S. Departments of Commerce (Bureau
of Industry and Security) codified at 15 CFR, Parts 700-799;
Homeland Security (Customs and Border Protection) codified at 19 CFR,
Parts 1-199; State (Directorate of Defense Trade Controls) codified at
22 CFR, Parts 103, 120-130; and Treasury (Office of Foreign Assets Control)
codified at 31 CFR, Parts 500-599, United States Executive Order 13224, the
Arms Export Control Act, the International Traffic in Arms Regulations, the
Export Administration Act, the International Emergency Economic Powers Act,
the Trading with the Enemy Act, and (ii) all comparable applicable laws
outside the United States.

 

 

 "FDA" means the U.S. Food and Drug Administration.

 

 

 "Governmental Entity" means any federal, state, provincial, municipal,
foreign, or other court, judicial body, administrative agency,
commission, governmental or regulatory authority or similar body, including
but not limited to the SEC, the FDA, the Department of Health and
Human Services, the Centers for Medicare and Medicaid Services, the Department
of Veterans Affairs, and the EMEA.

 

 

 "Governmental Order" means any order, judgment, injunction, decree, writ,
stipulation, determination or award, in each case, entered by or with
any Governmental Entity.

 

 

 "Hazardous Substance" means any substance that is: (i) listed, classified
or regulated pursuant to any Environmental Law; (ii) any petroleum product
or by-product, natural gas, synthetic gas, and any mixtures
thereof, asbestos-containing material, lead-containing paint or
plumbing, polychlorinated biphenyls, radioactive materials, radon, or
per- and polyfluoroalkyl substances; or (iii) any other substance which is
the subject of regulatory action by any Governmental Entity pursuant to any
Environmental Law.

 

 

 "Health Care Programs" means the Medicare program, any state Medicaid
program, TRICARE, any heath care program of the Department of Veterans
Affairs, the Maternal and Child Health Services Block Grant Program,
any federally-funded state social services block grant program, the State
Children's Health Insurance Program, or any similar U.S. or foreign programs.

 

 

 "Health Care Regulatory Laws" means any applicable law relating to
healthcare, including, without limitation the following (as amended from
time to time), (i) the Federal Food, Drug, and Cosmetic Act of 1938,
as amended (21 U.S.C.  301 et seq.), and (ii) the Public Health Service Act
(42 U.S.C.  201 et seq.), and all regulations promulgated thereunder
(including, but not limited to, 21 C.F.R. Part 1271).

 

 

 

 

 

 

A-6

 

 

 

 

 

 

 

 

 

 

 

 "HIPAA" means the security and privacy standards adopted pursuant to the
Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the
Health Information Technology for Economic and Clinical Health Act of
2009 (HITECH), as amended, and implementing regulations.

 

 

 "HSR Act" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended.

 

 

 "IEC" means an independent ethics committee.

 

 

 "Information Privacy and Security Laws" means all applicable laws
concerning the privacy, data protection, transfer, or security of
Personal Confidential Information, including, to the extent applicable,
the Fair Credit Reporting Act, Federal Trade Commission Act, CAN SPAM Act,
Telephone Consumer Protection Act, Telemarketing and Consumer Fraud and Abuse
Prevention Act, Children's Online Privacy Protection Act, the Payment Card
Industry Data Security Standards, the guidance of each Governmental Entity
that pertains to such laws, the General Data Protection Regulation (EU),
other state, and federal, data security laws, data breach notification laws,
and consumer protection laws.

 

 

 "Insider" means any individual who is an officer, director or employee of
the Company or any of its Subsidiaries.

 

 

 "Insurance Policies" means all material insurance policies and material
fidelity and surety bonds covering the assets, business, equipment,
properties, operations, employees, officers and directors.

 

 

 "Intellectual Property Rights" means any or all of the following and
all worldwide common law and statutory rights in, arising out of,
or associated therewith: (i) Patents; (ii) inventions (whether patentable or
not), invention disclosures, improvements, trade secrets, proprietary
information, know how, technology, technical data and customer lists, and all
documentation relating to any of the foregoing; (iii) Copyrights; (iv)
software and software programs; (v) domain names, uniform resource locators
and other names and locators associated with the internet or mobile
devices or platforms; (vi) industrial designs and any registrations
and applications therefor; (vii) Trademarks; (viii) all databases and data
collections and all rights therein; (ix) all moral and economic rights of
authors and inventors, however denominated, (x) all rights to obtain
renewals, continuations, divisions, or other extensions of legal protections
pertaining thereto, and (xi) any similar or equivalent rights to any of the
foregoing (as applicable).

 

 

 "IRB" means an institutional review board.

 

 

 "knowledge" means actual knowledge or awareness as to a specified fact or
event (i) in the case of the Company, of Jonathan Javitt or Brian Del Buono,
and (ii) in the case of BRPA or Merger Sub, Richard Ackerman, Bennett Kim,
or Lori Wittman.

 

 

 "Legal Requirements" means any federal, state, local, municipal, foreign or
other law, statute, constitution, principle of common law,
resolution, ordinance, code, edict, decree, rule, regulation, ruling
or requirement issued, enacted, adopted, promulgated, implemented
or otherwise put into effect by or under the authority of any Governmental
Entity, including but not limited to, the Securities Act, Exchange Act, rules
and regulations of the SEC, the Sarbanes-Oxley Act and rules and regulations
thereunder, the Nasdaq Listing Rules, Health Care Regulatory Laws, and Export
Control Laws, and including any (a) technical or scientific standard
to which adherence is required by any Governmental Entity and (b)
any mandatory rules or policies of non-governmental accreditation
or oversight bodies applicable to the Company Products.

 

 

 

 

 

 

A-7

 

 

 

 

 

 

 

 

 

 

 

 "Lien" means any mortgage, pledge, security interest, encumbrance, lien,
restriction or charge of any kind (including, without limitation, any
conditional sale or other title retention agreement or lease in the nature
thereof, any sale with recourse against the seller or any Affiliate of
the seller, or any agreement to give any security interest).

 

 

 "Merger Consideration" means (i) an aggregate of 50,000,000 shares of BRPA
Common Stock and (ii) the Earnout Consideration, if payable in accordance
with Section 1.8.

 

 

 "OFAC" means the Office of Foreign Assets Control of the U.S. Department
of Treasury.

 

 

 "Option Exchange Ratio" means the Exchange Ratio, but substituting "(i) the
sum of (a) 75,000,000 plus (b) the Earnout Cash Share Equivalent" in lieu of
"(i) 50,000,000"

 

 

 "Option Post-Earnout Exchange Ratio" means the Exchange Ratio, but
substituting "(i) the sum of (a) 50,000,000 plus (b) the number of
Earnout Shares actually distributed to Company Shareholders in
accordance with Section 1.8 plus (c) the Earnout Cash Post-Earnout Share
Equivalent" in lieu of "(i) 50,000,000".

 

 

 "Patents" means all patents and applications therefor and all reissues,
divisions, renewals, extensions, provisionals, continuations
and continuations-in-part thereof.

 

 

 "Permitted Liens" means (i) statutory Liens for Taxes, assessments or other
governmental charges, in each case, not yet delinquent or the amount or
validity of which is being contested in good faith and for which
adequate reserves have been established in accordance with U.S. GAAP,
(ii) mechanics', carriers', workers', repairers' and similar Liens arising
or incurred in the ordinary course of business, (iii) zoning, entitlement and
other land use and environmental regulations promulgated by any Governmental
Entity, (iv) covenants, conditions, restrictions, easements, rights of way,
encumbrances, defects, imperfections, irregularities of title or other Liens,
if any, that would not reasonably be expected to have a Company Material
Adverse Effect or BRPA Material Adverse Effect, as applicable, (v) with
respect to any leased real property, (a) the interests and rights of the
respective lessors with respect thereto and (b) any Lien permitted under
the applicable lease agreement and any ancillary documents thereto, (vi)
Liens created by BRPA or its successors and assigns, (vii) Liens disclosed in
the Company Schedules or the BRPA Schedules, (viii) Liens (other than
monetary liens) incurred in the ordinary course of business since the date of
the most recent Company Financial Statements or BRPA Financial Statements,
as applicable, (ix) licenses to Intellectual Property Rights granted in the
ordinary course of business, (x) Liens securing the Company's and its
Subsidiaries' existing credit facilities, (xii) statutory or contractual
Liens of lessors or Liens on the lessor's or prior lessor's interest,
and (xiii) Liens of public record.

 

 

 "Permitted Transferee" means (i) BRPA or an Affiliate of BRPA, (ii) if the
transferor is an entity, (x) its shareholders, partners, or members upon
the transferee's liquidation or (y) an entity, if such entity's equity
securities are 100% owned by the transferor or its shareholders, partners, or
members, or (iii) if the transferor is an individual, (x) a member of the
transferor's immediate family or a trust, the beneficiary of which is
the transferor or a member of the transferor's immediate family, who
receives BRPA Common Stock from the transferor by bona fide gift for estate
planning purposes, (y) a Person who receives BRPA Common Stock from the
transferor by virtue of the laws of descent and distribution upon the death
of the transferor, or (z) a Person who receives BRPA Common Stock from the
transferor pursuant to a qualified domestic relations order binding on the
transferor. As used herein, "immediate family" means a spouse, parent,
lineal descendants, the spouse of any lineal descendent, brothers or sisters,
or a trust, all of whose current beneficiaries are members of the immediate
family of the transferor.

 

 

 

 

 

 

A-8

 

 

 

 

 

 

 

 

 

 

 

 "Person" means any individual, corporation (including any non-profit
corporation), general partnership, limited partnership, limited
liability partnership, joint venture, estate, trust, company (including
any limited liability company or joint stock company), firm or
other enterprise, association, organization, entity or Governmental Entity.

 

 

 "Personal Confidential Information" means any information, in any form,
that could reasonably be used to identify, contact, or locate a
single person, that is governed, regulated, or protected by one or
more Information Privacy and Security Laws.

 

 

 "Protected Health Information" has the definition provided by 45
C.F.R. 160.103.

 

 

 "Proxy Statement" means the proxy statement filed by BRPA as part of the
Registration Statement with respect to the BRPA Special Meeting for the
purpose of soliciting proxies from BRPA Stockholders to approve the
BRPA Stockholder Matters (which shall also provide the BRPA
Stockholders with the opportunity to redeem their shares of BRPA Common Stock
in conjunction with a stockholder vote on the Business Combination).

 

 

 "Representative" means, with respect to any Person, any director, officer,
employee, agent, manager, consultant, advisor, or other representative of
such Person, including legal counsel, accountants, and financial advisors.

 

 

 "Schedules" means the Company Schedules and the BRPA Schedules.

 

 

 "SEC" means the U.S. Securities and Exchange Commission.

 

 

 "Securities Act" means the Securities Act of 1933, as amended.

 

 

 "Sponsor" means Big Rock Partners Sponsor, LLC.

 

 

 "Subsidiary" means, with respect to any Person, any other Person with
respect to which such first Person (alone or in combination with any of such
first Person's other Subsidiaries) owns (i) capital stock or other equity
interests having the ordinary voting power to elect a majority of the board
of directors or other governing body of such Person or (ii) a majority of the
outstanding voting securities of such Person.

 

 

 "Tax Opinion Counsel" means the Company's counsel.

 

 

 "Tax Opinion" means an opinion of Tax Opinion Counsel, in form and
substance reasonably satisfactory to the Company, dated as of the Closing
Date, substantially to the effect that, on the basis of
facts, representations and assumptions set forth in such opinion, the Merger
will qualify as a "reorganization" within the meaning of Section 368(a) of
the Code.

 

 

 "Tax" or "Taxes" refers to any and all federal, state, local and foreign
taxes, including, without limitation, gross receipts, income,
profits, sales, use, occupation, value added, ad valorem,
transfer, franchise, withholding, payroll, employment, excise and
property taxes, assessments, governmental charges in the nature of a tax
and duties together with all interest, penalties and additions imposed with
respect to any such amounts, and including (i) any liability of a predecessor
entity for any such amounts and (ii) any such amounts imposed by contract.

 

 

 

 

 

 

A-9

 

 

 

 

 

 

 

 

 

 

 

 "Trademarks" means trade names, logos, common law trademarks and service
marks, trademark and service mark registrations and applications therefor.

 

 

 "Transactions" means the transactions contemplated by this Agreement to
occur at or immediately prior to the Closing, including the Merger.

 

 

 "U.S. GAAP" means generally accepted accounting principles historically
and consistently applied in the United States and as in effect from time to
time.

 

 

 

 

 

 

 

 

 

 

A-10

 

 

 

 

 

 

 

 

 

  

 

 

 

  Exhibit B

 

 

 Form of Voting and Support Agreement

 

 

 [See attached]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B-1

 

 

 

 

     '

